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Abstract  
Epilepsy is one of the most common neurological disorders. Apart from seizures, 
patients are also affected by epilepsy comorbidities, such as cognitive 
impairment, side effects of antiepileptic drugs, and an increased risk of dying 
from sudden death. Within epilepsy research, recent efforts have been made to 
identify reliable biomarkers to advance the understanding of disease-
mechanisms, to individualize and optimize treatment and side-effect profiles and 
to enhance prediction of treatment success and disease progression. Biomarkers 
are objective measures of a normal or pathological biological process and, in the 
context of this PhD, neuroimaging biomarkers ideally enable in vivo 
measurements of (i) disease activity, (ii) treatment effects and (iii) risk of 
comorbidities and mortality. Employing functional and structural neuroimaging 
techniques, we studied potential neuroimaging biomarkers in three different 
domains of epilepsy. 
In the first project, we explored fMRI endophenotypes in a prototype of a genetic 
generalised epilepsy syndrome, namely juvenile myoclonic epilepsy (JME). 
Endophenotypes are heritable traits, closer related to the genotype than the final 
phenotype and are found frequently in non-affected family members of patients. 
Our study revealed potential functional endophenotypes and support a 
genetically determined neurodevelopmental disease mechanism in JME.   
The second project investigated fMRI markers of antiepileptic drug effects on 
cognitive networks in patients with refractory epilepsy. In two retrospective 
studies employing fMRI cognitive tasks, we isolated task- and medication-specific 
effects on working memory and language networks for Levetiracetam (study 1) 
and Topiramate and Zonisamide (study 2). 
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In the third project, we employed Voxel-Based-Morphometry in a retrospective 
analysis of structural imaging of patients who had died of sudden unexpected 
death in epilepsy (SUDEP) or were at high or low risk of SUDEP. We identified 
structural markers of high SUDEP risk, and discussed that these were at least 
partially specific, i.e. independent of disease progression and load.  
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Section 1: Introduction 
Chapter 1: Epilepsy and its comorbidities  
1.1 Definitions and Classifications 
 
1.1.1 Definition of seizures and epilepsy 
The International League Against Epilepsy (ILAE) defines a seizure as “a 
transient occurrence of signs and/or symptoms due to abnormal excessive or 
synchronous neuronal activity in the brain” (Fisher et al., 2005).  
The most recent conceptual definition of epilepsy does not only relate to the 
occurrence of seizures, but characterizes epilepsy as “a disorder of the brain 
characterized by an enduring predisposition to generate epileptic seizures, and 
by the neurobiological, cognitive, psychological, and social consequences of this 
condition” (Fisher et al., 2005).  
For the purpose of clinical diagnosis, an ILAE task force recently formulated an 
operational diagnosis in order to clarify the debate on seizure recurrence, as in 
the past epilepsy diagnosis required at least two unprovoked seizures. However, 
this may be inadequate in some patients, who e.g. acquired a brain lesion, such 
as a stroke, bearing a high risk of recurrence after the first seizure. (Fisher et al., 
2014) 
According to the operational definition, “epilepsy is a disease of the brain defined 
by any of the following conditions 
1. At least two unprovoked (or reflex) seizures occurring >24 h apart 
2. One unprovoked (or reflex) seizure and a probability of further seizures similar 
to the general recurrence risk (at least 60%) after two unprovoked seizures, 
occurring over the next 10 years 
	 24 
3. Diagnosis of an epilepsy syndrome.” (Fisher et al., 2014) 
 
 
1.1.2 Epidemiology 
Epilepsy is the most common neurological disease, affecting people of any age, 
race and different socioeconomic background. In industrialized countries, the 
incidence of epilepsy ranges from 40 to 70 per 100000/year (Sander, 2003). In 
European epidemiological studies, incidence rates of 43 to 47 per 100000 person 
years have been described in people of all ages (Forsgren et al., 2005). There is 
a disparity in epilepsy-burden and generally higher incidence rates in developing 
countries with 100 to 190 per 100000/year (Sander and Shorvon, 1996).  
The prevalence rates of active epilepsy range in most studies from 4 to 7 per 
1000 (Sander and Shorvon, 1996).  
Premature death is 2 to 3fold higher in people with epilepsy than in the general 
population, and is highest in those who suffer from symptomatic epilepsy and 
persistent neurological deficits. Epilepsy related deaths include sudden 
unexpected death in epilepsy (SUDEP), status epilepticus, consequences from 
seizures, including accidents, drowning, burns, aspiration pneumonia, iatrogenic 
(drug toxicity and idiosyncratic) and suicide (Devinsky et al., 2015; Neligan et al., 
2010). SUDEP will be addressed in more detail in chapter 1.4. 
 
1.1.3 Classification of seizures and epilepsies  
The classification of seizures and epilepsies is necessary both in a clinical and 
research setting. More importantly, it helps to find a more precise diagnosis and 
appropriate treatment choice.   
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The classification of seizures is based on the observable phenomenology. The 
ILAE established a standardised seizure classification in 1981, which is based on 
clinical manifestation and EEG findings only and has been revised in a 2010 
proposal. (Berg et al., 2010; “Proposal for revised clinical and 
electroencephalographic classification of epileptic seizures. From the 
Commission on Classification and Terminology of the International League 
Against Epilepsy,” 1981) 
Both classifications are based on the conceptual dichotomy of focal and 
generalised seizures: Whereas generalised seizures originate and rapidly spread 
within neuronal networks of both hemispheres, focal seizures arise from a region 
in one hemisphere. Focal seizures can spread within the hemisphere and/or to 
the contralateral hemisphere.  
The classification of epilepsies is based on information regarding seizure 
semiology, EEG findings, aetiology and associated conditions. Recognizing the 
heterogeneity of the epilepsies, the 1989 ILAE classification of the epilepsies and 
epileptic syndromes attempted to provide a syndromic classification. (“Proposal 
for revised classification of epilepsies and epileptic syndromes. Commission on 
Classification and Terminology of the International League Against Epilepsy,” 
1989) Over the last twenty years, epilepsy research had much advanced, 
particularly in the field of neuroimaging and genetics, and the new ILAE 
classification proposal from 2010 sought to take this into account.   
The previous aetiological terminology, idiopathic (no cause, likely genetic), 
symptomatic (related to a structural or metabolic cause) and cryptogenic 
(presumed symptomatic but no identifiable lesion), was abandoned, as it was felt 
that these labels were not always used precisely and associated with certain 
expectations of prognosis and treatment response. Instead, the terms genetic, 
structural/metabolic or unknown were proposed for classification of aetiology.  
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1.2 Pharmacological treatment and chronic epilepsy 
 
1.2.1 Initiation of treatment and pharmaco-resistance 
When starting anticonvulsant treatment, the antiepileptic drugs (AED) are chosen 
according to the type of epilepsy and tailored to the individual, e.g. the 
comorbidity profile of the patient. In addition, issues such as teratogenicity and 
drug interactions with contraception in women of childbearing age have to be 
considered.  
The majority of patients (60 to 70%) remain seizure free on antiepileptic 
medication. In about 80% of those, this is achieved with a single anticonvulsant, 
and in 10 to 15% with two agents. Approximately 30% develop treatment 
resistance, which is defined as persistence of seizures despite treatment with at 
least two tolerated anticonvulsants of appropriate choice and dosage. (Kwan and 
Brodie, 2000) 
Apart from treatment efficacy, drug tolerability becomes a major concern 
particularly in refractory epilepsy treatment. The SANAD (Standard and New 
Antiepileptic Drug) study compared carbamazepine with lamotrigine, topiramate, 
gabapentin and oxcarbazepine in focal epilepsies, and valproate with topiramate 
and lamotrigine in mainly generalised epilepsies. Though newer AED were not as 
effective, some of them, i.e. oxcarbazepine and lamotrigine, were better tolerated 
than older AED, in this case carbamazepine. (Marson et al., 2007a, 2007b) A 
follow-up study investigating overall available newer AED, such as levetiracetam 
and zonisamide, is under way. 
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1.2.2 Effects of AED on cognition  
There is a substantial body of literature on the cognitive effects of anticonvulsants 
and it is generally accepted that AED contribute to cognitive impairment in 
patients. Cognitive side effects are more likely to occur with rapid titration, high 
dosage and serum levels, and polytherapy (Mula and Trimble, 2009). Data with 
respect to differences between individual AED are limited and controversial. In 
addition, the interplay of several AED may be relevant and a recent study 
reported a higher inverse correlation of performance in executive functions with 
the total number of AED than with the overall daily dose (Witt et al., 2015). 
Cognitive impairment is likely multifactorial in nature and contributing factors are 
e.g. seizure frequency and disease onset during neurodevelopment. On the 
contrary, AED treatment may also “improve” cognition in the sense of preventing 
further deterioration through seizure control. (Pohlmann-Eden et al., 2015)  
In the following, specific AED relevant to this thesis will be discussed in more 
detail. 
 
 
1.2.3 AED relevant for this PhD 
1.2.3.1   Levetiracetam 
Levetiracetam is a broad-spectrum AED with efficacy in focal, generalised tonic-
clonic and myoclonic seizures. Its main anti-seizure mechanism is attributed to its 
binding to the ubiquitous synaptic vesicle protein SV2A. Further modes of action 
include reduction of high voltage activated calcium currents, inhibition of 
intracellular calcium release and AMPA inhibition. (Abou-Khalil, 2016; Kaminski 
et al., 2014) 
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Effect on cognitive function 
Most studies attribute a favourable cognitive profile to Levetiracetam. In a non-
controlled surveillance study of 401 patients before and 3 and 6 months after 
starting Levetiracetam, subjective improvement on cognitive scores was apparent 
in almost a third of patients, taking a mean dose of 1500 mg at both time points. 
Better baseline scores, late onset epilepsy, fewer initial AED and seizure control 
were predictive of cognitive outcomes. (Helmstaedter and Witt 2008) In a 
comparison study of patients on Carbamazepine or Levetiracetam monotherapy, 
almost all cognitive measures, including verbal memory and executive functions, 
improved with Levetiracetam but not Carbamazepine irrespective of seizure 
control, suggestive of a mild superior outcome with Levetiracetam (Helmstaedter 
and Witt, 2010). In children and adolescents with focal epilepsy, Levetiracetam 
treatment has been associated with long-term stability in seizure control and 
cognitive functions (Schiemann-Delgado et al., 2012).  
 
1.2.3.2   Topiramate  
 
Topiramate, initially approved for treatment of pharmaco-resistant focal 
epilepsies, is a broad-spectrum AED with efficacy in genetic generalised 
epilepsies and tonic-atonic seizures in Lennox Gastaut Syndrome. It is further 
approved for migraine prophylaxis. Its modes of action include blockade of 
voltage-gated calcium channels and reduction of activation frequency of voltage-
sensitive sodium channels, antagonism of alpha-amino-3-hydroxy-5-
methylisoxazole-4-proprionic acid (AMPA)/kainate subtypes of glutamate 
receptors and increase of GABA activity via interaction with the GABAA 
receptors. Like acetazolamide, it contains a sulfamate moiety, which likely 
contributes to its carbonic anhydrase inhibitor mechanism. (Abou-Khalil, 2016; 
Mula, 2012) 
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Effect on cognitive function 
Cognitive dysfunction has been described in patients with epilepsy, migraine and 
healthy controls characterised by reduced attention, psychomotor speed, short-
term memory and more specifically, impairment of expressive language and 
working memory. These deficits are noted even after single-dose administration 
and on steady-dose in mono- or combination therapy, irrespective of seizure 
control. Psychometric measures consistently improve after significant dose 
reduction or discontinuation. (Bootsma et al., 2008; Martin et al., 1999; Meador et 
al., 2005; Mula and Trimble, 2009; Thompson et al., 2000) Topiramate has been 
reported inferior with regards to its effect on cognition in comparison to 
gabapentin, lamotrigine, and valproate (Aldenkamp et al., 2000; Blum et al., 
2006; Gomer et al., 2007; Martin et al., 1999; Meador et al., 2005). 
 
1.2.3.3   Zonisamide 
 
Similar to Topiramate, Zonisamide is a broad spectrum AED with efficacy in focal 
and idiopathic generalized epilepsies. Its mechanisms of action include 
modulation of T-type calcium and voltage-sensitive sodium channels, 
augmentation of presynaptic GABA release, reduction of presynaptic glutamate 
release, down-regulation of GABA removing transporters and up-regulation of 
glutamate transporter 1 removal from the synaptic cleft. Like Topiramate, it 
contains a sulfamate moiety responsible for its weak carbonic anhydrase inhibitor 
mechanism. (Abou-Khalil, 2016; Schulze-Bonhage, 2015) 
 
 
Effect on cognitive function 
Zonisamide treatment leads to similar, probably less pronounced neurocognitive 
impairment (Mula and Trimble, 2009; Ojemann et al., 2001). 
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Underlying mechanisms of cognitive impairment patterns in patients on 
Zonisamide or Topiramate are poorly understood. As both contain a sulfamate 
moiety and language impairment has been described in other sufamate-
compound medication, i.e. sulthiame (Dodrill, 1975), it has been suggested that 
the carbonic anhydrase inhibition mechanism shared by these AED may 
contribute to the cognitive impairment pattern, with a possible specific sensitivity 
of the expressive language areas to sulfa-compounds (Burns et al., 2009; Mula, 
2012; Ojemann et al., 2001; Yasuda et al., 2013).  
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1.3 Juvenile myoclonic epilepsy  
 
1.3.1 Diagnostic criteria and clinical picture 
Juvenile myoclonic epilepsy (JME) is the most common genetic generalised 
epilepsy (GGE) syndrome affecting up to 12 % of all epilepsies with a high 
genetic predisposition (Berg et al., 2010; Delgado-Escueta et al., 2013; Zifkin et 
al., 2005). Patients present with symmetric, myoclonic jerks, mostly affecting 
upper limbs, generalized tonic clonic seizures and more rarely absence seizures. 
Myoclonic jerks without loss of awareness, occurring predominantly upon 
awakening, have been described as the hallmark of JME. Apart from this typical 
chrono-dependency, seizures can also occur from sudden awakening after a nap 
or from night sleep. Disease onset peaks between the age of 12 and 18 years, 
with a range of 6 to 25 years. The EEG typically shows a normal background and 
ictal generalized polyspikes (and waves) with myoclonic jerks. (Janz, 1985) The 
diagnostic criteria of the syndrome were recently refined. (Kasteleijn-Nolst Trenité 
et al., 2013) 
 
1.3.2 Seizure provocation and reflex traits 
Common reflex traits include photosensitivity, eye closure sensitivity, orofacial 
reflex myoclonus and praxis induction. 
Photosensitivity is the most frequent reflex trait in epilepsy in general and is 
genetically determined. A photoparoxysmal response (PPR), i.e. spike and wave 
discharge provoked by intermittent light stimulation (ILS), occurs in up to 50% of 
JME patients, and even in up to 90% with prolonged ILS (Appleton et al., 2000).  
Eye closure sensitivity occurs in 15–20% of JME cases and is defined as 
occurrence of spike-wave discharge within 2 s after slow eye closure (i.e. not 
	 32 
blinking). Clinically, patients will have eyelid myoclonus, sometimes accompanied 
by absence seizures. (Beniczky et al., 2012) 
Orofacial reflex myocloni are precipitated by language-related activities, such as 
reading and talking. They usually occur in primary reading epilepsy but are 
present in 25-30% of JME patients (Mayer et al., 2006; Wolf et al., 2015). 
Praxis induction describes seizure precipitation by cognitive tasks including a 
complex motor component. Clinically, patients will have myoclonic jerks in the 
active hand. Praxis induction is highly associated with JME, occurring in 24 to 
47% of patients (Guaranha et al., 2009; Matsuoka et al., 2000). 
 
1.3.3 Aetiology and histopathology 
Clinical MRI scans are non-lesional. However, early histopathological studies in 
patients with GGE report subtle grey and white matter abnormalities, suggestive 
of microdysgenesis (Meencke and Janz, 1984, 1985). These findings could not 
be replicated in a controlled and blinded study (Opeskin et al., 2000). Recent 
histopathological studies in epileptic baboons, a natural animal model of JME, 
report a reduction of cortical neurons, most pronounced in the primary motor 
cortex of the hand area and less so in the somatosensory cortex (Young et al., 
2013).  
 
1.3.4 Clinical genetics of JME 
The heritability in JME is high (0.7, (Nair and Thomas, 2004)) and a complex 
polygenetic inheritance is suspected in most cases, though Mendelian 
inheritance also exists in JME (Delgado-Escueta et al., 2013; Zifkin et al., 2005).  
Large epidemiological studies in unselected epilepsy populations report a high 
prevalence of first-degree relatives with epilepsy (Bianchi et al., 2003). Amongst 
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those, GGE had the highest prevalence with on average 5%. For first-degree 
relatives of JME, particularly siblings and offspring, there is an even higher risk 
for epilepsy with up to 6.2% and syndrome concordance is more pronounced 
than in other GGE syndromes, with 30% of affected first degree relatives also 
suffering from JME (Marini et al., 2004; Winawer et al., 2005). Twin studies show 
very high monozygous concordances with almost always identical syndromes 
within concordant pairs. (Koepp et al., 2014; Vijai et al., 2003)  
 
 
1.3.5 Treatment and prognosis 
Patients are advised to avoid major seizure precipitants, such as sleep 
deprivation and relative alcohol withdrawal as caused by binge drinking. 
Antiepileptic medication, particularly after occurrence of the first generalised tonic 
clonic seizure, is initiated in the majority of patients. Valproate with its anti-
myoclonic effect is particularly effective in JME, though preferred in male given its 
teratogenicity. First-line choices in women are Lamotrigine and Levetiracetam. 
(Kasteleijn-Nolst Trenité et al., 2013) 
Remission on antiepileptic treatment occurs in approximately two-thirds of new 
onset JME cases. Long-term remission is described in up to 30%, though most 
patients in these long-term follow-up cohorts still remain on AED treatment, 
making it difficult to evaluate true remission rates. (Geithner et al., 2012; Koepp 
et al., 2014; Senf et al., 2013)  
 
 
1.3.6 Psychiatric comorbidities 
In the initial syndrome description, Janz (1985) anecdotally reported immature 
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and impulsive behavior in JME patients, contributing to poor seizure control and 
social adaption. Two studies corroborated increased impulsivity and risk-taking 
behaviour in patients with poor seizure control (Wandschneider et al., 2013; 
Zamarian et al., 2013).  
Psychiatric disorders have been reported in up to 47% of patients, particularly 
mood, anxiety and cluster B personality disorders (de Araujo Filho and Yacubian, 
2013). One study identified an association of comorbid cluster B personality 
disorders, moderate-to-severe degrees of anxiety traits and prevalence of 
seizures triggered by praxis-induction or speech with poor seizure control 
(Guaranha et al., 2011) . 
 
 
 
 
1.3.7 Frontal lobe dysfunction – behavioural and imaging 
studies  	
Though JME patients have average intellectual abilities, even long-term seizure-
free patients present ‘real-world problems’ (Thomas et al., 2014), leading to 
poorer socioeconomic outcomes, such as higher unemployment rates (Camfield 
and Camfield, 2009). There is increasing evidence that dysfunction within 
thalamo-frontocortical networks leads to impairment of higher frontal lobe 
functions, such as working memory (WM), planning and risk-taking behaviour 
(Wandschneider et al., 2013; Zamarian et al., 2013). Other cognitive functions, 
e.g. hippocampal-related episodic memory, are relatively preserved, although 
there have been reports on more widespread cognitive impairment (Lin et al., 
2013).  
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1.3.7.1 Working memory in JME 	
The first study of WM performance in JME (Swartz et al., 1994) investigated 
visual WM in patients with frontal lobe epilepsy (FLE) and used JME patients as 
a patient control group. Surprisingly, JME patients had similarly impaired WM 
function as FLE patients when compared to healthy controls. A subsequent 
18FDG-PET study employing the same cognitive task showed widespread 
decreased 18FDG-uptake in the ventral premotor cortex, caudate and dorsolateral 
prefrontal cortex at resting state (Swartz et al., 1996). This was consistent with 
the poor performance on the WM task. More recent fMRI WM studies reported 
varying results: Roebling and colleagues (2009) employed the Sternberg Item 
Recognition Test, a visual-spatial WM task, and found no differences in 
performance and activation patterns between JME patients (n = 19) and controls. 
Vollmar and colleagues (2011) investigated a larger (n = 30) JME patient 
population with a more challenging visual spatial n-back WM task. Though 
performance again did not differ between groups, patients displayed abnormal 
motor cortex co-activation with fronto-parietal WM networks during increasing 
cognitive demand. Subsequent combined functional and structural connectivity 
analyses showed decreased connectivity between prefrontal and fronto-polar 
regions, possibly accounting for dysfunction of cognitive frontal lobe functions, 
and increased connectivity between the motor and prefrontal cortex. These 
observations may help to explain the mechanism of praxis-induction, or 
cognitively triggered myoclonic jerks, in JME (Vollmar et al., 2012).  
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1.3.7.2 Executive function and risk-taking behaviour in JME 	
Behavioural studies on executive functions, such as planning, response 
inhibition, cognitive flexibility and verbal fluency describe varying degrees of 
impairment. Amongst these, verbal fluency is most consistently affected 
(Devinsky et al., 1997; Pascalicchio et al., 2007; Piazzini et al., 2008; Sonmez et 
al., 2004; Thomas et al., 2014; Wandschneider et al., 2012).  
Few studies relate executive functions to findings on structural, functional and 
metabolic imaging. In a quantitative MR spectroscopy (MRS) study, Savic and 
colleagues (2004) compared patients with either JME or GGE with generalized 
tonic clonic seizures (GTCS) to a group of healthy controls. N-acetyl aspartate 
(NAA) is a neuron specific metabolite. Reduced levels can be associated with 
neuronal dysfunction or damage (Savic et al., 2000). Within the frontal lobes, 
NAA concentrations were reduced in the JME group in relation to both healthy 
controls and GTCS patients. In addition, JME patients with low frontal NAA 
concentrations showed frontal lobe dysfunction on a brief neuropsychological 
assessment. In contrast, frontal lobe functions were spared in JME patients with 
normal NAA concentrations, GTCS patients and controls. Hence, although a 
prefrontal neuronal lesion may be present in some JME patients, JME seems to 
be a heterogeneous condition. Low NAA levels did not correlate with any other 
clinical parameter, such as current seizure frequency or seizure number over 
lifetime. 
Pulsipher et al. (2009) aimed to investigate the integrity of thalamo-frontocortical 
networks in relation to executive function in recent onset JME. Twenty JME 
patients within 12 months of diagnosis were compared to an epilepsy control 
group of 12 patients with recent onset Benign Childhood Epilepsy with 
Centrotemporal Spikes (BECTS) and 51 healthy controls. Participants were 
assessed with three subtests of the Delis-Kaplan Executive Function System (D-
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KEFS) and a questionnaire for parents, the Behavior Rating Inventory of 
Executive Function (BRIEF). JME patients performed less well than controls on 
D-KEFS Inhibition. Behavioral Regulation and Metacognition scores of the BRIEF 
were also significantly lower in the JME group. Quantitative MRI measurements 
revealed smaller thalamic volumes and greater frontal CSF in JME patients than 
in healthy controls and BECTS-patients. Thalamic and frontal volumes predicted 
D-KEFS performance only for the JME group. 
In a resting FDG-PET study (McDonald et al., 2006), regional cerebral rates of 
glucose uptake values (rCMRGlc) were regressed on various executive function 
test scores in patients with frontal lobe epilepsy, JME and healthy controls. In the 
JME group, frontal hypometabolic values predicted impairment on measures of 
figural fluency and cognitive flexibility. 
O’Muircheartaigh and colleagues (2011) reported subtle dysfunctions in verbal 
fluency, comprehension and expression, mental flexibility and response inhibition 
in a cohort of 28 JME patients. In a structural and diffusion tensor MRI (DTI) 
study, voxel-based morphometry revealed reductions in grey matter volume in 
the supplementary motor area and posterior cingulate cortex. Fractional 
anisotropy (FA) in the supplementary motor area predicted performance in tasks 
of word naming and expression. Grey matter volumes of the posterior cingulate 
cortex and FA correlated with scores on the mental flexibility task. The authors 
describe their JME cohort as relatively high functioning but with 
neuropsychological evaluation revealing subtle cognitive impairments. 
 
Another frontal lobe function, engaging working memory networks, the 
orbitofrontal cortex and SMA, is decision making. Impaired experienced-related 
learning and impulsive decision-making have been described in a behavioural 
study in JME patients (Zamarian et al., 2013). A recent fMRI study investigated 
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impulsivity in JME using the Iowa Gambling Task (IGT), which is a measure of 
decision-making under ambiguity, and correlated IGT performance with activation 
patterns during a working memory task (Wandschneider et al., 2013) (Figure 
1.1). Subjects are instructed to choose from four decks of cards, which award 
virtual monetary gains and losses. Card deck choices are indicative of either 
advantageous or disadvantageous long-term choices, however participants are 
not informed about the IGT’s contingencies. Apart from overall advantageous or 
disadvantageous decision-making, learning from previous card choices can be 
assessed. The authors report overall no differences in card-choices and both 
groups, JME patients and healthy controls learned throughout the task. However, 
post hoc analysis revealed a greater proportion of patients with seizures than 
seizure-free patients having difficulties in advantageous decision-making and 
learn less from previous experience than both seizure-free patients and controls. 
Overall poor IGT performance was associated with increased activation within 
the dorsolateral prefrontal cortex (DLPFC). Impaired learning and ongoing 
seizures were associated with bilateral mesial prefrontal cortex and SMA, right 
superior frontal gyrus and left DLPFC activation. Findings suggest a dysfunction 
within macroscopically “normal” working memory networks, which implicates 
decision-making particularly in patients with poor seizure control. 
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Figure 1.1 (Wandschneider et al., 2013). Association of working memory 
network activation with learning in patients. A subgroup analysis in patients 
with ongoing seizures showed a bilateral medial prefrontal cortex and pre-SMA, a 
left dorsolateral prefrontal cortex (DLPFC), and right superior frontal gyrus 
activation in nonlearners compared to learners. (p < 0.005 unc.) (sz, seizures). 
 
 
 
1.3.7.3 Possible confounds of cognitive function 	
 
Cognitive abilities of patients with epilepsy in general can be modulated by 
disease activity, subclinical epileptiform discharges, and medication. Evidence for 
GGE and JME in particular is outlined. 
 
Disease activity 
Parameters of disease activity include seizure frequency and disease duration. 
Pascalicchio and colleagues (2007) reported a positive correlation of disease 
duration and the risk of cognitive impairment in JME. Vollmar and colleagues 
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(2011) observed abnormal motor-cortex co-activation in an fMRI working memory 
task, which was more prominent in patients with a more active disease and 
shorter seizure-free interval.  
 
Subclinical epileptiform discharges 
The phenomenon of transitory cognitive impairment (TCI) during subclinical 
epileptiform discharges has been reported in up to 50% of epilepsy patients 
(Binnie, 2003). Associated deficits were reported to be site and material specific, 
i.e. impairment occurs in the cognitive domain related to the area where 
subclinical discharges occur.  
However, the distinction between subclinical and clinically evident discharges is 
challenging, as illustrated by Porter et al. (1973). They applied a paroxysm-
triggered method to measure reaction time as an indicator of responsiveness at 
specific time points during spike-wave discharges of absence seizures. Fifty-four 
percent of reaction times were reported abnormal at the onset of spike-wave 
discharges. The relationship of generalized spike-wave discharges and cognitive 
functions have been mostly studied in patients with absence seizures 
(Blumenfeld, 2005). The level and nature of cognitive impairment are highly 
variable and depend on tests applied (Binnie, 2003). Impairments have been 
especially observed in tasks requiring a response to verbal questions, decision-
making, complex motor performance and short-term memory. Deficits were more 
subtle when discharges occurred without any obvious clinical manifestation 
(Binnie, 2003; Blumenfeld, 2005). Greater discharge generalization and 
amplitude, as well as longer duration and fronto-central distribution, have been 
associated with worse performance in some studies (Blumenfeld, 2005). 
In JME, Lavandier and colleagues (2002; cited by (Hommet et al., 2006)) 
investigated performance on cognitive tasks in relation to subclinical EEG 
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discharges. Executive function tasks were administered during continuous EEG 
and video monitoring. In view of the circadian seizure distribution in JME, the 
assessment was always performed in the morning. Patients who presented 
epileptiform discharges during rest were significantly more impaired on tests of 
abstract reasoning, concept formation and mental flexibility than patients without 
paroxysmal EEG changes. There was no increase of EEG abnormalities during 
the cognitive tasks.  
 
Antiepileptic medication 
Several studies attribute adverse effects of antiepileptic medication on cognition 
(for overview see e.g. Hermann et al., 2010). Processing speed and sustained 
attention are among the domains most vulnerable. In the studies reviewed here, 
antiepileptic medication was varied and the study samples were relatively small, 
rendering the statistical analysis of the impact of specific antiepileptic drugs 
difficult. Swartz and colleagues (1994) divided patients into groups with sedative 
(phenobarbital, primidone, and/or Dilantin) and non-sedative (carbamazepine 
and/or valproic acid) medications. They found no association between the type of 
medication and the performance variables correct responses and reaction time. 
Roebling and colleagues (2009) compared patients on valproic acid (VPA) to 
untreated patients or patients on lamotrigine (LTG) monotherapy respectively. 
The VPA-group was significantly more impaired on the verbal memory test and 
the authors concluded that cognitive dysfunction in this cohort is at least partially 
caused by medication side effects. On the contrary, Vollmar et al. (2011) reported 
a beneficial VPA effect in JME. In their fMRI working memory study, abnormal left 
motor cortex co-activation correlated negatively with an increasing daily VPA 
dose, implying a “normalisation” of function through VPA, which may also reflect 
its beneficial effect in suppressing motor seizures.  
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1.3.8 Genetic imaging biomarkers: the endophenotype concept 
Identifying culprit genes has proven difficult in complex inherited diseases, such 
as epilepsy. Given the strong link between genetic variations, neurodevelopment 
and function of brain regions (Bigos and Weinberger, 2010), advanced functional 
and structural imaging techniques can be used to improve phenotype 
characterization. This can ultimately help to understand effects of the genotype 
onto the phenotype and to increase the power of genetic analyses (Siniatchkin 
and Koepp, 2009). How highly heritable cognitive fMRI activation patterns are, 
has been shown in a twin study employing an n-back working memory paradigm 
(Blokland et al., 2011), a task similar to the one employed for projects of this 
thesis (see general methods section).  
  
Intermediate biological phenotypes are also called endophenotypes. 
Gottesman and Gould (Gottesman and Gould, 2003) define endophenotypes as 
follows: 
   ” 1.   The endophenotype is associated with illness in the population. 
2. The endophenotype is heritable. 
3. The endophenotype is primarily state-independent (manifests in an 
individual whether or not illness is active). 
4. Within families, endophenotype and illness co-segregate.[...] 
5. The endophenotype found in affected family members is found in non-
affected family members at a higher rate than in the general population.“ 
 
As discussed in previous chapters, medication or disease activity represent 
confounds on cognitive networks; isolating a disease related causal component is 
therefore challenging (Meyer-Lindenberg, 2012). One approach to control for 
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such confounds is to study unaffected first-degree relatives in heritable 
neurodevelopmental conditions.  
Spencer and colleagues (2012) employed the Embedded Figure Task in patients 
with autism, their unaffected siblings and healthy controls. Autism is a presumed 
neurodevelopmental condition with a high heritability and siblings of patients 
have a more than 20 times higher risk than the general population to develop the 
same condition. Both patients and healthy siblings showed atypical activation 
patterns with reduced activation in the visual association cortex and enhanced 
activation in fronto-temporal regions compared to controls.  
In an fMRI working memory study, unaffected, cognitively intact siblings of 
patients with schizophrenia showed increased activation within the dorsolateral 
prefrontal cortex (DLPFC) when compared to controls (Callicott et al., 2003). The 
same “imaging trait” had been previously described in patients with schizophrenia 
(Spence et al., 1998; Weinberger et al., 1986). As abnormal activation patterns 
within the DLPFC in patients with schizophrenia or their siblings has been a 
robust finding in several studies (Cannon and Keller, 2006; Karlsgodt et al., 2007; 
Perlstein et al., 2001), it has been successfully used as a quantitative imaging 
trait in combination with candidate gene studies, e.g. COMT (Egan et al., 2001), 
and in genome-wide association studies (GWAS) (Potkin et al., 2009).  
 
Though imaging studies in first-degree relatives of epilepsy patients are rare, 
behavioural and neurophysiological studies have identified potential 
endophenotypes in juvenile myoclonic epilepsy, the syndrome relevant for this 
thesis:   
 
Neuropsychological studies 
Levav et al. (2002) investigated 10 JME families, 25 with childhood absence 
epilepsy (CAE), 30 TLE and 16 healthy control families. One affected family 
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member defined epilepsy families. The test battery was age-group adapted and 
assessed sustained attention, encoding and verbal memory, executive and 
focused attention and attentional flexibility/regulation of impulsivity. Comparing all 
scores, relatives' performance tended to fall between those of the patients' group 
and controls'. Among the relatives, JME relatives acquired the lowest scores for 
sustained attention and mental flexibility.  
Iqbal and colleagues (2015) assessed 22 pairs of JME patients and unaffected 
siblings during and without video-EEG monitoring. Performance was compared to 
a control group. The neuropsychological test battery included tests of 
intelligence, visual-spatial skills, language, memory, attention and reaction time, 
as well as executive functions. Patients were more impaired than controls on 
tests of semantic and phonemic fluency. Siblings held an intermediate position 
between patients and controls and significantly differed from controls on 
psychomotor speed and phonemic verbal fluency. In addition, patients more 
frequently reported behavioural traits associated with executive dysfunction (i.e. 
impulsivity) on a behaviour rating scale. Impaired cognitive performance 
appeared to be independent of subclinical EEG discharges, as no discharges 
were recorded during testing.  
Wandschneider et al. (2010) investigated performance on a complex prospective 
memory (PM) paradigm in JME patients, their unaffected siblings and healthy 
controls. Prospective memory (PM) describes the ability to fulfil previously 
planned intentions (Ellis, 1996). Successful PM performance is indispensable for 
managing activities of daily living, for example, remembering to post a letter or to 
attend a doctor’s appointment. 
The employed PM paradigm allowed the evaluation of different phases of 
prospective memory, namely intention formation, intention retention, intention 
initiation and execution. Patients and siblings developed less complex plans than 
controls during intention formation. During intention execution, both groups 
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presented significantly more rule breaks than controls. Patients additionally 
completed fewer tasks and presented impairment in some executive functions, 
i.e. verbal fluency and response inhibition. It is assumed that PM performance is 
highly dependent on executive functions (Kliegel et al., 2000). Hence, 
performance during each PM phase was correlated post-hoc with scores on 
executive function measures. As expected, planning abilities predicted overall 
performance during intention formation, and response inhibition and planning 
performance during intention execution. In a post-hoc subgroup analysis, there 
was only a significant correlation between intention formation and planning in the 
healthy control group. Surprisingly, patients and siblings were unimpaired on a 
specific measure for planning performance (Tower of London task). This may 
indicate that patients and siblings fail to use their planning abilities efficiently 
when they are needed in more cognitively demanding tasks, such as the PM 
paradigm.  
 
Neurophysiological studies 
Atakli and colleagues (1999) reported 27% asymptomatic siblings with EEG 
abnormalities. 10.4% had 4-6 Hz spike/polyspike and wave paroxysms, 10.4% 
slow wave paroxysms, and 6.25% focal spike and wave activity during 
hyperventilation. 
A Transcranial Magnetic Stimulation (TMS) study (Akgun et al., 2009) showed a 
higher motor threshold (RMT), a longer CSP (cortical silent period) and a shorter 
central motor conduction (CMCT) time in JME patients. In unaffected siblings, 
CSP was also prolonged, suggesting a potential impairment of supraspinal or 
intracortical inhibitory mechanisms. Similarly, Badawy and colleagues (2013) 
employed TMS to measure motor threshold and paired pulse transcranial 
magnetic stimulation in patients with focal or genetic generalised epilepsy 
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syndromes and their unaffected siblings. In all siblings of epilepsy patients, 
cortical excitability was higher than in healthy controls; however, among siblings 
it was most prominent in siblings of JME patients. Only drug naïve new onset 
JME patients had a lower motor threshold (i.e. increased excitability) than their 
unaffected siblings. 
 
 
1.3.9 Structural neuroimaging in JME  
Clinical MRI in JME patients are normal, however volumetric studies of high- 
resolution MRI identified changes of the mesial frontal and orbitofrontal cortices 
(Alhusaini et al., 2013; O’Muircheartaigh et al., 2011; Woermann et al., 1999), 
and anterior cingulate (Cao et al., 2013). Imaging analysis of the micro-
architecture in JME, employing DTI-based parcellation and tractography, 
revealed increased structural connectivity between central motor and prefrontal 
cognitive (pre-SMA) networks, but decreased connectivity within prefrontal 
cognitive networks (pre-SMA to orbitofrontal), providing an explanation for both 
cognitively triggered jerks and cognitive impairment in JME (Vollmar et al., 2012). 
Thalamic volume changes were identified within 12 months of disease onset, 
indicative of an early or neurodevelopmental disruption of the thalamo-fronto-
cortical circuit (Pulsipher et al., 2009). This was corroborated by a longitudinal 
study describing altered cortical developmental trajectories in recent onset JME 
cases compared to their peers with attenuation of age-related decline in cortical 
volume, thickness, and surface area. These changes were mainly observed in 
higher-association fronto-parietal-temporal regions (Lin et al., 2014). 
  
	 47 
1.4 Sudden Unexpected Death in Epilepsy 
 
1.4.1 Definitions and epidemiology 
SUDEP (sudden unexpected death in epilepsy) refers to a sudden death, often 
occurring after a generalised convulsive seizure, in a person who suffers from 
epilepsy but is otherwise healthy. It is the most common cause of epilepsy 
related death. (Surges and Sander, 2012) 
It has been defined as “sudden, unexpected, witnessed or unwitnessed, 
nontraumatic and non-drowning death in patients with epilepsy, with or without 
evidence for a seizure and excluding documented status epilepticus, in which 
postmortem examination does not reveal a toxicologic or anatomic cause of 
death.” (Nashef, 1997; Nashef et al., 2012) 
A recent revision of the SUDEP definition distinguishes definite SUDEP, where 
autopsy or direct observation of the terminal event exclude a concomitant 
condition as cause of death, from probable SUDEP, where autopsy was not 
carried out, and possible SUDEP, where a competing cause of death is present. 
(Nashef et al., 2012) In Near-SUDEP, an individual with epilepsy is successfully 
resuscitated from a cardiorespiratory arrest and investigations cannot identify a 
structural cause. (Nashef et al., 2012) 
Patients with epilepsy have a 20-fold increased risk of sudden death compared to 
the general population (Ficker et al., 1998). SUDEP risk varies depending on the 
type of epilepsy population, with the highest incidence in patients with chronic 
refractory epilepsy (1.1 to 5.9 per 1000 person-years (Annegers et al., 2000; 
Timmings, 1993)), epilepsy surgery candidates and particularly in those who 
continue experiencing seizures after surgery (6.3 to 9.3 per 1000 person-years; 
Shorvon and Tomson, 2011). As it often occurs in relatively young adults, it is 
associated with a disproportionate number of potential years of life lost and 
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second only to stroke when compared to other frequent neurological conditions 
(Thurman et al., 2014). 
 
1.4.2 Risk factors  
A recent meta-analysis of four major case-control studies of SUDEP compared 
289 SUDEP cases with 958 living epilepsy controls. The frequency of 
generalised tonic clonic seizures (GTCS) was identified as the major risk factor of 
SUDEP, with an odds ratio of 15.46 (95% confidence interval (CI) 9.92 – 24.10) 
for at least three GTCS per year (Hesdorffer et al., 2011). Further epilepsy 
related significant risk factors, but with an odds ratio < 2, were duration of 
epilepsy longer than 15 years (OR 1.95, 95% CI 1.45 – 2.63); disease onset 
below the age of 16 (OR 1.72, 95% CI 1.23 – 1.40) and polytherapy (OR 1.95, 
95% CI 1.09 – 3.47). After adjusting for GTCS frequency, a further pooled 
analysis of three case-control studies concluded that neither the use of specific 
AEDs nor polytherapy were associated with increased SUDEP risk (Hesdorffer et 
al., 2012).  
Most deaths occur unwitnessed, during night time and in sleep (Nashef et al., 
1998; Nobili et al., 2011; Ryvlin et al., 2013). There is evidence that nocturnal 
seizures constitute an important independent risk factor for SUDEP (OR 3.9, 95% 
CI 2.5–6.0 when compared to living controls) (Lamberts et al., 2012), and 
nocturnal supervision leads to a significant decrease of SUDEP risk (Langan et 
al., 2005). Similarly to sudden infant death syndrome (SIDS), most deaths 
occurred in prone position (Liebenthal et al., 2015). 
A meta-analysis of placebo-controlled randomised trials reports a more than 7-
fold decrease of SUDEP incidence in those treated with efficacious AED doses 
compared to those receiving placebo (Ryvlin et al., 2011), stressing the 
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importance to revise treatment in patients with refractory epilepsy in order to 
reduce SUDEP risk. 
 
 
1.4.3 Neuropathological findings 
A recent audit of 154 post mortem reports from UK neuropathology centres 
(Thom et al., 2015) identified macroscopic brain abnormalities in 52% of cases, 
including malformations of cortical development (MCD), perinatal infarcts and low 
grade tumours. Mild brain swelling was reported in almost a third of cases. 
Abnormalities of the hippocampus, including asymmetry, mal-rotation and 
volume-loss, were present in 28% of cases. Microscopic pathology (in 89% of 
cases) mainly identified malformations (MCD and vascular, 15%), tumours (7%) 
and hippocampal sclerosis (21%). Toxicological studies report reduced or non-
detectable post-mortem AED levels in patients presumed to be on medication, 
though post-mortem AED levels may be unreliable (Tomson et al., 2016; Zhuo et 
al., 2012). 
Post-mortem genetic analysis for common long QT-syndrome (LQTS) genes in 
an Australian SUDEP cohort revealed variants in KCNH2 and SCN5A in 13% of 
cases, stressing the importance of post mortem testing for relevant ion channel 
genes (Tu et al., 2011). 
 
 
1.4.4 Theories of SUDEP mechanisms 
1.4.4.1 Respiratory mechanisms 
As demonstrated in a retrospective study of 16 SUDEP cases while being 
monitored on video-telemetry units (MORTEMUS study (Ryvlin et al., 2013), 
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SUDEP usually occurs after a generalised tonic-clonic seizure followed by early 
centrally mediated fatal cardiorespiratory dysfunction. However, respiratory 
parameters other than respiratory rate were not monitored, and further factors, 
such as upper airway obstruction and prone position (14 of 16 cases), may well 
have contributed to hypoxemia apart from centrally driven apnoea.  
Ictal hypoxemia has been described in one third of generalised and partial 
seizures and has been associated with temporal onset and contralateral seizure 
spread (Bateman et al., 2008). Central mechanisms of hypoventilation are 
supported by stimulation studies of mesial temporal and insular regions resulting 
in respiratory inhibition (Dlouhy et al., 2015; Kaada and Jasper, 1952).  
Several animal models, including DBA/1, DBA/2 mice and Htr2c knockout mice, 
confirm seizure-induced respiratory arrest and death. In DBA/2 mice, it has been 
shown that seizures inhibit the ponto-medullary respiratory control network 
(Massey et al., 2014). Aiba and Noebels (2015) recently demonstrated that in 
mice carrying mutations in Kv1.1 potassium channels (−/−) and Scn1a sodium 
ion channels (+/R1407X) seizures lead to irreversible spreading depression in the 
dorsal medulla, preventing auto-resuscitation via these cardiorespiratory centres.  
 
 
1.4.4.2 Cardiac mechanisms 	
Seizures are associated with a variety of cardiac abnormalities, including brady- 
and tachyarrhythmias, asystole and repolarization abnormalities, such as QT 
prolongation. Tachycardia is much more common during seizures (57% of all 
seizures) than bradycardia (2%) and asystole (0.5%), and is correlated with 
seizure generalisation. There is evidence that arrhythmias in some cases may be 
secondary to hyperkapnia and hypoxia. (Massey et al., 2014; Rugg-Gunn et al., 
2016)  
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Heart rate variability (HRV) is a measure of autonomic nervous system control on 
cardiac activity and reduced HRV has been associated with an increased rate of 
cardiac death. In chronic refractory epilepsy, HRV is interictally and peri-ictally 
depressed, particularly in patients with temporal lobe epilepsy and at night 
(Massey et al., 2014; Tomson et al., 2016), and may normalise with successful 
epilepsy surgery in TLE (Hilz et al., 2002). A potential role of HRV in SUDEP 
pathomechanisms remains however unproven. 
 
 
 
1.4.4.3 Central nervous system mechanisms and EEG markers 	
Postictal generalised EEG suppression (PGES) is frequently observed after 
generalised tonic-clonic seizures and has been reported in monitored SUDEP 
cases (Lhatoo et al., 2010; Seyal et al., 2012). It is linked with ictal respiratory 
dysfunction and duration of the tonic phase (Lhatoo et al., 2010). The 
mechanisms underlying PGES are unclear but it has been suggested to reflect 
central cerebral shut-down leading to inhibition of respiratory centres in the 
brainstem (Lhatoo et al., 2010). Later risk of SUDEP was associated with longer 
PGES in a case-control study of monitored patients, suggesting that PGES could 
be a predictor of SUDEP (Lhatoo et al., 2010). However, these findings have not 
been replicated so far (Surges et al., 2011). 
 
 
1.4.4.4 The role of Serotonin 	
Serotonin (5-HT) plays an important role in respiratory control and its dysfunction 
may therefore increase the risk of SUDEP, as shown in several animal models.  
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5-HT neurons are mainly located in the raphe nuclei of the brainstem and project 
to and stimulate the respiratory neurons in the nucleus of the solitary tract (NTS), 
nucleus ambiguus, pre-Bötzinger complex and other nuclei in the brainstem. 
Serotonin neurons in the midbrain cause cortical arousal as response to 
hyperkapnia. Mice lacking the 5-HT2C receptor present with seizures and 
associated rapid death due to respiratory arrest. (Richerson et al., 2016) Peri-
ictal respiratory arrest in DBA/2 mice has been prevented by treatment with 
selective serotonin reuptake inhibitors (SSRI) and in humans with refractory 
epilepsy, SSRIs have been associated with less severe ictal hypoxaemia 
(Bateman et al., 2010; Massey et al., 2014). Lmx1bf/f/p mice, where 5-HT neurons 
are absent, present with apnoea, high mortality in the neonatal period and do not 
adequately arouse during sleep as response to hyperkapnia. They also have a 
decreased seizure threshold and are at risk of ictal respiratory arrest. (Hodges et 
al., 2009; Massey et al., 2014) 5HT dysfunction has also been reported in 
another sudden death entity, sudden infant death syndrome (Massey et al., 
2014). 
 
 
1.4.4.5 Adenosine theory 	
Adenosine is released as a response to high-energy consumption, e.g. caused 
by a seizure, to suppress neuronal activity and limit neuronal injury, hence acting 
as an endogenous anticonvulsant. However, adenosine is also involved in 
respiratory control in the brainstem and increased activation of adenosine 
receptors there will lead to suppression of respiratory and cardiovascular 
functions. Prolonged seizures can lead to impaired clearance of released 
adenosine, causing over-activation of adenosine receptors, which may trigger 
apnoea and cardiac arrest. (Shen et al., 2010) 
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1.4.5 Genetic studies 
There is evidence of genetic susceptibility from genes that have been identified in 
individuals who died from SUDEP. These include genes of potentially fatal 
cardiac arrhythmias, such as LQTS and catecholaminergic polymorphic 
ventricular tachycardia (CPVT), and genes associated with specific epilepsy 
syndromes with frequent sudden death, most commonly Dravet syndrome. 
(Goldman, 2015) 
Discovery of the cardiac voltage-gated sodium channel SCN5A in the brain has 
lead to the hypothesis that mutations in ion channels expressed both in the brain 
and heart may cause a combined neuro-cardiac phenotype (Goldman et al., 
2016; Hartmann et al., 1999). In LQTS, which is most commonly caused by 
mutations in KCNH2, KCNQ1 and SCN5A, a seizure phenotype (i.e. personal or 
family history of seizures) has been described in almost a third of patients 
(Massey et al., 2014). Mice with a point mutation in the LQTS gene KCNQ1 
accounting for 50 % of LQTS cases have cardiac arrhythmias, seizures and 
sudden death (Massey et al., 2014). Catecholaminergic polymorphic ventricular 
tachycardia is a dysrhythmia presenting with stress-induced syncope and is 
associated with a high mortality in young adults (Postma et al., 2005). It is 
caused by a defect in the ryanodine receptor (RYR2) and similar to LQTS, a 
combined phenotype of arrhythmias and seizures has been described in families 
affected by RYR2 mutations (Goldman et al., 2016). 
Dravet syndrome is a severe refractory epilepsy syndrome with childhood onset 
after the first year of life. Many patients succumb to sudden death. The genetic 
cause is in 80% of cases a loss-of-function mutation in SCN1A, which is both 
expressed in brain and heart, facilitating potentially fatal cardiac arrhythmias. 
(Massey et al., 2014) 
Two recent studies were carried out in 18 (Leu et al., 2015) and 61 SUDEP 
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(Bagnall et al., 2015) cases respectively. Leu and colleagues (2015) analysed 
rare, protein-changing variants from whole-exome sequences in the SUDEP 
cohort and identified a significantly increased genome-wide burden of deleterious 
variants, suggesting a polygenic SUDEP causation. Bagnall and colleagues 
(2015) identified candidate pathogenic variants in LQTS-associated genes in 7%, 
in dominant variant arrhythmia genes in 15% and in epilepsy genes in 25% of 
SUDEP cases. Mutations in epilepsy genes were most commonly found in 
DEPDC5 (six cases).  
 
 
1.4.6 Imaging studies 
Imaging studies implicate areas of cortical and brainstem autonomic control in 
patients at risk of SUDEP. 
Tang and colleagues (Tang et al., 2014) employed resting state functional MRI 
connectivity analysis of thirteen regions of interest, involved in cardiorespiratory 
control, in patients at high and low risk of SUDEP. High risk patients were defined 
as those with early onset (< 16 years of age) intractable epilepsy, frequent GTCS 
(>3/year) and polytherapy. Low risk patients did not have any of the above risk 
factors. The high risk patients showed a significant decrease in the resting-state 
functional connectivity between the pons and the right thalamus, the midbrain 
and the right thalamus, bilateral anterior cingulate cortex and the right thalamus, 
and between the left and right thalamus when compared to the low risk group. 
Mueller and colleagues (2014) described volume loss in brainstem regions 
involved in autonomic control, predominantly in the region of the periaqueductal 
grey, colliculi raphe and reticular formation and extending into the diencephalon 
in patients with mesial temporal lobe epilepsy (TLE). This was more severe and 
even extending to the medulla oblongata in two cases of mesial TLE who later 
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died of SUDEP. In addition, graph analysis was indicative of impaired interaction 
between those regions in the SUDEP cases. 
 
 
 
1.4.7 Commonalities with sudden death in infants and toddlers 
Several similarities between SUDEP, sudden infant death syndrome (SIDS) and 
sudden unexplained death in childhood (SUDC) have been reported. SIDS is 
defined as sudden death of an infant below the age of 12 months, whereas 
SUDC occurs in toddlers. As in SUDEP, SIDS and SUDC remain unexplained by 
most mortem and death scene examination. Both more often occur unwitnessed, 
presumably in sleep and victims are found in prone position. (Krous et al., 2004, 
2005) There has been an association with a family history of febrile seizures in 
SUDC and some authors argue that SIDS and SUDC may be caused by not yet 
diagnosed epilepsy and potentially autonomic seizures or seizures with apnoea 
only (Kinney et al., 2015; Watanabe et al., 1982). Neuropathological studies in 
SIDS report brainstem abnormalities, i.e. brainstem gliosis and abnormalities of 
medullary nuclei containing 5-HT neurons (Paine et al., 2014; Richerson et al., 
2016). Similar to SUDEP, SIDS has been linked to 5-HT dysfunction leading to 
respiratory and arousal deficits (Kinney et al., 2009b). 
Dentate gyrus abnormalities in the hippocampus were reported in a large subset 
of 153 sudden infant death syndrome cases, and may reflect defective neuronal 
migration and proliferation (Kinney et al., 2015). Hippocampal and temporal lobe 
anomalies were also described in 62% of sudden unexplained death in childhood 
cases (Kinney et al., 2009a),  creating a potential link between 
hippocampal/temporal lobe maldevelopment, susceptibility to seizures, and 
sudden death. Microdysgenetic features of the hippocampal formation included 
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dentate gyrus and subicular anomalies, granular nodular heterotopia, 
subventricular neuroblasts and hamartia, all indicative of aberrant 
neurodevelopment.  
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Chapter 2: Neuroimaging in epilepsy  
2.1 Structural MRI 
2.1.1 Clinical MRI sequences 
Structural brain imaging is part of the diagnostic work-up in epilepsy and of 
particular importance if epilepsy surgery is considered, since identification of an 
epileptogenic lesion will give the patient a higher chance of becoming seizure-
free after surgery (Duncan et al., 2016). The basic imaging protocol as 
established by the ILAE includes whole-brain T1-weighted and T2-weighted 
imaging acquired with the minimum slice thickness possible in two orthogonal 
planes, and a volumetric T1-weighted acquisition for three-dimensional 
reconstruction (“Recommendations for neuroimaging of patients with epilepsy. 
Commission on Neuroimaging of the International League Against Epilepsy,” 
1997).  
After a review of presurgical MRI data in the epilepsy centre in Bonn, Germany, 
most epilepsy centres use an optimized MRI-protocol for all epilepsy patients as 
follows (Saini et al., 2009; Wellmer et al., 2013): 
A three-dimensional volumetric T1-weighted imaging with 1 mm isotropic voxels, 
providing excellent grey-white matter contrast to identify e.g. malformations of 
cortical development (MCD); T2-weighted imaging (axial and coronal) to assess 
hippocampal architecture and cystic tissue components of other lesions; fluid-
attenuated inversion recovery imaging (FLAIR; axial and coronal) to identify 
hippocampal sclerosis, inflammation, tumours and MCDs; and T2* gradient echo 
or susceptibility-weighted imaging (axial) for vascular and calcified lesions, such 
as cavernomas and arteriovenous malformations. 
Imaging diagnostics in epilepsy have greatly advanced in the last decades, 
mainly due to improvement of scanners, acquisition protocols and imaging 
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processing (Duncan et al., 2016). Despite this, no lesions are identified with 
visual evaluation of conventional MR imaging in up to 30% of patients with 
presumed focal epilepsies.  
However, in those cryptogenic or MRI-negative cases undergoing surgery, histo-
pathological examination of the resected specimens often reveals subtle 
epileptogenic lesions, in most cases MCDs (Bernasconi et al., 2011). 
This has led to increased application of imaging post-processing techniques, 
mainly employed on three-dimensional T1 volume scans, with the goal to 
improve the detection of subtle abnormalities of brain tissue overlapping with the 
epileptogenic zone, undetectable on visual inspection. 
The field of computational neuroanatomy, or morphometry, has much advanced 
and to date, several fully automated post-processing imaging tools are available 
to capture and quantify regional differences of brain structure through 
mathematical models of tissue characteristics and cortical features, such as 
cortical thickness, surface area and folding complexity. (Bernasconi et al., 2011) 
 
Beyond their application in individual patients in a clinical setting, these 
techniques have been broadly used to identify general patterns of structural 
abnormalities in groups of different epilepsy syndromes. Identification of patterns 
of structural pathology reaching beyond the presumed epileptogenic focus in 
“focal” epilepsy syndromes, and, vice versa, detection of regional structural 
abnormalities in presumed genetic “generalised” epilepsies has challenged the 
traditional dichotomy of focal versus generalised epilepsy syndromes.  
 
In the following, automated post-processing tools relevant to this thesis will be 
discussed. 
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2.1.2 Automated post-processing tools 
2.1.2.1 Voxel-based morphometry 
Voxel-based morphometry (VBM) is a fully automated, objective image-
processing framework to assess regional differences in tissue volume at a voxel 
level and is one of the most popular computational anatomy tools. Usually, grey 
matter is examined but it can also be used to assess white matter changes, 
though with decreased sensitivity. (Ashburner and Friston, 2000)  
The software package Statistical Parametric Mapping (SPM), which has been 
designed for the analysis of brain imaging data trough the assessment of 
spatially extended statistical processes, offers one option to analyse VBM data.  
 
Preprocessing 
There are three basic preprocessing steps, including tissue classification, 
normalisation to a common space and spatial smoothing. 
 
Tissue classification 
Prior to tissue segmentation, non-brain parts are removed via skull-stripping. 
Inhomogeneities of the magnetic field will cause intensity nonuniformities, 
resulting in different intensities for the same tissue class in different regions. This 
is corrected for by using bias correction prior to applying tissue segmentation. 
The tissue is then segmented into grey matter, white matter and cerebrospinal 
fluid (CSF). Additional probability maps can be used to guide the segmentation 
process, i.e. the segmentation process is restricted and driven by a map for each 
tissue class that indicates how probable it is to be present at a certain voxel in 
the image. These tissue probability maps are problematic in cohorts that may 
deviate from these maps, e.g. children.  
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Normalisation 
Images are normalised to a standard space to enable voxel-wise comparisons 
across subjects. There are two main normalisation methods available in 
Statistical Parametric Mapping (SPM): a low-dimensional SPM default 
normalisation, which uses pre-existing symmetric tissue probability maps as a 
reference atlas, and a high-dimensional DARTEL (Diffeomorphic Anatomical 
Registration using Exponentiated Lie algebra) normalisation, which creates a 
study specific reference atlas (Ashburner, 2007). In DARTEL normalisation, 
registration starts by creating a mean of all images. This is then used as initial 
template; the images are registered to this template and subsequently averaged 
again. This procedure is repeated several times and eventually results in a highly 
accurate mean template and deformation fields, describing how local structures 
were adjusted to match the mean template. Deformations are finally used to warp 
the initial images into standard space. 
Voxel-wise volume changes due to normalisation can be derived from the 
deformation fields as Jacobian determinants. This information can be used to 
apply modulation, which means that the normalised grey matter segments are 
multiplied with the Jacobian determinants to correct for volume changes due to 
normalisation. Hence original local volumes will be preserved even in standard 
space. 
 
Spatial smoothing 
The normalised tissue segments are then convolved with a Gaussian function, 
which is referred to as smoothing. Since statistical analysis will be done with 
parametric tests, smoothing is done to ensure that random errors have a 
Gaussian distribution. In addition, smoothing compensates for small registration 
errors and renders the analysis sensitive to effects that approximately match the 
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size of the smoothing kernel. Usually, a smoothing kernel of full width at half 
maximum of 4-12 mm is recommended. After smoothing, each voxel represents 
a weighted mean of its own and neighbouring voxels’ values. 
 
 
SPM8 toolbox 
The SPM8 toolbox is an extension of the “classical” VBM8 method, but uses a 
different segmentation approach. 
Firstly, the segmentation approach is based on an adaptive Maximum A Posterior 
(MAP) technique without the need for a priori information about tissue 
probabilities. The Tissue Probability Maps are only used for spatial normalisation.  
The resulting MAP estimation is adaptive, as local parameter variations (i.e. 
means and variance) are modelled as slowly varying spatial functions (Rajapakse 
et al., 1997), accounting for intensity inhomogeneities and other local variations 
of intensity.  
Secondly, a Partial Volume Estimation (PVE) with a mixed model of at most two 
tissue types is used during segmentation. Images are initially segmented into 
grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) based on the 
MAP estimation. This is followed by a PVE of two additional mixed classes, 
namely GM-WM and GM‐CSF. As single voxels may contain more than one 
tissue type, this will result in an estimation of the fraction of each tissue type 
present in each voxel. 
Thirdly, two denoising methods are applied:  A spatially adaptive nonlocal means 
(SANLM) denoising filter (Manjón et al., 2010) that will remove noise while 
preserving edges; and a classical Markov Random Field (MRF) approach to 
include spatial prior information of adjacent voxels into the segmentation 
estimation (Rajapakse et al., 1997). 
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Finally, for DARTEL normalisation an already existing DARTEL template in 
Montreal Neurological Institute (MNI) space is used, which was derived from 550 
healthy control subjects of the IXI‐database (http://www.braindevelopment.org) 
and is provided in MNI space for six different iteration steps of DARTEL 
normalisation.  
(http://dbm.neuro.uni-jena.de/vbm8/VBM8-Manual.pdf) 
 
 
Statistical analysis 
Parametric statistical testing is usually applied in a mass-univariate approach, i.e. 
the same test is applied to each voxel simultaneously. The general linear model 
and Gaussian random field theory to account for multiple comparisons are 
employed as described for fMRI in chapter 2.2.4. 
 
 
 	  
	 63 
2.2 Functional MRI 
2.2.1 Principles of functional MRI 
Functional MRI is a non-invasive imaging technique that utilizes regional 
haemodynamic changes as a surrogate marker of neuronal activity. It relies on 
the principle that regional cortical increase of neural activity causes a local 
increase in cerebral blood flow (rCBF) and volume (rCBV). Resulting changes of 
the magnetic properties of blood can then be imaged with fMRI.  
Functional imaging techniques measure signal changes caused by the blood-
oxygen-level-dependent (BOLD) contrast, which describes the susceptibility 
changes of oxygenated and deoxygenated blood. 
The change in regional blood flow exceeds the additional metabolic demand so 
that there is a relative increase of oxygenated arterial blood to deoxygenated 
venous blood at the capillary level and hence a decrease of deoxyhaemoglobin 
concentration. While oxyhaemoglobin has diamagnetic properties, 
deoxyhaemoglobin is paramagnetic and leads to local inhomogeneities of the 
magnetic field and a shortened effective spin–spin relaxation time T2*. As cortical 
activation is associated with a reduction of deoxyhaemoglobin concentration, it 
results in a local prolongation of the T2* time. Magnetic resonance sequences, 
such as echo planar imaging (EPI), are highly sensitive to local T2* changes and 
can hence measure the signal increase in activated brain regions.  
As the signal increase is only about 2% and regional changes in rCBF and rCBV 
last for seconds, data sampling must be sufficiently long and usually implies 
repeated scanning of the brain region of interest with a repetition time (TR) of 
several seconds to collect a few hundred data volumes over time. (Logothetis, 
2008) 
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2.2.2 Preprocessing of fMRI data 
2.2.2.1 Realignment 
During this first step of preprocessing, the imaging time series are realigned to 
the same space to correct for subject’s head motion during the scanning.  
This step is important for data interpretation, as head movement even by a few 
mm will result in different positions of every volume in the acquired time series. 
Hence it is not warranted that each voxel within the time series represents the 
same anatomical region throughout the whole fMRI task.  
 
2.2.2.2 Normalisation 	
To enable group analyses and comparisons, each subject’s data have to be 
transformed into a standard anatomical space to ensure a voxel-wise 
comparability. This process is called spatial normalisation and entails creating a 
mean image from the realigned time series to provide a better signal to noise 
ratio than a single volume. With a combination of linear and non-linear 
transformations, the mean image is then normalised to a template image in 
common space and resulting transformation parameters are applied to the whole 
time series of images. 
As the data is in standard anatomical space, results can then be reported in 
standardized coordinate systems. (Ashburner et al., 2000) 
 	
2.2.2.3        Smoothing 	
Spatial smoothing creates an average of each voxel value and its neighbouring 
voxels, resulting in a blurring of the brain image. Smoothing increases the signal-
to-noise ratio and as most fMRI acquisitions contain a significant amount of 
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noise, smoothing helps to achieve more consistent regional image intensities.  
Smoothing is also advised prior to statistical analysis in SPM, as parametric tests 
are based on the assumption that the data follow Gaussian distribution, which is 
satisfied by smoothing.   
A Gaussian kernel of known width is applied to each voxel. The width of the 
Gaussian is described as the width of the kernel, at half of the maximum of its 
height - the Full Width at Half Maximum (FWHM). The FWHM usually has 4-16 
mm and approximately a FWHM of twice the voxel size results in appropriate 
smoothness to carry out statistical analysis. (Friston et al., 2000) 
 
 
2.2.3 Statistical analysis 
Statistical parametric mapping is utilized for statistical analysis of functional 
mapping, i.e. fMRI studies. Statistical parametric maps (SPMs) are also known 
as T- or F-maps, which refers to the concept that under the null-hypothesis their 
distribution of voxel values is usually according to the F or student’s T distribution 
(Friston, 2005). SPMs analyse spatially extended data by constructing complex 
statistical processes to test hypotheses about regionally specific effects. To 
achieve this, statistical parametric mapping mainly utilizes  
1. the general linear model (GLM) to explain spatially continuous data and 
2. the Gaussian random field theory to account for the problem of multiple 
comparisons when analysing brain volumes by adjusting p values to 
control for false positive rates. 
 
2.2.3.1 The general linear model 	
The general linear model is described by the equation 
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y = Xß + ε 
where the measured signal y is a linear combination of explanatory variables in 
the matrix X and a residual error term ε. The contribution of each explanatory 
variable to the total signal is unknown, which is expressed by the unknown 
scaling factor β for each variable.  
In the design matrix of the fMRI model, each row corresponds to an observation 
(i.e. each scan) and each column to a model parameter, which may correspond 
to designed effects or confounds, and the residual error column. The design 
matrix is displayed graphically by SPM.  
The relative contribution of each of these columns to the observed effect is 
controlled by the parameters β, which can be estimated using standard least 
squares. Some of these parameters may be of interest, and the remaining of no 
interest and are hence treated as nuisance variables. The null hypothesis (i.e. no 
relationship between the experimental model and the voxel data) can be tested 
by calculating T statistics for a particular linear combination, or contrast. T-
statistics are obtained by dividing the contrast of parameter estimates by the 
standard error of that contrast. 
Usually, a mass-univariate approach is used, in which every voxel location 
across images is tested for effects by employing a general linear model. Variance 
is firstly analysed at each voxel. T-statistics of these results are then created, 
followed by a Z score equivalent for the T-statistic before creating a statistical 
parametric map, or T-map.  
False positives are accounted for by correcting the significance value for multiple 
comparisons. An inference is then drawn from this statistical parametric map and 
voxels in which an effect is reliably present are located.  
Prior to the statistical analysis, fMRI time series are temporally filtered in order to 
remove low-frequency noise. Regressors are then convolved with the 
haemodynamic response function (HRF) of the BOLD effect to account for its 
	 67 
delayed response. The scans cannot be treated as independent observations 
since one scan is usually correlated to the following. This is accounted for by a 
temporal smoothing function of the time-series. 
 	
2.2.3.2 Movement parameters 	
The magnetic field of an MRI scanner contains regional inhomogeneities and the 
T2* weighted acquisitions used for fMRI are particularly susceptible to these 
effects, causing a signal change of up to 10%. If a study participant moves his 
head during the experiment in one of these zones of regional intensity changes, 
the acquired voxels will have a higher value, which requires further correction 
beyond the realignment during the preprocessing procedure. Hence realignment 
parameters resulting from the preprocessing steps are included as covariates 
into the design matrix. Including movement parameters into the model also helps 
to control for the impact this movement may have had on cognitive performance 
at that time (e.g. the subject is coughing during the experiment and hence cannot 
fully concentrate on the task). 
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Chapter 3: Imaging biomarkers of epilepsy 
 
3.1 Concept of biomarkers in epilepsy 
Biomarkers are objectively measurable characteristics of a normal or pathological 
biological process (Trusheim et al., 2007). Within epilepsy research, recent 
efforts have been made to identify reliable biomarkers to advance the 
understanding of disease-mechanisms, or epileptogenesis, to individualize and 
optimize treatment and enhance treatment prediction (Engel, 2011). Ideally, 
biomarkers can be a direct measure of disease activity and treatment effects, an 
indicator of how well a patient functions, and hence may substitute clinically 
meaningful endpoints to increase the yield of clinical trials (Koepp, 2016; 
Pitkänen et al., 2016).  
This is particularly necessary since 
1. the diagnosis of epilepsy relies on seizure occurrence, although it is now 
known that epilepsy encompasses far more than seizures, e.g. cognitive 
impairment and psychiatric comorbidities, which can even precede 
seizure onset and progress beyond seizure control (e.g. (Camfield and 
Camfield, 2009; Jennum et al., 2011)). In presumed genetically 
determined epilepsies, few neuro-imaging studies so far suggest that 
functional and structural alterations in neural circuits are already present 
at disease onset (Lin et al., 2014; Pulsipher et al., 2009) but these cannot 
be fully related to epileptogenesis/neurodevelopment and separated from 
medication and seizure effects. 
2. epilepsy is mainly treated with antiepileptic medication in a trial-and-error 
approach, as so far, treatment response and occurrence of side effects 
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cannot be predicted after the first seizure. Biomarkers are necessary to 
identify those likely to respond to treatment or experience side effects. 
3. epilepsy is associated with a high morbidity and mortality, with SUDEP 
constituting one of its worst outcomes. Though risk factors for potentially 
fatal disease are known, biomarkers for early prediction of progressive 
and pharmacoresistant disease are necessary to tailor treatment early 
and to develop and evaluate the success of prevention strategies.  
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3.2 Imaging biomarkers in epilepsy 
Advances in imaging techniques and the recent advent of meta-analytic 
techniques have helped to understand commonalties in imaging findings. For 
example in fMRI, reproducible patterns of activation or deactivation elicited by 
cognitive tasks could be identified, such as the default mode network, a set of 
brain regions, which are commonly deactivated during goal-directed tasks 
(Bullmore, 2012; Raichle et al., 2001). Several “imaging traits” have so far been 
identified in complex neuropsychiatric diseases, such as schizophrenia or autism 
(Ecker et al., 2010; Spence et al., 1998; Weinberger et al., 1986), rendering 
neuroimaging an attractive tool to analogously identify reliable disease 
biomarkers in epilepsy.  
 
 
3.2.1  Biomarkers of treatment response: pharmacological fMRI 
3.2.1.1 Principles of pharmacological fMRI 
 
Pharmacological fMRI (ph-MRI) is a promising emerging application of functional 
MRI to assess regional network effects of and treatment response to specific 
AED. However, ph-MRI studies in epilepsy are so far rare and usually of small 
sample sizes (Koepp, 2011), which may be due to several methodological 
difficulties: 
The signal change in fMRI related to the drug is low; hence drug effects are 
generally studied as an interaction effect in task-related fMRI, i.e. task-related 
activation patterns for a drug are compared to those without the drug or placebo. 
Drugs can influence the BOLD signal both at a neuronal and vascular level 
complicating the interpretation of the effects observed. As the BOLD signal is 
contaminated by low-frequency noise, detection of slowly evolving medication 
	 71 
effects can be challenging (Mehta and O’Daly, 2011). A more epilepsy-specific 
problem is, that patients usually are already on AED treatment, therefore the 
study design has to control for effects of co-medication in addition to other 
confounders, such as disease activity, syndrome and comorbidities (Beltramini et 
al., 2015).  
Nevertheless, ph-MRI has the major advantage that it can investigate effects of 
pharmacological agents at a network level and remotely from regions of highest 
target receptor densities, whereas PET and molecular studies can define target 
receptor occupancy and affinity without necessarily translating effects to large-
scale networks (Mehta and O’Daly, 2011). Hence fMRI enables a system 
evaluation of networks underlying behavioural effects of a drug, independent of 
its biochemical mechanism of action. As AEDs often target several receptor sub-
types with varying regional distribution and AED efficacy differs across these 
targets, fMRI can monitor the combined effect of these interactions across 
multiple brain regions (Borsook et al., 2006). A further advantage is that fMRI 
does not use ionizing radiation and has no known biological side effects.  
So far, ph-MRI has been widely applied in affective disorders, addiction and 
schizophrenia (Nathan et al., 2014). Overall, these studies show that 
pharmacological agents with known clinical efficacy have consistent effects on 
disease relevant neural networks and modulation of brain activation at treatment 
baseline is a potential surrogate marker for long-term efficacy (Nathan et al., 
2014).  
 
3.2.1.2 Application with antiepileptic drugs 
 
Carbamazepine and Oxcarbazepine 
Jokeit and colleagues (2001) were the first to employ ph-MRI in an epilepsy 
group. They studied the relationship of mesio-temporal fMRI activation and  
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carbamazepine (CBZ) concentrations in 21 patients with refractory TLE. Most 
patients were on monotherapy and a visual-spatial memory retrieval task was 
employed. The extent of task and syndrome specific fMRI activation within the 
medial temporal lobe was negatively correlated with the CBZ serum levels. The 
effect was most marked with close to toxic drug levels.  
Employing a graph theoretical approach and resting state fMRI in a TLE cohort 
treated with CBZ or Oxcarbazepine (OXC) and comparing to those who were on 
other AEDs, Haneef and colleagues (2015) report altered hubness in those on 
CBZ/OXC, which refers to less highly connected nodes linking distant parts of the 
brain. Whereas betweeness centrality, or hubness, was reduced within the limbic 
circuit and thalamus with CBZ/OXC use, it was increased in default mode 
regions, i.e. cingulate and posterior cingulate/precuneus. 
Previous data in TLE suggests a “re-distribution” of hub regions with high 
betweeness centrality to mainly paralimbic and temporal association cortices 
(Bernhardt et al., 2011). It is therefore tempting to speculate that CBZ/OXC may 
have a region-specific effect on disease-related network changes. 
 
Valproate 
An EEG-fMRI study attributes VPA treatment response among patients with GGE 
to regional differences in generalized spike and wave discharge (GSWD) 
generators (Szaflarski et al., 2013). Spike-related activation in VPA-resistant 
patients was increased in the medial frontal cortex and anterior insular bilaterally 
when compared to VPA-responders. The effect remained apparent in the medial 
frontal cortex even after controlling for spike-counts, but there was no difference 
between groups in the thalamus. Hence in the VPA-resistant group, seizure 
generators may be more cortically distributed. 
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Levetiracetam 
Functional MRI data from individuals with amnestic mild cognitive impairment, 
which is associated with a risk of Alzheimer’s disease, demonstrated that 
dysfunctional, increased hippocampal activation in the dentate gyrus/CA3 was 
normalised by low-dose LEV treatment with improvement of memory 
performance (Bakker et al., 2012, 2015). 
 
Topiramate 
Five functional MRI studies employing an expressive language task in healthy 
subjects, epilepsy and migraine patients after a single dose or on steady-state 
Topiramate treatment report reduced activation in language relevant regions, i.e. 
dominant inferior and middle frontal gyri, superior temporal gyrus (De Ciantis et 
al., 2008; Jansen et al., 2006; Szaflarski and Allendorfer, 2012; Tang et al., 
2016), and a failure to deactivate task-negative regions, including the default 
mode network (Szaflarski and Allendorfer, 2012; Tang et al., 2016; Yasuda et al., 
2013). 
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Chapter 4: Overall aims of studies  
 
The studies presented in this PhD thesis use advanced functional and structural 
neuroimaging techniques to investigate potential imaging biomarkers of epilepsy 
in three different, but inter-connected domains: 
(1) Genetic fMRI phenotypes in juvenile myoclonic epilepsy; group 
comparisons will be performed between patients, their unaffected siblings 
and healthy controls, to identify functional alterations specific to the 
genetic underpinnings of the syndrome, in contrast to more disease-
related changes. 
(2) The effect of specific antiepileptic drugs on cognitive fMRI activation 
patterns in treatment-resistant focal epilepsy; group comparisons will be 
carried out in patients who are on Levetiracetam (LEV), a drug with a 
presumed normalizing effect on cognitive networks, and patients who are 
not on LEV. In a second study, patients on medication associated with a 
negative cognitive profile, namely Topiramate or Zonisamide, will be 
compared to those who are on LEV. The overall aim of these projects is 
to establish drug specific effects on cognitive networks. 
(3) Structural imaging markers of sudden unexpected death in epilepsy; in a 
retrospective study, structural imaging data will be compared in patients 
who later died of SUDEP, living epilepsy controls at risk of SUDEP and 
healthy controls. The aim of this study is to identify regional brain 
changes associated with SUDEP risk and to identify in vivo biomarkers to 
assist determination of the pathophysiology of SUDEP. 
 
All three domains share that studies are focused on at-risk populations, i.e. 
at-risk of (1) developing epilepsy, (2) developing side effects and 
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responding/non-responding to treatment and (3) dying from epilepsy. Thus, 
identifying imaging biomarkers can inform clinical decision-making and 
development of preventative or disease-modifying treatment in several 
aspects:  
Imaging biomarkers can be “preventive” in a sense that they can help to 
identify those individuals at risk. They can be used as surrogate markers to 
measure treatment effects and they can help to measure risk severity, which 
could be particularly helpful in monitoring the success of risk reduction in 
SUDEP. 
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Section 2: Experimental studies 
Chapter 5: Common methods 	
This chapter describes experimental methods that were used for more than one 
of the studies described in chapter 6 to 9. Methods specifically applied in one 
study only are described in the relevant chapters. 
 
5.1 Ethical approval 
All studies were approved by the Research Ethics Committee of the University 
College London Institute of Neurology and University College London Hospitals. 
For prospectively acquired data, written informed consent was obtained from all 
study participants. 
 
5.2 Subjects 
Patients were recruited from outpatient clinics at the National Hospital for 
Neurology and Neurosurgery, London, and the Epilepsy Society, Chalfont St 
Peter. Healthy control data was taken from previous control cohorts acquired for 
functional and structural MRI studies (Stretton et al., 2012; Vollmar et al., 2011) 
on the same GE Excite HDx 3T scanner (General Electric, Wakashua, 
Milwaukee, WI, USA) at the MRI Unit of the Epilepsy Society, Chalfont St Peter. 
They were initially recruited from hospital staff, students and friends or carers of 
recruited patients. Healthy controls had no history of neurological disease and no 
family history of epilepsy and had a normal neurological examination.  
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5.3 MRI 
MRI scans were acquired on a GE Excite HDx 3T scanner (General Electric, 
Wakashua, Milwaukee, WI, USA) at the Epilepsy Society MRI Unit, Chalfont St 
Peter, UK.  
Standard imaging gradients were used with a maximum strength of 40 mT/m and 
slew rate of 150 T/m/s. All images were acquired with an 8-channel phased array 
head-coil for reception and the body coil for transmission.  
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5.4 functional MRI 
Gradient-echo planar T2*-weighted images were acquired, providing blood 
oxygenation level dependent (BOLD) contrast. The acquisition consisted of 50 
axial slices in AC-PC orientation with 2.4 mm thickness and 0.1 mm gap, 
providing full brain coverage. Slices had a 64 x 64 in plane matrix with 3.75 x 
3.75 mm voxel size. Repetition time was 2500 ms and echo time 20 ms. 
Accelerated parallel imaging with a Sense factor of two was used. All fMRI 
acquisitions were preceded with four excitations to ensure steady magnetization 
before the paradigm started and data was recorded. 
Images for the functional paradigms were acquired with the same sequence but 
of different total duration.   
 
5.4.1 fMRI paradigms 
All paradigms were explained in detail before the MRI scan, using printed 
instructions with screenshots of the paradigm presentation. Paradigms were 
presented by in-house software and presentations were synchronized to the MRI 
scanner via a TTL trigger signal. The paradigm presentation was projected on a 
semi-transparent screen in front of the MRI scanner, which could be seen by the 
subjects via a mirror system attached to the head-coil. 
Appropriate vision was tested for every subject before the fMRI acquisition. MRI 
compatible frameless glasses were provided to subjects with impaired vision if 
needed. 
A MRI compatible joystick was provided at the right hand side for responses 
during the Dot Back paradigm, which was positioned individually for comfortable 
use. 
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5.4.1.1 Dot Back paradigm 	
The Dot Back paradigm is an n-back task to assess visual-spatial working 
memory (Kumari et al., 2009; Figure 5.1). Yellow dots were presented every 2 
seconds randomly in the four corners of a diamond shape on the screen. 
Participants were instructed to respond to the dots sequentially by using a 
joystick with their right hand. Participants monitored the locations of dots and 
were instructed to move the joystick to the position of the currently presented dot 
in the ‘0 Back’ condition or to the position of the dot in the previous (1 Back) or 
two (2 Back) presentations earlier. The three conditions (0, 1 and 2 Back) lasted 
30 seconds and were repeated five times in a pseudorandom order and 
alternated with rest blocks of 15 seconds. During the total duration of 11:15 
minutes of the paradigm, 272 EPI volumes were acquired. 
 
 
 
Figure 5.1. Illustration of the n-back working memory task. Participants monitor 
the locations of dots at a given delay of the original occurrence (0, 1, or 2 Back) and 
responded by moving a joystick corresponding to the location of the current or 
previously presented dot. The crosshair indicates the participant’s response. 
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5.4.1.2 N-Back task 
The N-Back task assessed verbal working memory. Single words were presented 
for 3 seconds each in 30 seconds blocks. In the control condition (“Is it bird?”), 
participants were instructed to respond with the joystick as soon as they read the 
word “bird”. During the actual working memory condition, “Two back”, subjects 
were asked to respond with the joystick when a word was repeated which they 
read two presentations earlier. As resting condition, 15 seconds of crosshair 
fixation were interleaved.  
 
5.4.1.3 Verbal fluency paradigm 
The verbal fluency is a covert task for language and executive function. Subjects 
were presented with single letters presented every 3 seconds in blocks of 30 
seconds and were instructed to think of any word starting with the presented 
letter every time the letter is presented. These blocks alternated with 30-seconds 
rest blocks with presentation of an asterisk. The task lasted 5:10 minutes and 
120 EPI volumes were acquired. 
 
 
5.4.2 Functional MRI analysis 
All fMRI analyses were performed with the SPM 8 software 
(www.fil.ion.ucl.ac.uk/spm/), including preprocessing, first level single subject 
analyses, group analyses and functional connectivity analyses. 
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5.4.2.1 Preprocessing 	
The preprocessing described in this section was applied identically to the data of 
all cognitive paradigms. 
 
Realignment 
 
Images were realigned for movement correction using the SPM realignment 
function. Realigned images were not resliced to avoid unnecessary interpolation, 
which could result in loss of image quality. The realignment parameters were 
stored in each image’s header file and were taken into account before the next 
preprocessing step. A mean image was created from the realigned time series 
and saved. 
 
Normalisation 
A scanner and acquisition specific template in MNI space was used since the 
image contrast and spatial distortions from our acquisition differed considerably 
from the standard EPI template provided within SPM. This template had also 
been used in a previous, related fMRI study in JME, employing the same fMRI 
paradigms (Vollmar et al., 2011). Images of all subjects were normalised to this 
template. 
 
Smoothing 
Normalised images were smoothed with an 8 x 8 x 8 mm FWHM Gaussian 
kernel. All further statistical analyses were carried out on these realigned, 
normalised and smoothed images. 
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5.4.2.2 First level statistical analysis 	
Single subject statistical analysis was carried out applying a full factorial block 
design. Each task condition was modelled separately. Movement parameters 
were entered as regressors of no interest.  
 
Dot Back paradigm 
Task conditions were modelled separately as 30-s blocks and convolved with the 
SPM canonical haemodynamic response function. For each subject, contrasts 
were defined by comparing task conditions against rest or comparing cognitive 
task conditions (‘1 Back’ and ‘2 Back’) against the control task (0 Back). Hence 
by controlling for motor response and visual attention, only cortical activation due 
to the working memory load was revealed. 
 
N-Back paradigm 
Task conditions were modelled separately as 30-s blocks and convolved with the 
SPM canonical haemodynamic response function. For each subject, contrasts 
were defined by comparing cognitive task conditions (Two Back) against the 
control task (Is it bird?). 
 
Verbal fluency paradigm 
The verbal fluency paradigm contained only one condition and only one contrast 
against the baseline, i.e. rest, was defined. 
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5.5 Standardized neuropsychological test battery 
A battery of standardized tests assessing expressive language and verbal 
comprehension, verbal and non-verbal learning, as well as several frontal lobe 
functions was administered to all participants, who had cognitive fMRI. 
Administered tests and acquired scores are detailed in Table 5.1. 
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Table 5.1. Neuropsychological Test Battery 
 
Cognitive 
ability 
Test Score 
Verbal IQ National Adult Reading Test (NART revised) IQ points 
Verbal 
Comprehension 
Vocabulary and Similarities subscales of the 
Wechsler Adult Intelligence Scale (WAIS)  
raw score 
Expressive 
Language 
McKenna Picture naming task  raw score 
Verbal Learning List Learning subtest of the Adult Memory 
and Information Processing Battery (AMIPB, 
Coughlan and Hollows, 1985) 
sum of raw 
scores 
list 1-5 
Nonverbal 
Learning 
Design Leaning subtest of the AMIPB sum of raw 
scores 
design 1-5 
Psychomotor 
speed 
Trail-Making Test form A (Reitan & Wolfson, 
1985) 
 
time (s) 
Mental 
Flexibility 
Trail-Making Test (form B-A) (Reitan & 
Wolfson, 1985) 
 
time (s) 
Verbal Fluency Letter Fluency: “F”, “A”, “S” 
Category Fluency: “Animals”, “Fruits”, 
“Vegetables” 
average of 
totalled number 
of words letter/ 
category in 1 
minute 
Working 
Memory 
Digit Span and Arithmetic subtests of the 
WAIS 
sum of raw 
scores 
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5.6 Statistical analysis of demographical and behavioural 
data 
Data were analysed using SPSS Statistics Versions 17.0 and 20.0 (IBM).  
Prior to statistical analysis, histograms were created to check whether datasets 
were normally distributed. In addition, Levene’s test for homogeneity of variance 
was employed. Parametric or non-parametric tests were used accordingly. Chi-
square tests were applied to categorical data. The level of significance was set at 
p < 0.05. 
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Chapter 6: fMRI endophenotypes in JME 
6.1 Summary 
Rationale: JME is a heritable genetic generalized epilepsy syndrome, 
characterized by myoclonic jerks that are frequently triggered by cognitive effort. 
Impairment of frontal lobe cognitive functions has been reported in patients with 
JME and their unaffected siblings. In a recent functional magnetic resonance 
imaging study we reported abnormal co-activation of the motor cortex and 
increased functional connectivity between the motor system and prefrontal 
cognitive networks during a working memory paradigm, providing an underlying 
mechanism for cognitively triggered jerks.  
Methods: In this study, we used the same task in 15 unaffected siblings (10 
female; age range 18–65 years, median 40) of 11 of those patients with JME (six 
female; age range 22–54 years, median 35) and compared functional magnetic 
resonance imaging activations with 20 age- and gender-matched healthy control 
subjects (12 female; age range 23–46 years, median 30.5).  
Results: Unaffected siblings showed abnormal primary motor cortex and 
supplementary motor area co-activation with increasing cognitive load, as well as 
increased task-related functional connectivity between motor and prefrontal 
cognitive networks, with a similar pattern to patients (p < 0.001 uncorrected; 20-
voxel threshold extent).  
Conclusions: Findings in unaffected siblings suggest that altered motor system 
activation and functional connectivity is not medication- or seizure-related, but 
represents a potential underlying mechanism for impairment of frontal lobe 
functions in patients and siblings, and so constitutes an endophenotype of JME.  
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6.2 Introduction 
Juvenile myoclonic epilepsy (JME) is a common genetic generalised epilepsy 
syndrome (Berg and Millichap, 2013; Zifkin et al., 2005), characterized by 
symmetric, myoclonic jerks, mostly affecting upper limbs, generalised tonic-clonic 
seizures and more rarely absence seizures (Janz, 1985; Kasteleijn-Nolst Trenité 
et al., 2013). A complex polygenetic aetiology is suspected in most cases 
(Delgado-Escueta et al., 2013) and clinical genetic studies support a high genetic 
predisposition: first degree relatives have an increased risk for epilepsy with up to 
six percent affected, mostly with genetic generalized epilepsy syndromes (Vijai et 
al., 2003). Reports on high syndrome concordance amongst first-degree relatives 
of 30% (Marini et al., 2004) and very high monozygous concordance reported by 
twin studies support a major heritable disease component (Corey et al., 2011; 
Vadlamudi et al., 2004). 
Reflex-mechanisms of seizure precipitation are common in JME, including photic-
stimulation but also cognitively triggered jerks by reading, decision-making or 
planned movement, leading to jerking of the body part, which is engaged in task 
execution, usually the hand (Guaranha et al., 2009; Koepp et al., 2016; Matsuoka 
et al., 2000, 2005).   
Neuro-behavioural findings of impaired working memory and executive functions 
(Devinsky et al., 1997; Sonmez et al., 2004; Wandschneider et al., 2012) 
corroborated evidence from advanced imaging studies for subtle structural and 
functional changes within the dorsolateral prefrontal and medial frontal lobes and 
thalamo-fronto-cortical pathways (Koepp et al., 1997; O’Muircheartaigh et al., 
2011, 2012; Pulsipher et al., 2009; Savic et al., 2000). In a previous study at our 
centre (Vollmar et al., 2011, 2012), the interaction of motor and cognitive 
networks in JME was investigated using an n-back functional MRI (fMRI) task, 
which assesses visual-spatial working memory with increasing cognitive demand 
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and also entails a complex motor component (Kumari et al., 2009). Patients with 
JME showed an abnormal motor-cortex co-activation with increasing task 
demand during the working memory task. In addition, both functional and 
structural connectivity were increased between cortical motor areas and 
dorsolateral prefrontal cognitive networks, and decreased within prefrontal 
cognitive networks (pre-supplementary motor area to fronto-polar regions), 
providing a potential underlying mechanism for both cognitively triggered jerks 
and cognitive impairment in juvenile myoclonic epilepsy. Although a 
“normalisation” of this altered co-activation with increasing doses of the anti-
epileptic drug sodium valproate was observed, it could not be disentangled 
whether motor system hyperconnectivity to cognitive networks is a disease-
underlying mechanism or a consequence of seizures and/or treatment.  
Since JME has a high heritability and neuro-behavioural studies in unaffected 
siblings have described traits of its broader phenotype, such as frontal lobe 
cognitive impairment (Wandschneider et al., 2010), this study aimed to 
investigate whether motor system co-activation during a working memory task is 
an endophenotype of JME. Endophenotypes are manifest in an individual 
whether or not the condition is active, are heritable and are found more frequently 
in non-affected family members of diseased individuals than in the general 
population (Gottesman and Gould, 2003). Since the genetic risk for epilepsy is 
higher for siblings of JME patients than their offspring or parents and syndrome 
traits have also been more frequently reported in siblings than in other first-
degree relatives, this study focused on investigating unaffected siblings 
(Jayalakshmi et al., 2006). Index patients and siblings are also more likely to be 
comparable for age, upbringing and socioeconomic background than patients 
and other first-degree relatives. The specific hypotheses of this study were, that 
unaffected siblings of JME patients will show  
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(1) abnormal fMRI activation patterns compared to healthy controls in previously 
defined region of interest in the motor cortex of JME patients, and  
(2) increased functional connectivity between the motor system and fronto-
parietal cognitive networks.  
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6.3 Methods 
6.3.1 Study population 
Fifteen unaffected siblings of 11 JME patients participated after contact with the 
consent of the related JME index patient. Juvenile myoclonic epilepsy patients 
were either identified from a previous functional MRI study (n = 5) (Vollmar et al., 
2011) or recruited from University College London Hospitals epilepsy outpatient 
clinics (n = 6). Twenty healthy controls were also included 
(Siblings/patients/controls: 10/6/12 females; age: Siblings: median 40 (IQR: 21) 
years; patients: 35 (23); controls: 30.5 (7)). Siblings and controls were 
comparable for age (Mann-Whitney U = 98.500, p = 0.086), gender (Pearson 
Chi-square p = 0.686) and IQ (Table 6.1).  
All index patients had a typical history of JME with myoclonic jerks, generalised 
tonic-clonic seizures and, in some, absence seizures. Disease onset was in 
adolescence, EEGs showed generalised polyspike wave complexes and clinical 
MRI were normal.   
Three patients reported movement-related jerks in the active hand: one when 
playing the guitar and writing down musical notes simultaneously; one when 
playing the violin or touch-typing on a screen; one patient reported jerks during 
tasks requiring fine motor skills. 
No sibling had ever experienced seizures; except for one who had suffered two 
clearly provoked (sleep deprivation) generalised tonic-clonic seizures, over 20 
years prior to study participation, without any further seizures, and without 
antiepileptic medication.  
In five JME families, other relatives apart from the index patient suffered from 
epilepsy. There was a family history of febrile convulsions in two cases.  
Healthy controls had no history of epilepsy or other neurological disease and no 
family history of epilepsy. 
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6.3.2 MRI data acquisition 
MRI data were acquired on a GE Excite HDx 3 Tesla scanner (General Electric 
Medical Systems, Milwaukee, WI, U.S.A) with a multichannel head coil. A 50 
slice gradient echo planar imaging sequence was used in axial orientation with 
2.4 mm thickness and 0.1 mm gap providing full brain coverage. Slices had a 64 
x 64 matrix, voxel size was 3.75 x 3.75 mm. Repetition time was 2500 ms, echo 
time was 25 ms.  
 
6.3.3 fMRI working memory paradigm 
An adaptation of the visual-spatial n-back working memory task was employed 
(Kumari et al., 2009), as in the previous JME study at our centre (Vollmar et al., 
2011). Dots were presented randomly in four possible locations on a screen. 
Participants responded by moving a joystick with their right hand. They monitored 
the locations of dots and had to move the joystick to the position of the currently 
presented dot in the ‘0 Back’ condition or to the position of the dot in the previous 
presentation (1 Back) or two (2 Back) presentations earlier. Each condition lasted 
30 seconds, was repeated five times in a pseudorandom order and alternated 
with rest blocks of 15 seconds. During the total duration of the paradigm (11 min 
20 s), 272 echo planar imaging volumes were acquired.  
 
 
6.3.4 fMRI processing and analysis 
Functional MRI data were analysed with Statistical Parametric Mapping-8 (SPM8, 
www.fil.ion.ucl.ac.uk/spm). Images were realigned, normalised to an acquisition-
specific echo planar imaging template in Montreal Neurological Institute space, 
resampled to isotropic 3 x 3 x 3 voxels and smoothed with an 8 x 8 x 8 mm 
kernel.  
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Single subject statistical analysis was carried out applying a full factorial block 
design. Movement parameters were entered as regressors of no interest. Task 
conditions were modelled separately as 30 seconds blocks and convoluted with 
the SPM canonical haemodynamic response function.  
For each subject, contrasts were defined by comparing task conditions against 
rest and comparing task conditions with working memory load (‘1 Back’ and ‘2 
Back’) against the control task (0 Back). Hence by controlling for motor response 
and visual attention, only cortical activation due to the working memory load was 
revealed.  
Subjects with fMRI activation of at least p > 0.05 uncorrected at single subject 
level for the relevant contrasts were included into the second level analyses. 
At the second level, one sample t-tests were employed to explore group effects. 
Group comparisons were then carried out employing two-sample t-tests or a full 
factorial design. The level of significance was set at p < 0.001 uncorrected with an 
extent threshold with minimum cluster size of 20 voxels (Lieberman and 
Cunningham, 2009). Where appropriate, performance during the n-back task was 
entered as a regressor of no interest. 
Functional MRI results were rendered on a 3D surface previously created from 
the Montreal Neurological Institute_152_T1 data set (Vollmar et al., 2011).  
 
 
 
6.3.5 Independent component and functional connectivity 
analyses 
An independent component analysis was carried out using MELODIC from the 
FMRIB software library (FSL, http://www.fmrib.ox.ac.uk/fsl/) to identify different 
network components.  
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A 4D file of the realigned, normalised and smoothed images was created for 
each subject. Image data were prefiltered with a high-pass filter with a cut-off at 
100 s. The algorithm was restricted to identify 32 components common across all 
subjects. Motor and working memory components were visually identified at the 
group level. Individual timeseries for each component were extracted for each 
subject using Dual Regression (Filippini et al., 2009). 
Subsequently, for each subject and each component, connectivity maps were 
generated by regressing the timeseries in a general linear model including 
movement parameters as regressor of no interest. Group comparisons were 
carried out employing two-sample t-tests or a full factorial design.  
 
 
6.3.6 Behavioural data 
All participants underwent a standardized neuropsychological assessment. The 
Nelson Adult Reading Test was used as an index of intellectual level (Nelson, 
1982). The Vocabulary and Similarities subtests from the Wechsler Adult 
Intelligence Scale III were used to measure verbal comprehension and the Digit 
Span and Mental Arithmetic subtests from the same scale provided a measure of 
working memory. Expressive language functions were measured using the 
Graded Naming Test (McKenna and Warrington, 1983). The List Learning and 
Design Learning Subtests from the Adult Memory and Information Processing 
Battery measured verbal and visual learning respectively (Baxendale et al., 2008). 
The Trail Making Test provided a measure of psychomotor speed (Trail Making A) 
and mental flexibility (Trail Making B-A). Participants also completed measures of 
letter and category fluency.  
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6.3.7 Statistical analysis of clinical and behavioural data 
Behavioural and clinical data were analysed using SPSS Statistics Version 20.0 
(IBM). Mann-Whitney U Test was applied to non-parametric data and Chi-square 
tests to categorical data. The level of significance was set at p < 0.05. 
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6.4 Results 
6.4.1 Dot-back task performance 
Both, siblings and healthy controls performed equally well during the ‘0 Back’ 
condition (success rate median (IQR) siblings: 95 (10)%; controls: 93 (11); Mann-
Whitney U = 143.000, p = 0.831). However, siblings performed worse in the ‘1 
Back’ (Siblings: 77 (43), controls: 92.5 (11.75); Mann-Whitney U = 82.000 p = 
0.023) and ‘2 Back’ condition (Siblings: 55 (41), controls: 88 (31.5); Mann-
Whitney U = 69.500, p = 0.006). Performance measures were therefore entered 
as regressors of no interest in the fMRI group comparisons. 
 
 
 
 
6.4.2 Performance on standardised neuropsychometry 
There were no significant group differences in performance on the 
neuropsychological test battery. The results are detailed below in Table 6.1. 
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Table 6.1. Neuropsychological test results 
 
Cognitive measures controls siblings Statistical analysis* 
Median (IQR) Median 
(IQR) 
U p 
IQ 
NART  
 
110 (10) 
 
107 (19) 
 
71.500 
 
0.574 
WAIS-III (raw scores) 
Verbal Comprehension 
Vocabulary  
Similarities  
Working Memory 
Digit Span 
Arithmetics 
 
 
50 (21) 
26.5 (12) 
 
17 (6) 
14 (10) 
 
 
49 (24) 
24 (5) 
 
20 (5) 
14 (7) 
 
 
73.000 
51.000 
 
43.000 
68.000 
 
 
0.935 
0.196 
 
0.080 
0.862 
Expressive Language 
Graded Naming Test 
 
23 (5) 
 
23 (7) 
 
64.500 
 
0.567 
Verbal Learning 
List Learning (AMIPB) 
(Trials 1-5) 
 
 
56  (13) 
 
 
56 (6) 
 
 
46.000 
 
 
0.215 
Nonverbal Learning 
Design Learning 
(AMIPB) 
(Trials 1-5) 
 
 
 
40 (11) 
 
 
 
36 (11) 
 
 
 
60.500 
 
 
 
0.152 
Psychomotor speed 
Trail Making Test A 
(seconds) 
 
 
25 (15) 
 
 
25 (13) 
 
 
    66.000 
 
 
0.413 
Mental flexibility 
Trail Making Test time 
B-A (seconds)  
 
 
19 (13) 
 
 
23 (18) 
 
 
    49.500 
 
 
0.235 
Verbal fluency 
categorical fluency  
letter fluency  
 
18 (3) 
14 (5) 
 
18 (5) 
14 (4) 
 
    60.000 
    82.000 
 
0.808 
0.862 
 
*The Mann-Whitney U Test was applied for behavioural measures. All variables are 
reported as raw items, except for Trail Making Test (time in seconds) and verbal IQ 
points. AMIPB: The Adult Memory and Information Processing Battery; NART: National 
Adult Reading Test; WAIS: Wechsler Adult Intelligence Scale 
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6.4.3 fMRI group effects siblings and controls 
In the ‘0 Back’ condition, due to the right hand motor-response all subjects 
showed a left central and bilateral supplementary motor area activation (Figure 
6.1 A). By controlling for motor response and subtracting ‘0 Back’ from ‘1 Back’ 
and ‘2 Back’, cortical activations due to working memory were isolated. All 
participants showed significant bilateral prefrontal and parietal working memory 
network activation (Figure 6.1 A-C). 
 
6.4.4 fMRI group differences between siblings and controls 
There were no group differences detectable during the ‘0 Back’ condition (Figure 
6.1 D). However, in the ‘1 minus 0 Back’ contrast, there was a significant 
difference in activation patterns between siblings compared to controls within the 
region of interest, the motor cortex. The effect became more prominent and 
extended to the supplementary motor area with increasing cognitive demand in 
the ‘2 minus 0 Back’ contrast.  
To disentangle whether the differences between siblings and controls observed 
were due to an increase of the task-positive network or an impaired deactivation 
of the task-negative network in siblings relative to controls, we masked the 
results either by group effects of the task-positive (‘2 minus 0 Back’) or task-
negative network (‘0 minus 2 Back’) for controls (Figure 6.1 E, F). Areas of 
difference corresponded to the task-negative network in controls. Hence the 
effect observed in the motor system in siblings is due to impaired deactivation of 
this area with increasing working memory load. There were no areas of greater 
activation in controls compared to siblings.  
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Figure 6.1. Group fMRI activation from working memory and group differences. 
Group fMRI activation maps from JME siblings and healthy controls (A-C) show cortical 
activation for the three different task conditions: motor cortex and supplementary motor 
area for ‘0 Back’ (A), bilateral frontal and parietal activation for ‘1 minus 0 Back’ and ‘2 
minus 0 Back’ (B, C).  
Lower row (D-F), activation patterns in siblings compared to controls (inclusively 
masked for task-dependent deactivation maps of healthy controls (p < 0.001 
uncorrected; 20 voxel threshold extent)): no difference for the ‘0 Back’ condition (D), but 
attenuated deactivation in the motor cortex (E) and the supplementary motor area (F) 
with increasing task demand in the working memory contrasts was seen.  
 
 
 
6.4.5 Areas of task-related deactivation in siblings and controls 
To further explore group differences secondary to impaired deactivation in 
siblings, group maps of the task negative network are displayed in Figure 6.2. 
Whereas controls deactivate the primary motor cortices with increasing cognitive 
task demand, as well as areas in the default mode network, i.e. precuneus and 
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medial frontal and orbitofrontal areas, the group effect in siblings shows less 
deactivation in these areas. 
 
 
 
Figure 6.2. Group effect of task-dependent deactivation in controls and siblings 
for the two negative working memory contrasts (‘Dot Back 0 minus 1’, ‘Dot Back 0 
minus 2’). In controls, the task negative contrast shows bilateral deactivation of the 
motor cortex and supplementary motor area with increasing task demand, as well as 
deactivation of the precuneus and medial prefrontal areas (default mode network). Less 
group deactivation effects in these areas are observed in siblings (p < 0.001 
uncorrected; 20 voxel threshold extent) 
 
 
6.4.6 fMRI group differences and differences in task 
performance 
To control for performance effects, in addition to treating performance as a 
confounder of no interest, a post-hoc group comparison between contrasts ‘1 
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minus 0 Back’ in siblings and ‘2 minus 0 Back’ in controls were performed, since 
controls’ performance accuracy in the ‘2 Back’ condition was comparable to 
siblings’ accuracy in the ‘1 Back’ condition (success rate median (IQR) siblings ‘1 
Back’: 77 (43) %; controls ‘2 Back’: 88 (31.5); Mann-Whitney U = 121.000, p = 
0.347), (Figure 6.3). As in the previous analysis, siblings show an attenuated 
deactivation of the motor areas and parts of the default mode network. There 
were no areas of greater activation in controls compared to siblings.  
 
 
 
Figure 6.3. Post hoc group comparisons of fMRI activation patterns during 
comparable working memory task performance. Siblings’ performance accuracy 
during the ‘1 Back’ was comparable to controls’ performance during ‘2 Back’ condition. 
There was attenuated deactivation in the bilateral lateral primary motor cortex and left 
supplementary motor area, as well as in the left medial prefrontal cortex for ‘1 minus 0 
Back’ in siblings compared to ‘2 minus 0 Back’ in controls (p < 0.005 uncorrected; 20 
voxel threshold extent; inclusively masked for areas of task-related deactivation in 
controls). There were no areas of higher activation in controls.  
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6.4.7 fMRI group differences between patients, siblings and 
controls 
Contrast images for ‘1 minus 0 Back’ and ‘2 minus 0 Back’ of siblings, controls 
and the 11 JME index patients were entered in a full-factorial design with group 
as factor.  
Performance accuracy was different between the three groups for the ‘2 Back’ 
performance (Kruskal-Wallis Test: ‘0 Back’ X2 = 0.337, p = 0.845; ‘1 Back’ X 2 = 
5.757, p = 0.056; ‘2 Back’ X 2 = 8.178, p = 0.017). Post-hoc group comparisons 
showed that these performance differences were due to siblings performing 
worse than controls, with JME patients’ performance accuracy being comparable 
to controls’ and siblings’ ‘2 Back’ performance (patients vs. controls: Mann-
Whitney U = 72.000, p = 0.123; patients vs. siblings: Mann-Whitney U = 56.500, 
p = 0.180).  
Performance scores were entered as regressors of no interest. There were no 
differences in activations between JME patients and siblings for either working 
memory contrasts (not shown). In a conjunction analysis of areas activating in 
both JME patients and siblings more than controls, common areas of significant 
activations in the left primary motor cortex were identified (Figure 6.4). 
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Figure 6.4. Conjunction analysis. In a conjunction analysis of patients greater 
than controls and siblings greater than controls for ‘Dot Back 1 minus 0’ and ‘Dot 
Back 2 minus 0’, patients and their siblings share significant areas of co-
activation in the left motor cortex when compared to controls. (conjunction, p < 
0.005 uncorrected; 20 voxels threshold extent) 
 
 
To control for the effect of age, we performed a post-hoc group comparison and 
entered age as additional regressor of no interest, which did not change overall 
results (Figure 6.5). In subgroup analyses in patients and siblings, we correlated 
activation patterns during the ‘2 minus 0 Back’ and ‘1 minus 0 Back’ contrasts 
with age. This did not show an effect within the region of interest, the left primary 
motor cortex and supplementary motor area (data not shown). 
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Figure 6.5. Post hoc group comparisons of fMRI activation patterns after 
correcting for age.  
Age was entered as additional nuisance variable into the model. Siblings compared 
to controls (A, B) showed attenuated deactivation in the motor cortex and SMA with 
increasing task demand in the working memory contrasts (p < 0.001 uncorrected; 20 
voxel threshold extent).  
At a lower threshold (p < 0.005 uncorrected; 20 voxel threshold extent), attenuated 
deactivation is seen in similar regions in JME patients when compared to controls 
(C, D). 
In a conjunction analysis of patients greater than controls and siblings greater than 
controls for the two working memory contrasts (E, F), patients and their siblings 
share significant areas of co-activation in the left motor cortex. (conjunction, p < 
0.005 uncorrected; 20 voxels threshold extent) 
Maps were inclusively masked for task-dependent deactivation maps of healthy 
controls.  
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6.4.8 Functional connectivity  
From the 32 independent components identified by independent component 
analysis, two components of interest were chosen for further group comparisons 
(Figure 6.6): The component located in the left central region and representing 
the motor response (Figure 6.6 A) and the component comprising the bilateral 
prefrontal and parietal working memory network (Figure 6.6 C).  
Compared to controls, JME siblings showed increased functional connectivity of 
the left motor cortex and supplementary motor area to the dorsolateral prefrontal 
and superior parietal cortex, which are part of the working memory network 
(Figure 6.6 B). Functional connectivity analysis of the working memory 
component showed increased connectivity to bilateral motor cortices in siblings 
than controls (Figure 6.6 D). There were no areas of higher connectivity in 
controls for these two components. 
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Figure 6.6. Group independent component analysis and functional connectivity in 
siblings compared to healthy controls. A: This figure shows the motor network 
component common to all subjects (FSL figure) and its corresponding group average 
signal time course during the experiment. The signal time course for the motor 
component shows constant response amplitude throughout the different task paradigms 
(0, 1 and 2 Back and rest). B: Group comparison of functional connectivity patterns in 
siblings and healthy controls are demonstrated for the motor component.  Siblings show 
increased connectivity to fronto-parietal cognitive networks when compared to controls 
(p < 0.005; 20 voxels threshold extent). There were no areas of increased connectivity 
in controls. C: The working memory network component common to all subjects is 
demonstrated (FSL figure). Its corresponding group average signal time course is 
modulated by task demand and shows increased activation with higher cognitive 
demand during the actual working memory conditions (1 and 2 Back).  D: Group 
comparison of functional connectivity patterns in siblings and healthy controls for the 
working memory component shows increased connectivity to central motor areas, as 
well as the medial prefrontal cortex as part of the default mode network (D; p < 0.001; 
20 voxels threshold extent). There were no areas of increased connectivity in controls. 
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6.5 Discussion 
This study showed co-activation of the primary motor cortex and supplementary 
motor area during a functional MRI working memory task in unaffected siblings of 
JME patients, similar to patterns seen in JME ( Vollmar et al., 2011). In controls, 
we observed a relative attenuation of activations in the motor cortices with 
increasing task demand. In JME patients and siblings, motor areas remained co-
activated with task-positive working memory networks, resulting in increased 
functional connectivity between the motor system and fronto-parietal cognitive 
networks.  
 
6.5.1 Functional endophenotypes of JME  
Using a conjunction analysis of working memory activation, we identified 
common areas of impaired attenuation of task-negative networks within the motor 
cortex for both patients and siblings. We conclude that motor cortex co-activation 
is not a consequence of seizures or medications. This supports the hypothesis 
that there is a heritable component of the disease, and represents an 
endophenotype of JME, defined as an intermediate phenotype that appears to be 
more frequently present in non-affected family members than in the general 
population. Since siblings do not suffer from seizures, this finding is clearly not 
solely an association with the full JME phenotype. However, in view of its 
regional specificity our finding is very likely to be related to pathomechanisms of 
the disease with its particular seizure type, i.e. motor seizures, and fronto-cortical 
cognitive dysfunction. This is corroborated by studies showing a modulation of 
motor cortex co-activation by disease severity and treatment (Vollmar et al., 
2011). In a recent twin study (Blokland et al., 2011), fMRI activation patterns 
during the n-back working memory task have been shown to be significantly 
heritable and regions of interest identified here, i.e. the precentral gyrus and 
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supplementary motor area, have been among the regions with the highest 
heritability estimates. Thus, seizures and neuro-behavioural comorbidities may 
share this underlying functional mechanism. Longitudinal studies and imaging 
studies in recent onset genetic generalized epilepsies, as well as JME, identified 
subcortical and fronto-cortical abnormalities, which relate both to seizures and 
neuro-behavioural comorbidities (Pulsipher et al., 2009; Tosun et al., 2011). 
Some behavioural studies in genetic generalized epilepsies identified cognitive 
impairment even prior to disease onset (Hermann et al., 2012), suggesting that 
epilepsy and its comorbidities may reflect different degrees of disease with a 
shared underlying pathological condition, which may be a genetically determined 
neurodevelopmental dysfunction (Helmstaedter et al., 2014).  
Previous imaging studies of unaffected siblings have been conducted mainly in 
schizophrenia and autism to control for the effect of disease severity and 
treatment and to identify potential imaging endophenotypes (Callicott et al., 2003; 
Spencer et al., 2012). Like JME, these are considered highly heritable, 
neurodevelopmental conditions with neuro-behavioural characteristics, which 
extend beyond the cardinal disease features and are frequently found in non-
affected relatives. Such endophenotypes are intermediate biological phenotypes 
associated with the disease in the population, which are more closely related to 
the genotype than the final phenotype, increasing the yield for identifying 
susceptibility genes (Callicott et al., 2003). Studying the physiological 
mechanisms underlying neuro-behavioural impairments in unaffected siblings 
may help to understand biological effects of susceptibility genes (Callicott et al., 
2003).  
Statistical analyses of the blood oxygen level dependent contrast at single 
subject level do not directly reflect a quantitative measure of activation and 
findings at group level cannot be easily used to quantify activation at a single 
subject level. In the first instance, this would involve studying large cohorts to 
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establish quantitative normative data of task-related activation. Therefore, it is 
unlikely that one would be able to conclude from the scan data in one subject 
whether the trait is present or not in that individual. However in schizophrenia, 
results from functional MRI group analyses have been used successfully in a 
probabilistic approach for gene discovery in conjunction with genome-wide 
association (Potkin et al., 2009), whilst imaging studies in siblings of patients with 
epilepsy are rare (Scanlon et al., 2013). Analysis of a quantitative imaging trait in 
affected families, like motor cortex co-activation, may increase the yield of 
genetic studies for identifying culprit genes for JME, which so far has proven 
difficult. 
 A recent transcranial magnetic stimulation study in individuals with generalised 
and focal epilepsies and their asymptomatic siblings reported cortical hyper-
excitability in the asymptomatic siblings compared to healthy controls, which was 
more prominent in generalised epilepsy syndromes. The cortical excitability 
profile in asymptomatic siblings was similar to those in patients. Only drug naïve 
new onset JME patients had a lower motor threshold, i.e. higher excitability, than 
their asymptomatic siblings. (Badawy et al., 2013)  
 
To identify whether motor cortex co-activation is more prominent in patients with 
JME, we carried out a group comparison of JME patients and siblings, which did 
not show an effect. This may be a false negative finding due to the relatively 
small sample of 11 index patients. An alternative explanation for the lack of a 
difference could be that motor system co-activation “normalised” with high doses 
of Valproate (Vollmar et al., 2011) and was less prominent in our cohort of 11 
patients: all were on medication with seven out of 11 on Valproate; six patients 
were seizure-free and none of the patients reported daily jerks.  
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To further investigate whether motor cortex co-activation is more prominent in 
patients than siblings, drug-naïve JME patients have to be studied (Badawy et 
al., 2013). 
In a post-hoc analysis, our findings survived a further correction for age. Disease 
onset during adolescence coincides with an important phase of brain 
development. Normal cortical maturation involves thickening or thinning of grey 
matter during childhood and adolescence, following different developmental 
trajectories depending on the cortical region and neural system. Grey matter 
thinning may be associated with synaptic pruning, apoptosis and ongoing 
myelination, and has been correlated with cognitive and behavioural 
development. (Jernigan et al., 2011) Decrease in grey matter first involves 
primary sensorimotor cortices, then secondary and eventually multimodal 
cortices during late adolescence, such as the dorsolateral prefrontal cortex 
(Shaw et al., 2008). However, there is also evidence for continuous 
developmental changes in primary cortical areas during late adolescence 
(Giorgio et al., 2010). These crucial processes of cortical brain maturation and 
functional refinement may be implicated in JME. Mutations in one causative 
candidate gene, EFHC1, have recently been linked to alterations of several 
neural development steps, including migration, connection formation and 
apoptosis, the latter potentially leading to maintenance of hyperexcitable neurons 
(de Nijs et al., 2013). There is some evidence from longitudinal structural imaging 
studies in children with idiopathic epilepsy compared to controls describing 
disrupted patterns of brain development, mainly implicating prefrontal and 
parietal cortices (Tosun et al., 2011). Therefore, aberrant activation patterns may 
be more prominent in younger subjects. However, this effect was not seen in a 
subgroup correlation analysis (Figure 6.5). Considering that all our patients, and 
most of the siblings were older than adolescence (patients: age range 22 to 54 
years; siblings: 18 to 65 years), this may be a false negative finding and a 
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potential age effect should be explored in future, preferably recent onset cohorts. 
 
 
6.5.2 Abnormal fMRI activation patterns are markers of 
dysfunction 
Motor system co-activation appears to be not only a disease marker, but is 
related to cortical network dysfunction. In our previous studies, we suggested that 
motor cortex co-activation with functional hyper-connectivity and increased 
microstructural connectivity between the prefrontal cognitive cortex (pre-
supplementary motor area) and motor system is a potential underlying 
mechanism of cognitively triggered jerks and frontal lobe impairment in JME 
(Vollmar et al., 2011). Connectivity between the pre-supplementary motor area 
region and the fronto-polar cortex was reduced, providing an explanation for 
impaired frontal lobe functions in JME. In addition, thalamic inhibition of the 
supplementary motor area and premotor cortex has been shown to be decreased 
in association with reduced structural connectivity within thalamo-cortical motor 
control circuits which leads to alteration of task-modulated functional connectivity 
with subsequent impairment of frontal lobe functions (O’Muircheartaigh et al., 
2012). The effect appeared more prominent in patients with persisting seizures. 
Likewise, impairment in experienced-related learning and impulsive decision 
making have been directly related to increased supplementary motor area 
activation in treatment refractory JME patients (Wandschneider et al., 2013).  
Comparative studies of patients and controls however have failed to disentangle 
whether structural and functional changes are part of disease-underlying 
mechanisms or consequence of seizures and/or treatment. In our current study, 
we control for the impact of seizures and medication by studying unaffected 
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siblings. Similar findings in affected and unaffected family members support the 
contention that altered structural and functional cortico-cortical connectivity is part 
of the genetically determined disease-underlying mechanisms. To compare our 
current with previous findings in JME patients, task-related, but not resting-state 
functional connectivity was assessed. In a recent meta-analysis of over 7000 
functional maps the main explicit activation networks were identified and 
compared to those identified in 36 subjects during resting state functional MRI 
(Smith et al., 2009). Major covarying network components of the task-related 
analysis were very similar to those in the resting brain (Laird et al., 2011). A task-
related functional connectivity analysis approach appears appropriate in JME, 
since symptoms become more apparent during certain activities or with 
increasing cognitive demand. 
As in patients, unaffected siblings show increased functional connectivity 
between working memory networks and motor systems and vice versa. Siblings 
demonstrate this imaging trait, but they do not experience seizures, which 
indicates that additional environmental and/or genetic factors are necessary to 
develop the full JME phenotype. On the other hand, motor cortex co-activation 
and hyper-connectivity may not only be a genetic marker but may be associated 
with disease traits in siblings. Previous studies have shown subtle frontal lobe 
impairment in unaffected JME siblings (Levav et al., 2002; Wandschneider et al., 
2010), especially when performing a cognitively challenging task which required 
integration of several frontal lobe functions (Wandschneider et al., 2010). In the 
current study, siblings performed less well on the highly demanding fMRI working 
memory task, although they do equally well on the standardized 
neuropsychological test battery. Hence altered task-related functional 
connectivity between motor and cognitive networks demonstrated in this study 
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may be responsible for subtle cognitive impairments in siblings that are similar to 
those in patients.  
 
6.5.3 Impaired task-related deactivation of motor systems  
Motor cortex co-activation in siblings and patients compared to controls was due 
to attenuated deactivation of the motor systems. Group effects of task-related 
deactivations showed deactivation of areas of the motor cortex in controls, but to 
a lesser degree in siblings (Figure 6.2). In patients, an independent component 
analysis previously identified a “modulated motor” component during the n-back 
working memory task, which demonstrated that, similarly to the working memory 
component here (Figure 6.6), the motor component was modulated with 
increasing working memory task demand (Vollmar et al., 2011). In the current 
cohort, functional connectivity in siblings was increased between working 
memory networks and areas, which were deactivated in controls, i.e. motor 
cortices and the medial prefrontal cortex as part of the default mode network. 
Due to increased functional coupling of cognitive and motor networks in JME 
patients and their unaffected siblings, functional segregation of motor areas from 
task-active cognitive networks and their deactivation during a highly demanding 
working memory task may be impaired, which may account for the poorer 
performance in siblings during the fMRI working memory task in this study.  
 
6.5.4 Limitations 
Interictal epileptic discharges have been reported in up to 27% of unaffected 
siblings of JME patients (Atakli et al., 1999) and may therefore be also present in 
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our sibling cohort. A recent sibling study (Iqbal et al., 2009) controlling for 
interictal epileptic activity by performing video EEG recordings prior to and during 
neuropsychological assessment reported subtle cognitive impairment in siblings 
and patients independently of interictal epileptic discharges. Given the low 
sensitivity to detect interictal epileptic discharges routine EEGs were not 
performed in siblings for this study. We also postulate that fMRI is a far more 
sensitive tool to detect subtle neuronal dysfunction in clinically unaffected 
individuals and this has already been achieved in previous cognitive functional 
MRI studies despite the absence of impairment on routine neuropsychological 
tests (Spencer et al., 2012; Vollmar et al., 2011). 
One of the siblings had experienced two seizures more than 20 years prior to 
study participation. However, these seizures were clearly provoked. There was 
no evidence of further unprovoked seizures and no antiepileptic medication had 
been taken. As affected participants were defined as individuals with recurrent 
unprovoked seizures, this participant was not excluded from the study. Excluding 
this dataset from the analysis did not alter the overall results. 
 
6.5.5  Conclusion 
Attenuated deactivation of the motor system and increased functional 
connectivity between fronto-parietal cognitive networks and the motor cortex 
occurred both in JME patients and their unaffected siblings during a functional 
MRI working memory task. Our findings most likely reflect an imaging 
endophenotype of JME, representing the shared underlying genetic risk of JME 
in both disease-affected and -unaffected siblings, and therefore providing a 
potential biomarker for future genetic imaging studies.   
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Chapter 7: The effect of Levetiracetam on fMRI 
working memory activations in temporal lobe 
epilepsy  
7.1 Summary 
Rationale: We used functional MRI and a left-lateralising verbal and a right-
lateralising visual-spatial working memory (WM) paradigm to investigate the 
effects of Levetiracetam (LEV) on cognitive network activations in patients with 
drug-resistant temporal lobe epilepsy (TLE).  
Methods: In a retrospective study, we compared task-related fMRI activations 
and deactivations in left (53) and right (54) TLE patients treated with or without 
LEV. In patients on LEV, activation patterns were correlated with the daily LEV 
dose.  
Results: We isolated task- and syndrome-specific effects. Patients on LEV 
showed normalisation of functional network deactivations in the right temporal 
lobe in right TLE during the right-lateralising visual-spatial task and in the left 
temporal lobe in left TLE during the verbal task. In a post-hoc analysis, a 
significant dose-dependent effect was demonstrated in right TLE during the 
visual-spatial WM task: the lower the LEV dose, the greater was the abnormal 
right hippocampal activation. At a less stringent threshold (p < 0.05, uncorrected 
for multiple comparisons), a similar dose effect was observed in left TLE during 
the verbal task: both hippocampi were more abnormally activated in patients with 
lower doses, but more prominently on the left.  
Conclusions: Our findings suggest that LEV is associated with restoration of 
normal activation patterns. Longitudinal studies are necessary to establish 
whether the neural patterns observed here translate to drug-response. 
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7.2 Introduction 
Anti-epileptic drugs suppress seizures, but also cause cognitive and behavioural 
impairment. How AEDs affect specific epileptogenic and cognitive networks is 
poorly understood (Loring et al., 2011). In the first pharmacological fMRI study in 
epilepsy, a correlation between Carbamazepine (CBZ) levels and memory 
retrieval-related fMRI activations within the mesial temporal lobes was observed, 
which may explain the negative effect of CBZ on cognitive function (Jokeit et al., 
2001). We showed recently that patients with temporal lobe epilepsy (TLE) due to 
unilateral hippocampal sclerosis failed to deactivate the diseased hippocampus 
with increasing cognitive demands during an n-back working memory task 
(Stretton et al., 2012). Failure to deactivate the hippocampus was associated with 
poor performance (Cousijn et al., 2012; Stretton et al., 2012). Using the same 
working memory paradigm, we observed a valproate (VPA) dose-dependent 
“normalisation” of impaired de-activation within the motor system in patients with 
juvenile myoclonic epilepsy (JME) (Vollmar et al., 2011).  
Akin to VPA in genetic generalised epilepsies (GGE), Levetiracetam (LEV) is one 
of the most prescribed AEDs in focal epilepsies, and considered to be particularly 
efficacious with a positive cognitive side-effect profile (Helmstaedter and Witt, 
2010; Schiemann-Delgado et al., 2012).  
The aim of this retrospective study was to assess the effect of LEV on fMRI de-
activation patterns during working memory tasks in TLE patients. We 
hypothesized that patients treated with LEV show greater de-activation within 
temporal lobe epileptogenic networks compared to those not on LEV. 
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7.3 Methods 
7.3.1 Study population 
A total of 107 patients with medically refractory TLE (53 left TLE, 59 on LEV) 
undergoing presurgical evaluation at the National Hospital for Neurology and 
Neurosurgery were included in this study. For further demographic and clinical 
characteristics see Table 7.1. 
Fifty-nine patients (30 left TLE) were treated with LEV in combination with other 
AEDs, the most frequent being Carbamazepine (CBZ; Left TLE LEV +/- CBZ 
11/11; right TLE 12/8) and Lamotrigine (LTG; left TLE LEV +/- LTG 8/10; right 
TLE 9/8).  
Across groups, there was an equal distribution of Topiramate (TPM) and 
Zonisamide (ZNS) co-medication, which are known to have potential cognitive 
side effects (TPM: X2=2.845, p=. 416; ZNS: X2 = 3.009, p = 0.390). All patients 
had a structural 3T MRI and video-EEG to confirm side of seizure onset.  
Hippocampal sclerosis (HS) was the most frequent pathology, in particular in left 
TLE patients on LEV (X2=5.618, p = 0.019, see Table 7.2 for further details on 
pathologies).   
 
 
7.3.2 MRI data acquisition and fMRI paradigms 
MRI data were acquired on a GE Excite HDx 3T scanner with a multichannel 
head coil. A modified version of the n-back task was used for a visual-spatial and 
verbal WM paradigm. In the visual-spatial task, dots were presented randomly in 
four locations on a screen (Kumari et al., 2009). Participants monitor the 
locations of dots at a given delay of the original occurrence (0, 1, or 2 Back) and 
responded by moving a joystick corresponding to the location of the 
	 117 
current/previously presented dot. In the verbal n-back task, a sequence of words 
was randomly presented on a screen. During the control condition (“Is-it-bird?”), 
participants had to respond using a joystick whenever they read the word “bird”. 
During the actual working memory condition, participants had to indicate 
whenever a word had only been displayed two presentations earlier (“2 Back”). 
For more details see the Common Methods Chapter 5.4.1 and 5.4.2.
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Table 7.1. Demographic and clinical parameters 
 Left TLE Right TLE Analysis 
Clinical parameters on LEV 
(n= 27) 
no LEV 
(n= 26) 
on LEV 
(n= 29) 
no LEV 
(n= 25) 
X2 df p  
Gender female 
age in years 
14 
38 (19) 
14 
40 (20) 
23 
39 (15) 
17 
40 (22) 
6.35 
.648 
3 
3 
.096 
.885 
disease duration in years 17 (22) 16 (26) 16 (23) 17 (20) 1.737 3 .629 
Seizure frequency 
   SPS per month 
   CPS per month 
   GTCS per year 
 
0 (1.6) 
4 (7) 
0 (1.75) 
 
0 (4) 
6 (14) 
0 (0) 
 
0 (2.5) 
2.5 (11) 
0 (0) 
 
0 (8) 
6 (9) 
0 (0.5) 
 
1.086 
4.250 
2.144 
 
3 
3 
3 
 
.780 
.236 
.543 
Number of patients with 
mesial temporal seizure 
semiology 
 
 
20 
 
 
16 
 
 
20 
 
 
14 
 
 
2.979 
 
 
3 
 
 
.395 
number of current AEDs 2.5 (2.0) 3.0 (2.0) 3.0 (2.0) 3.0 (3.0) 6.240 3 .100 
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Number of previous AEDs 2 (2) 5 (4.5) 2 (3) 5 (4.5) 16.58
1 
3 .001 
 
All variables except gender are shown as median (IQR).  Chi-Square test was employed for gender and seniology, and Kruskal-Wallis test for all 
other variables. AED = antiepileptic drug; CPS = complex partial seizure; GTCS = generalised tonic-clonic seizure; LEV = levetiracetam; SPS = 
simple partial seizure; p < 0.05 
Post-hoc group comparisons revealed that the significant difference in number of previous AEDs is due to patients on LEV having had fewer 
previous AED than those without LEV (Mann-Whitney U = 706.000; p < 0.001).  
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Table 7.2. Distribution of pathologies 
 
 Left TLE Right TLE Analysis 
Type of 
pathology 
on LEV 
n = 30 
no LEV 
n = 23 
on LEV 
n = 29 
no LEV 
n = 25 
X2 df    p 
 
  HS 
  HS +   
cavernoma 
  HS + FCD 
  HS + DNET 
  DNET 
  FCD 
  cavernoma 
  other  
  MRI negative 
 
23 
 
0 
0 
1 
2 
0 
1 
2 
0 
 
11 
 
0 
0 
0 
3 
2 
1 
2 
4 
 
13 
 
1 
0 
0 
3 
0 
4 
4 
4 
 
9 
 
0 
1 
0 
1 
0 
1 
6 
7 
 
11.978 
 
3.271 
2.680 
2.680 
1.486 
7.356 
3.363 
3.965 
8.929 
 
3 
 
3 
3 
3 
3 
3 
3 
3 
3 
 
.007 
 
.352 
.444 
.444 
.686 
.061 
.339 
.265 
.030 
 
DNET= dysembryoplastic neuroepithelial tumor; FCD= focal cortical dysplasia; HS= 
hippocampal sclerosis; LEV= levetiracetam; TLE= temporal lobe epilepsy p < 0.05 
Post-hoc group comparisons revealed that a significant difference in number of patients with 
HS is caused by left TLE patients on LEV being more likely to have HS than all other groups 
(LTLE on LEV vs. RTLE on LEV: X2=7.323, p = 0.007; LTLE on LEV vs. LTLE without LEV: 
X2=5.618, p = 0.019; LTLE on LEV vs. RTLE without LEV: X2=10.431, p = 0.001). The 
difference in MRI negative cases is mainly driven by the difference between patients with 
RTLE without LEV and LTLE on LEV (X2=9.329, p = 0.003). 
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7.3.3 fMRI processing and analysis 
A-priori models were chosen with regard to our experimental design. Models 
were estimated using a general linear model (GLM) implemented in SPM8 
(www.fil.ion.ucl.ac.uk/spm). The GLM then estimated which voxels with greater 
change in blood oxygenation dependent (BOLD) signal fit which condition 
specified in the model, i.e. the BOLD signal was the outcome variable. 
Both tasks were of a blocked design and modelled at a single-subject level 
using a box-car function for each of the conditions. We created contrast images 
for each subject to explore the patterns of activation and deactivation in both 
tasks. For the task-related activations, contrasts comparing the most difficult 
WM condition with the control task were generated (”2 minus 0 Back” and “2 
Back minus Is-it-bird?”). For task-related deactivations, we used the opposite 
contrasts (”0 minus 2 Back” and “Is-it-bird? minus 2 Back”). We excluded nine 
patient data-sets due to lack of deactivation. 
To explore task specific effects of LEV at a group level, a full-factorial design 
with group and LEV treatment as factors was built. All other AEDs, and 
presence or absence or HS, were entered as covariates of no-interest to control 
for interactions.  
In a post-hoc analysis, task-related deactivation patterns were correlated with 
the daily LEV dose: Right TLE Median (IQR) 2500 (1000) mg, left TLE 2500 
(1000) mg; Mann-Whitney U Test p = 0.860. All patients divided the daily dose 
into a morning (8-10 am) and an evening dose (6- 8 pm). 
The level for significance was p < 0.001 uncorrected with a 20 voxels threshold 
extent (Lieberman and Cunningham, 2009). 
 
	 122 
7.3.4 Behavioural data 
Standardized frontal lobe tests were administered to all participants (Table 7.3). 
As cognitive outcome variables we used verbal IQ; raw scores for category and 
verbal fluency, digit span backwards and Wisconsin Card Sorting Test 
categories. Performance accuracy on the fMRI WM tasks (2 Dot Back, 2 N-
Back) was reported as a percentage.  
 
7.3.5 Statistical analysis of clinical and behavioural data 
We used SPSS Statistics Version 17.0 (SPSS Inc.,Chicago,IL,USA) for 
comparisons across all four groups (left/right TLE with/without LEV) and 
Pearson’s Chi-Square tests for dichotomous data, i.e. gender, semiology, HS-
frequency. Kruskal-Wallis tests were employed for all other data. 
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Table 7.3.Kruskal-Wallis test of cognitive performance measures in patients 
 
 Left TLE Right TLE Analysis 
Cognitive 
Measures 
on LEV 
Median (IQR) 
without LEV 
Median (IQR) 
on LEV 
Median (IQR) 
without LEV 
Median (IQR) 
    X2 df     p  
Verbal IQ 93 (17) 94 (23.5) 93 (19) 99 (21.5) 2.552 3 .466 
Letter fluency 12.5 (6.25) 11.5 (9) 14 (8) 15 (11) 3.680 3 .298 
Category fluency 19 (10) 18 (7) 19 (8) 18 (8) .490 3 .921 
Digit Span bckw 4 (1) 4 (1) 4 (2) 3.5 (1.75) .351 3 .950 
WCST 
categories 
 
6 (1) 
 
6 (1) 
 
6 (1) 
 
6 (3) 
 
1.404 
 
3 
 
.705 
2-DB % correct  52 (31) 61 (33) 54 (33) 65 (40) 1.983 3 .576 
2-NB % correct 93.5 (23.75) 98 (14) 97 (15.75) 97 (14) 1.573 3 .665 
 
 p < 0.05 bckw= backwards; DB= Dot Back; LEV= Levetiracetam; NB= N-Back; WCST= Wisconsin Card Sorting Test
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7.4 Results 
 
7.4.1 Performance during the fMRI working memory 
paradigms 
Performance on the WM tasks was comparable for all groups (Table 7.3).  
 
7.4.2 Performance on standardised neuropsychometry 
There were no significant group differences (Table 7.3). 
 
7.4.3 fMRI group effects  
Group effects for task-positive and –negative networks during the highest 
working memory load condition are shown in Figure 7.1. 
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Figure 7.1. Group effects during the two fMRI working memory paradigms. Task-
positive and –negative activation maps are demonstrated for the highest working 
memory load during the verbal (A, B) and visual-spatial (C, D) working memory task for 
all patients. All participants show activation of the task-relevant bilateral prefrontal and 
parietal areas of the working memory network during both the verbal and visual-spatial 
task (A, C). The task-negative contrast shows deactivation within the mesial and lateral 
parietal, mesial prefrontal and temporal structures, which are areas of the default mode 
network (B, D); p < 0.001, 20 voxels threshold extent 
 
 
7.4.4 fMRI group differences 
We isolated task and syndrome specific LEV effects on deactivation patterns 
(Figure 7.2). Patients on LEV and 28 healthy controls from a previous study 
(Stretton et al., 2012) showed similar patterns of deactivation. Compared to 
patients without LEV, those on LEV showed an augmentation of task-related 
deactivation in the “affected” temporal lobe, i.e. left mid-temporal gyrus in left 
TLE during the verbal, and right hippocampus in right TLE during the visual-
spatial task (Figure 7.2 B). The reverse contrast (On LEV>No LEV) showed no 
effect for either working memory paradigm (not shown).  
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No LEV effect was observed in left TLE during the visual-spatial and in right 
TLE during the verbal working memory task. 
We conducted the same analysis in patients treated with CBZ (22 left, 20 right 
TLE) or LTG (18/17) vs. those without CBZ (31/34) or LTG (35/37). No 
comparable effects were observed.  
 
 
7.4.5 Post-hoc analysis in patients on LEV 
In a post-hoc analysis, a significant dose-dependent LEV effect was 
demonstrated (Figure 7.2 C) in right TLE during the visual-spatial working 
memory task: the lower the LEV dose, the lesser the right hippocampal 
deactivation. At a less stringent threshold (p < 0.05, uncorrected for multiple 
comparisons) a similar dose effect was observed in left TLE during the verbal 
task (Figure 7.2 C). 
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Figure 7.2. Group comparisons between patients with and without Levetiracetam 
(LEV) during the two working memory (WM) fMRI paradigms.  
Group maps of areas of task-related deactivation networks in controls and all patients 
during the left- and right-lateralising task, are demonstrated. Whereas healthy controls 
and patients on LEV show similar patterns of deactivation, patients without LEV show 
less deactivation in the medial temporal lobe areas than both controls and patients on 
LEV in either lateralising task (Figure A). During the verbal WM task, left TLE patients 
without LEV significantly fail to deactivate the left mid-temporal gyrus (Figure B; left TLE 
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without LEV > left TLE with LEV, p < 0.001, 20 voxels threshold extent). During the 
right-lateralising visual-spatial task, patients with right TLE who are not treated with LEV 
fail to deactivate the right hippocampus (Figure B; right TLE without LEV > right TLE 
with LEV, p < 0.001, 20 voxels threshold extent).  
A post-hoc analysis in patients treated with LEV demonstrated a dose-dependent effect 
of mesial temporal lobe deactivation through LEV. The lower the LEV dose, the lesser 
the right hippocampus is deactivated during the visual-spatial WM task (Figure C; p < 
0.001, 20 voxels threshold extent). A similar dose effect is observed in left TLE patients 
during the verbal WM task at a lower level of significance (Figure C; p < 0.05, 
uncorrected): The left > right hippocampus becomes less strongly deactivated with 
lower LEV dose. Figure C was inclusively masked for task-related deactivation networks 
(p < 0.05).  
CTR= healthy controls; LEV= Levetiracetam; LTLE= left temporal lobe epilepsy; RTLE= 
right temporal lobe epilepsy; WM= Working memory 
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7.5 Discussion 
We demonstrate a dose-dependent, task-specific effect of LEV on functional 
network activations in TLE.  
 
7.5.1 LEV effect on task-related deactivation 
Progressive deactivation of mesial temporal structures during cognitive tasks 
has been associated with improved performance in healthy controls and patient 
cohorts (Bakker et al., 2012; Cousijn et al., 2012; Stretton et al., 2012). LEV’s 
dose-dependent facilitation of the deactivation in this study suggests a 
beneficial drug-effect on cognitive networks in TLE. Since working memory 
performance was equal across groups, the observed effect was not influenced 
by performance.  
Underlying hippocampal sclerosis was more frequent in left TLE patients on 
LEV than in all other groups, but hippocampal sclerosis distribution did not differ 
between right TLE patients on/without LEV (X2 = 0.352, p = 0.352). We 
controlled for the effect of hippocampal sclerosis diagnosis, which ensures that 
our findings are not driven by the difference in hippocampal sclerosis 
frequencies.  
Dose-dependency was more apparent in the more demanding non-verbal task. 
To ensure adequate performance in the 2-back condition of the Dot-back task, a 
greater task-related deactivation may be required. We did not find similar effects 
for CBZ or LTG, suggesting our findings are LEV-specific. 
 
7.5.2 Limitations 
Longitudinal data is lacking to determine whether LEV led to seizure reduction 
and/or improvement of cognitive functions. A further limitation is the number of 
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AED combinations, although distribution was equal for the most commonly 
prescribed other AEDs.   
 
7.5.3 Conclusions 
Our findings in TLE are consistent with previous findings in JME showing a 
Valproate dose dependent reduction of abnormal motor-system co-activation 
and enhanced working memory activations (Vollmar et al., 2011). These effects 
were not associated with better performance or seizure-control, but suggest that 
AEDs affect epileptogenic and cognitive networks differentially. Our sample 
included only drug-resistant patients, thus it would be an important to establish 
whether the neural patterns observed here translate to drug-responsive TLE 
patients in a longitudinal study.   
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Chapter 8: The effect of Topiramate and 
Zonisamide on fMRI verbal fluency activations in 
refractory epilepsy  
8.1 Summary 
Rationale: We used a functional MRI (fMRI) language task to investigate the 
effects of Topiramate (TPM), Zonisamide (ZNS) and Levetiracetam (LEV) on 
cognitive network activations in focal epilepsy patients.  
Methods: In a retrospective, cross-sectional study, we identified patients from 
our clinical database of verbal fluency fMRI studies that were treated with either 
TPM (n=32) or ZNS (51). We matched 62 patients for clinical parameters who 
took LEV, but neither TPM nor ZNS. We entered antiepileptic co-medications as 
nuisance variables, and compared out-of-scanner psychometric parameters for 
verbal fluency and working memory between groups.  
Results: Out-of-scanner psychometric data showed overall poorer performance 
for TPM compared to ZNS and LEV, and poorer working memory performance 
in ZNS-treated patients compared to LEV-treated patients. We found common 
fMRI effects in patients taking ZNS and TPM, with decreased activations in 
cognitive frontal and parietal lobe networks compared to those taking LEV. 
Impaired deactivation was only seen with TPM.  
Conclusions: Our findings suggest that TPM and ZNS are associated with 
similar dysfunctions of frontal and parietal cognitive networks, which is 
associated with impaired performance. TPM is also associated with impaired 
attenuation of language-associated deactivation. These studies imply 
medication specific effects on the functional neuroanatomy of language and 
working memory networks. 
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8.2 Introduction 
Amongst newer antiepileptic drugs (AED) highest rates of cognitive impairment 
have been reported for Topiramate (TPM; Topamax; Janssen-Cilag, Neuss, 
Germany) and Zonisamide (ZNS; Zonegran; EISAI, Tokyo, Japan) leading to 
early treatment discontinuation (Arif et al., 2009). For TPM, cognitive 
dysfunction is specifically characterised by impairment of expressive language 
and working memory. Zonisamide treatment leads to similar, less pronounced 
impairment (Mula and Trimble, 2009; Ojemann et al., 2001). The mechanisms 
of these specific impairment patterns are poorly understood. Five cognitive fMRI 
studies employed language tasks in two healthy participants, five to 16 epilepsy 
and ten migraine patients after a single dose or on steady-state TPM treatment. 
Taken together, the following patterns of dysfunctional activation emerge: 
• decreased activation in task-positive regions, i.e. dominant inferior and 
middle frontal gyri (De Ciantis et al., 2008; Jansen et al., 2006; Szaflarski 
and Allendorfer, 2012) 
• failure to deactivate task-negative regions, including the default mode 
network (Szaflarski and Allendorfer, 2012; Tang et al., 2016; Yasuda et al., 
2013) 
Only one study investigated potential pathomechanisms of cognitive impairment 
due to ZNS, describing decreased current-source density of high beta 
frequency in regions relevant to language and working memory during a verbal 
fluency task (Kwon and Park, 2013). All of the above studies are hampered by 
small sample sizes. 
We therefore aimed to investigate in a larger group of patients than previous 
studies, how TPM and ZNS alter fMRI activation patterns, in order to early 
identify patients at risk of developing cognitive side effects. Based on previously 
observed beneficial effect of Levetiracetam (LEV; Keppra; UCB, Brussels, 
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Belgium) on cognitive networks in focal epilepsy (Wandschneider et al., 2014), 
we aimed to control for disease related effects by selecting patients on LEV as 
a comparison group. 
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8.3 Methods 
8.3.1 Study population  
In this cross-sectional study, we chose patients retrospectively from a clinical 
database of patients with drug refractory epilepsy, who had undergone clinical 
language fMRI scans at the UCL Chalfont Centre for Epilepsy (UK) between 
03/2010 and 10/2015 as part of their presurgical evaluation. All patients were 
adults and seen at the adult epilepsy clinics of the National Hospital for 
Neurology and Neurosurgery (NHNN) and Chalfont Centre for Epilepsy. We 
included patients who were taking one of the following three AEDs, TPM, ZNS 
or LEV, either alone or with other AEDs as co-medications.  
As requirements for patients’ testability with the language fMRI paradigm, all 
patients had to be literate, proficient in English language and cognitively able to 
understand the simple task instructions (see paradigm description below). Our 
standard clinical language fMRI paradigm is conducted covertly, and hence we 
could not control for task compliance. For this reason, we excluded all patients 
without activations of language relevant regions (inferior and middle frontal gyri) 
from the analysis. We also excluded patients with data acquired post-
operatively as well as those with large lesions or tumors (>2 cm) to avoid 
problems with imaging normalisation and further statistical analysis. Seventy-
eight patients on LEV, 51 on ZNS and 32 on TPM were eligible. To create more 
balanced group sizes and ensure that TPM and ZNS groups were comparable 
in demographics and clinical characteristics to the LEV group, we employed 
propensity score matching. We started with the ZNS and TPM groups and to 
each group, looked for propensity-matched LEV patients for the variables of age 
at scan, age at disease onset, gender, language laterality index (middle and 
frontal gyri), total number of medications and lesion laterality using propensity 
scores in SPSS Version 21.0. We included 51 patients on ZNS, 32 on TPM and 
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62 on LEV in the final analysis. All patients suffered from refractory focal 
epilepsy and ictal EEG data was available in 86% of cases. See table 8.1 and 
8.2 for further clinical details. 
 
8.3.2 MRI data acquisition  
Gradient-echo planar images were acquired for blood oxygen level dependent 
(BOLD) contrast on a 3T General Electric Excite HDx scanner (General Electric, 
Milwaukee, WI, U.S.A.).   
Each volume comprised 50 contiguous oblique axial slices, providing full brain 
coverage, with 2.5 mm slice thickness, 64 × 64 matrix with a 24 cm field of view, 
3.75 mm × 3.75 mm in-plane resolution, 25 ms echo time, 2.5 seconds 
repetition time. 
 
8.3.3 fMRI verbal fluency paradigm 
Patients performed a covert verbal fluency task lasting for 5.5 minutes. During 
the paradigm, 30 seconds blocks of task alternated with 30 seconds blocks of 
cross-hair fixation as a control condition. Patients were instructed to covertly 
generate words starting with a visually presented letter (A, D, E, S, W). 
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Table 8.1. Clinical parameters 
 
 on LEV 
n=62 
on ZNS 
n=51 
on TPM 
n=32 
df p 
age (Median, IQR), years 34 (26-42) 35 (29-42) 35 (28-47) 2 .804 
male gender 27 28 14 2 .43 
Handedness (right/left/ 
ambidextrous) 
 
55/5/1 
 
42/7/1 
 
25/6/1 
 
4 
 
.631 
age at onset  
(Median, IQR), years 
 
14 (7-21) 
 
13 (6-19) 
 
11 (6-18) 
 
2 
 
.610 
duration (Median, IQR), 
years 
 
18 (12-26) 
 
22 (13-31) 
 
23 (10-30) 
 
2 
 
.362 
ictal EEG available 52 45 28 2 .64 
Lesion 
none/bilateral/left/right 
 
25/2/19/16 
 
26/0/15/10 
 
15/3/6/8 
 
6 
 
.284 
Dose (Median, IQR), mg 2000 (1250-
3000) 
225 (150-
400) 
312.5 (200-
500) 
2 N/A 
number of AED  
(Median, IQR) 
patients on mono-vs. 
polytherapy 
 
2 (2-3) 
 
5/57 
 
2 (2-3) 
 
4/47 
 
3 (2-3) 
 
4/28 
 
2 
 
2 
 
.245 
 
.730 
 
laterality index  
(Median, IQR) 
 
.75  (.53-
.85) 
 
.77 (.55-.92) 
 
.72 (.23-.84) 
 
2 
 
.391 
scanned on upgraded 
scanner 
 
26 
 
27 
 
8 
 
2 
 
.041 
 
Pearson’s Chi-Square was employed for dichotomous variables and Kruskal-
Wallis test was employed for all other variables.     
p < 0.05; AED = antiepileptic drug; IQR = interquartile range between pair of 
quartiles; LEV = Levetiracetam; TPM = Topiramate; ZNS = Zonisamide 
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Table 8.2. Epilepsy syndromes 
 
 LEV 
n= 55 
ZNS 
n=51 
TPM 
n=31 
Non-localisable 5 6 7 
Left/right hemispheric 1/6 6/6 3/4 
Left/right/bi-temporal 16/11/4 9/7/2 3/5/1 
Left/right/bi-frontal 3/0/1 5/4/1 2/2/0 
Left/right/bilateral 
fronto-temporal 
 
2/1/0 
 
1/0/1 
 
0/1/0 
Left/right parietal 2/1 1/2 1/0 
Left/right temporo-parietal 1/0 0 1/1 
 
 LEV = Levetiracetam; TPM = Topiramate; ZNS = Zonisamide 
 
 
8.3.4 fMRI data analysis 
Functional MRI analysis was performed using Statistical Parametric Mapping-8 
(SPM8), version 4290 (http://www.fil.ion.ucl.ac.uk/spm/). Preprocessing 
included realignment, spatial normalisation to a template in Montreal 
Neurological Institute (MNI) Space, resampling to isotropic 3 x 3 x 3 voxels and 
smoothing with a Gaussian kernel of 8 mm full-width at half maximum (FWHM). 
We performed the statistical fMRI analyses at single subject and then at group 
level. At single subject level, the task was modelled by convolving the vector of 
block onsets with a canonical haemodynamic response function (HRF) to create 
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regressors of interest. Movement parameters were included as confounds. 
Contrast images for each subject were created for task-relevant activation and 
deactivation.  
At second level, we firstly explored activation and deactivation maps during the 
verbal fluency task in each patient group employing one-sample t-tests (Figure 
8.1, Figure 8.2). For group comparisons, second level analysis was conducted 
entering the activation contrast of each patient into a full factorial design with 
group (LEV, ZNS, TPM) as factor. All other AEDs were entered as regressors of 
no interest. As the scanner was upgraded in 2013, this was entered as an 
additional covariate of no interest (scanned on upgraded scanner yes/no). An 
exploratory statistical threshold was set at p < 0.005 uncorrected with a 20 
voxels minimum cluster size extent threshold (Lieberman and Cunningham, 
2009). To be able to disentangle whether group differences were related to 
activation or deactivation, we masked the results with a binarized average task 
activation map of the patient controls, and subsequently with the binarized 
deactivation map to include the contrast relevant brain areas.   
The interpretation of the results at the single subject and group level was not 
blinded, as resultant maps represent t-maps at a predefined statistical 
threshold. We anatomically objectified peak activations from group comparisons 
with coordinates in MNI (Montreal Neurological Institute)-space (Table 8.4). 
 
8.3.5 Laterality index  
To control for differences in language laterality, we matched the groups for 
laterality indices. These were calculated with the Bootstrap method in the SPM8 
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LI toolbox (Wilke and Lidzba, 2007) for the verbal fluency activation contrast for 
each subject in the inferior frontal and middle frontal gyri. 
 
8.3.6 Behavioural data 
In those patients who had standard clinical psychometric testing at the time of 
the scan, we carried out subgroup analyses of performances. We included tests 
measuring cognitive domains reported to be affected by TPM and ZNS: Letter 
and category fluency; the WAIS Digit Span measure of short term and working 
memory; the Graded Naming Test (GNT) measure of expressive language 
function. (Baxendale et al., 2008) 
 
8.3.7 Statistical analysis of clinical and behavioural data 
Statistical analysis of clinical and behavioural data was conducted using SPSS 
version 21.0 (IBM). Chi-square tests were applied to categorical data and the 
Kruskal-Wallis and/or Mann-Whitney U Test to all other parameters. The 
statistical significant threshold was set at p < 0.05. 
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8.4 Results  
8.4.1 Performance on standardised neuropsychometry 
There were significant group differences in cognitive test performance with the 
exception of the Graded Naming Test (see Table 8.3).  
Post-hoc group comparisons revealed that for the digit span task, patients on 
LEV performed better than both those on ZNS and TPM (LEV vs. ZNS: 
U=451000, p = 0.002; LEV vs. TPM: U=120000, p < 0.001) (Mann-Whitney U 
Test), and those on ZNS performed better than patients on TPM (LEV vs. ZNS: 
U=205000, p = 0.007). TPM-treated patients performed less well than both 
LEV- and ZNS-treated for both fluency parameters (LEV vs. TPM: letter fluency 
U=177000, p < 0.001, category fluency U=149500, P < 0.001; ZNS vs. TPM: 
letter fluency U=237000, p = 0.047; category fluency U=145500, p < 0.001). 
There was no statistical difference between LEV- and ZNS-treated patients 
(letter fluency U=505500; p = 0.077; category fluency U=604500, p = 0.397).  
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Table 8.3. Cognitive performance  
 
 LEV ZNS TPM df p 
WAIS Digit 
Span  
 (median, IQR) 
n=42 
 
9 (7.5-11) 
n=36 
 
7 (6-9) 
n=20 
 
5 (4.75-7) 
 
 
2 
 
 
<.001 
letter fluency  
(median, IQR) 
n=38 
14.5 (10.25-
17.75) 
n=35 
12 (8-15) 
n=20 
10 (8-11.5) 
 
2 
 
.003 
categorical 
fluency 
(median, IQR) 
n=39 
 
18.5 (15-25.75) 
n=35 
 
17 (15-22) 
n=20 
 
12 (11-16) 
 
 
2 
 
 
<.001 
naming (GNT)  
(median, IQR) 
n=34 
17 (13.45-
21.25) 
n=28 
17 (14-20) 
n=15 
14 (10.5-17) 
 
2 
 
.391 
 
Kruskal-Wallis test, p < 0.05 
Scaled scores are presented for digit span and raw scores for all other cognitive 
parameters. 
GNT = Grades Naming Test; IQR = interquartile range between pair of 
quartiles; LEV = Levetiracetam; TPM = Topiramate; ZNS = Zonisamide 
 
 
8.4.2 fMRI group effects 
As demonstrated by one sample t-tests of task-relevant activations and 
deactivations, each AED group activated frontal language areas including the 
inferior and middle frontal gyri (IFG, MFG), bilateral supplementary motor areas 
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(SMA), as well as the left lateral parietal region, and deactivated areas of the 
default mode network (DMN), i.e. bilateral precuneus, posterior cingulate, 
angular gyrus, medial prefrontal and lateral temporal cortices (Figure 8.1, 8.2). 
 
 
 
Figure 8.1. Group activation and deactivation maps during the verbal fluency task. 
One-sample t-tests of functional MRI activation and deactivation maps for the three 
different patient groups on Levetiracetam, Zonisamide and Topiramate are demonstrated 
on a surface rendered brain template. Task relevant regions (red) include bilateral inferior 
and middle frontal gyrus (left > right), bilateral supplementary motor area, and the left 
dorsolateral parietal region.  
Areas of task-related deactivations (blue) include the bilateral precuneus, posterior 
cingulate, angular gyrus, medial prefrontal and lateral temporal cortex. 
 p < 0.005, 20 voxels threshold extent. 
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Figure 8.2. Group activation and deactivation maps during the verbal 
fluency tasks (slice view and glass brain). T-values are demonstrated as 
colour bars. Task relevant regions (orange-red) include bilateral inferior and 
middle frontal gyrus (left > right), bilateral supplementary motor area, and the left 
dorsolateral parietal region.  
Areas of task-related deactivations (blue) include the bilateral precuneus, 
posterior cingulate, angular gyrus, medial prefrontal and lateral temporal cortex. 
 p < 0.005, 20 voxels threshold extent 
L = left, R = right 
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8.4.3 fMRI group comparisons 
Patients on TPM showed reduced activation in the left MFG and left dorsal 
parietal region compared to those taking LEV (Figure 8.3, 8.4). Similarly, those 
on ZNS had reduced activation in the bilateral MFG and IFG, as well as the left 
dorsal parietal region when compared to patients on LEV (Figure 8.3 B, 8.4 B). 
Compared to LEV patients, TPM-, but not ZNS-treated, patients showed less 
task-related deactivation in the temporal regions and the rolandic opercula 
bilaterally, and right inferior parietal lobule and supramarginal gyrus (Figure 8.3 
C, 8.4 C).   
Comparing TPM- and ZNS-treated patients directly revealed greater activation 
in the temporal regions and the rolandic opercula bilaterally and the insular 
cortex, inferior parietal lobule, supramarginal gyrus, superior temporal gyrus 
and rolandic operculum on the right in the TPM group (Figure 8.3 D, 8.4 D). 
Group differences on the right were mainly due to impaired deactivation in 
comparison to LEV and ZNS (masked inclusively for LEV and ZNS group 
deactivation maps; shown in blue in Figure 8.3 D). Left-sided changes were 
located within LEV group activation maps and were hence due to greater task-
relevant activation in TPM (shown in red in Figure 8.3 D). 
There were no regions of greater activation in ZNS-treated patients compared 
to those on TPM.  
See Table 8.4 for a more detailed anatomical description of resultant regions 
from the individual group comparisons.  
 
 
 
 
	  	
	 145 
	
 
Figure 8.3. Group differences in fMRI activation maps during the verbal 
fluency task. Significant group differences between patients on Levetiracetam 
(LEV), Topiramate (TPM) and Zonisamide (ZNS) are demonstrated. Patients on 
TPM and ZNS have less activation in frontal and parietal cognitive networks than 
patients on LEV: In patients on TPM, activation is reduced in the left middle 
frontal gyrus (MFG) and left dorsal parietal region (A). In patients on ZNS, 
activation is reduced in the left MFG and bilateral inferior frontal gyrus (IFG), as 
well as the left dorsal parietal region (B). 
Looking at task-relevant deactivation networks, bilateral lateral temporal regions 
and rolandic opercula, and the right inferior parietal lobule and supramarginal 
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gyrus are less deactivated (shown in blue) in patients on TPM when compared to 
those on LEV (C).  
Compared to ZNS, TPM shows increased activation in the IFG, insular cortex and 
rolandic operculum on the left, and the insular cortex, inferior parietal lobule, 
supramarginal gyrus, superior temporal gyrus and rolandic operculum on the 
right. Differences in the left are mainly due to increased activation of task-relevant 
regions as shown in red (inclusively masked with LEV activation maps); on the 
right, activated regions mainly lie within task-negative areas, i.e. are due to 
impaired deactivation as shown in blue (inclusively masked with LEV and ZNS 
deactivation maps) (D). 
p < 0.005, 20 voxels threshold extent 
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Figure 8.4. Group differences in fMRI activation maps during the verbal fluency 
task (slice view and glass brain). T-values are demonstrated as colour bars. 
Patients on TPM and ZNS have less activation in frontal and parietal cognitive 
networks than patients on LEV: In patients on TPM, activation is reduced in the left 
middle frontal gyrus (MFG) and left dorsal parietal region (A). In patients on ZNS, 
activation is reduced in the left MFG and bilateral inferior frontal gyrus (IFG), as well 
as the left dorsal parietal region (B). 
Looking at task-relevant deactivation networks, bilateral lateral temporal regions and 
rolandic opercula, and the right inferior parietal lobule and supramarginal gyrus are 
less deactivated in patients on TPM when compared to those on LEV (C).  
Compared to ZNS, TPM shows increased activation in the IFG, insular cortex and 
rolandic operculum on the left, and the insular cortex, inferior parietal lobule, 
supramarginal gyrus, superior temporal gyrus and rolandic operculum on the right. 
When inclusively masked with LEV activation maps, differences in the left are mainly 
due to increased activation of task-relevant regions, and on the right, activated regions 
mainly lie within task-negative areas, i.e. are due to impaired deactivation, when 
inclusively masked with LEV and ZNS deactivation maps (D), see also Figure 8.3. 
p < 0.005, 20 voxels threshold extent 
L = left, R = right 
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Table 8.4. Coordinates and peak activations of resultant areas from 
group comparisons.  
 
 
MNI coordinates   (X Y 
Z) 
Z-score p 
patients on LEV > patients on TPM 
left dorsal parietal -48  -43  43 3.94 < 0.001 
left middle frontal gyrus -39  5  34 3.90 < 0.001 
left inferior temporal gyrus -54  -40  -20 3.55 < 0.001 
left superior temporal gyrus -45  14  -11 3.38 < 0.001 
left supplementary motor area -9  23  49 2.90    0.002 
patients on LEV > patients on ZNS 
left inferior frontal gyrus -42  5  34 4.07 < 0.001 
left dorsal parietal -27  -64  40 3.93 < 0.001 
left inferior temporal gyrus -48  -46  -11 3.35 < 0.001 
left middle frontal gyrus -45  32  28 3.68 < 0.001 
right inferior frontal gyrus 48  32  -2 3.51 < 0.001 
right middle frontal gyrus 36  50  7 3.20    0.001 
patients on TPM > patients on LEV 
left rolandic operculum -36  -31  19 3.48 < 0.001 
left temporal lobe -42  -25 -11 3.14    0.001 
left superior temporal gyrus -54  -7  4 3.17    0.001 
right rolandic operculum/ 
inferior parietal lobule/ 
supramarginal gyrus 
45  -25  22 3.88 < 0.001 
right temporal lobe 42  -19  -8 3.36 < 0.001 
right superior temporal gyrus 51  -13  7 3.16    0.001 
right precuneus 9  -49  55 2.96    0.002 
patients on TPM > patients on ZNS 
left inferior frontal gyrus -48  -1  19 4.07 < 0.001 
left insula -30  -4  13 3.00    0.001 
left anterior cingulate gyrus -18  35  16 3.35 < 0.001 
right rolandic operculum/ 
inferior parietal lobule/ 
supramarginal gyrus 
54  -13  22 3.98 < 0.001 
right insula/ right rolandic 48  -7  10 3.70 < 0.001 
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Coordinates are given in MNI space.    
LEV = Levetiracetam, MNI = Montreal Neurological Institute, TPM = Topiramate, ZNS = 
Zonisamide 
 
 	  
operculum/right superior 
temporal gyrus 
right medial frontal gyrus 12  56  16 3.31 < 0.001 
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8.5 Discussion 
In this study we demonstrate language paradigm specific fMRI effects with a 
decrease in frontal lobe and parietal lobe activations common to ZNS and TPM, 
and impaired deactivation in task-negative networks only seen for TPM.  
Our results concur with findings from previous studies on TPM, reporting 
decreased task-relevant frontal activation or/and impaired deactivation of task-
negative networks (Jansen et al., 2006; Szaflarski and Allendorfer, 2012; Tang 
et al., 2016; Yasuda et al., 2013), and demonstrate both mechanisms in a larger 
group of patients. Novel findings are that ZNS is associated with similar 
dysfunctional networks of task-activation, but that impaired deactivation appears 
to be specific to TPM, as shown both in comparison to both LEV- and ZNS-
treated patients.  
 
 
8.5.1 Effect of Topiramate and Zonisamide on fMRI cognitive 
networks 
The VF fMRI task usually leads to activation of frontal lobe areas, including 
most consistently the dominant IFG, MFG, anterior cingulate and pre-central 
cortices, as well as the insular, superior temporal and parietal cortices, and the 
cerebellum (contralateral to frontal activation) (Friedman et al., 1998; Phelps et 
al., 1997; Woermann et al., 2003). Dorsolateral frontal and parietal cortices 
activated by the VF task are also implicated in functional networks of working 
memory and attention (Coull, 1998; Owen et al., 2005). Given the low-demand 
control condition in the VF task employed in this study, activation of cognitive 
networks supporting general task performance, i.e. the working memory and 
sustained attention system, become apparent with increasing task demand, in 
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addition to activation of language specific frontal networks (Binder et al., 2009). 
Hence decreased activation in both regions relevant for expressive language 
function (i.e. IFG, MFG) and general cognitive task performance, i.e. the parietal 
cortex for sustained attention and the fronto-parietal working memory network, 
suggest suppression of several higher level cognitive domains by TPM and 
ZNS. 
 
8.5.2 Effect of TPM on task-related deactivation 
In TPM-treated patients, fMRI changes involved both activation and deactivation 
networks. Task-related deactivation refers to a decrease in BOLD signal during 
demanding motor or cognitive tasks, as compared to less demanding states, 
such as resting. Deactivation likely occurs because neural processes during 
these less demanding states are interrupted by engagement with the task and a 
shift from internal to external information processing. Successful task execution 
has been associated with effective deactivation of task-negative areas (Raichle 
et al., 2001; Seghier and Price, 2012). It has recently been demonstrated that 
the DMN is segregated into subspecialized nodes and, more relevant to our 
study, there is functional heterogeneity across DMN nodes with respect to 
different language tasks (Andrews-Hanna, 2012; Seghier and Price, 2012). In 
addition, areas involved in semantic and language processing show a large 
overlap with regions of the default mode network (i.e. angular gyrus, medial 
prefrontal cortex, IFG, posterior cingulate, ventral temporal lobe) (Binder et al., 
2009). Deactivation in those overlapping regions can be modulated by both task 
content, i.e. high semantic demands reducing deactivation, and increased task 
demands or difficulty leading to increased deactivation (Binder et al., 2009; 
Seghier and Price, 2012). In our study, patients on TPM fail to deactivate task-
relevant DMN nodes in comparison to patients taking ZNS or LEV, associated 
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with more cognitive impairment than those on ZNS, and these include areas 
implicated in language processing (i.e. right inferior parietal lobule, 
supramarginal gyrus). In addition, direct comparison to ZNS reveals that TPM 
leads to failed deactivation of language-task relevant DMN nodes on the right, 
but increased activation of language-relevant task positive regions on the left 
(Figure 8.3 D, 8.4 D). The latter, as demonstrated by psychometric out-of-
scanner data, is ineffective. 
 
8.5.3 Strength and limitations 	
A particular strength of our study is the big sample size. As a limitation, the 
statistical threshold used for the second level analysis, i.e. p < 0.005 
uncorrected, 20 voxel threshold extent, enables an exploratory view of the 
differences between AED treatment groups, though peak activations within 
implicated regions almost all survive p < 0.001, uncorrected (Table 8.4). 
Findings will need to be confirmed in a follow-up study with larger patient 
groups. 
Additional limitations include a potential case selection bias as our study only 
includes patients who continued treatment on TPM and ZNS and hence may 
have benefitted more and experienced fewer side effects than those who 
stopped it. A further potential confounder is the reason why a particular 
medication was chosen for a patient. All three drugs are broad-spectrum AED 
with an uncomplicated interaction profile with other AED and have been 
established for several years in the treatment of epilepsy in general, and in 
polytherapy in refractory epilepsy (Carmichael et al., 2013; Mbizvo et al., 2012; 
Pulman et al., 2014). However, we cannot control for treatment preferences in 
certain patients, e.g. choosing TPM in those who also suffer from migraines.  
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More than ten consultants are involved in epilepsy treatment at our centre, 
supporting that the AED profile of our groups is not driven by personal choices 
of a few individuals; however, AED choices may differ in our epilepsy centre to 
those in others. This may weaken the generalizability of our findings. 
In addition, the majority of patients were on co-medication and these may have 
contributed to both poor cognitive performance and observed fMRI activation 
patterns. Irrespective of specific AED effects, it has been shown that every 
additional AED leads to further cognitive impairment (Witt et al., 2015). AED 
plasma concentrations were not known at time of scanning. Though we cannot 
fully control for effect of co-medication, we matched groups for the median 
number of AED and individual co-medication AED were included as a regressor 
of no interest into the fMRI analysis model.   
Also, out of scanner psychometric data was only available in a subset of 
patients. 
Due to the retrospective study design, the effect of seizures on our findings 
could not be quantified in terms of frequency, severity or proximity to scan time. 
However, all patients suffered from refractory epilepsy and we therefore 
assume similar effects of seizures in all groups.  
Though all patients had focal epilepsy, different epilepsy syndromes were 
included (Table 8.2). Our study characterizes TPM and ZNS related disruption 
of language and working memory networks in a relatively large group of 
presurgical candidates of a big tertiary epilepsy referral centre. Though our 
findings are not fully generalizable as medical treatment strategies and drug 
choices may differ across epilepsy centres and countries observed fMRI results 
in this study still provide valuable information to interpret clinical language fMRI 
scans in a variety of patients.  
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8.5.4 Clinical applications and future directions 
With respect to clinical applications, task-, region- and AED-specific effects of 
TPM and ZNS may help to identify patients at risk of developing AED-related 
side effects at an early stage of treatment. Identifying language lateralization 
with fMRI is crucial for the risk assessment during planning for epilepsy surgery 
(Duncan et al., 2016). It would thus be important to establish whether fMRI 
changes due to TPM and ZNS can lead to mis-lateralization of language. In this 
study, as groups were matched for LI to increase the yield by including patients 
irrespective of language lateralization, we cannot comment on a potential effect 
of TPM and ZNS on LIs. In addition, a prospective longitudinal study, enabling 
fMRI and psychometric data collection before and when initiated on TPM and 
ZNS (ideally with plasma levels) will be more appropriate to answer this 
question.  
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Chapter 9: Structural imaging biomarkers of 
sudden unexpected death in epilepsy 
9.1 Summary 
Rationale: Sudden unexpected death in epilepsy (SUDEP) is a major cause of 
premature death in people with epilepsy. We aimed to assess whether 
structural changes potentially attributable to sudden death pathogenesis were 
present on MRI in people who subsequently died of sudden unexpected death 
in epilepsy.  
Methods: In a retrospective, voxel-based analysis of T1 volume scans, we 
compared grey matter volumes (GMV) in 12 cases of SUDEP (two definite, ten 
probable; eight males), acquired two years (Median, interquartile range [IQR] 
2.8) before death (Median (IQR) age at scanning 33.5 (22) years), with 34 
people at high risk (age 30.5 (12); 19 males), 19 at low risk (age 30 (7.5); 12 
males) of sudden death, and 15 healthy controls (age 37 (16); seven males). At 
risk subjects were defined based on risk factors of SUDEP identified in a recent 
combined risk factor analysis. 
Results: We identified increased GMV in the right anterior hippocampus/ 
amygdala and parahippocampus in SUDEP cases and people at high risk, 
when compared to those at low risk and controls. Compared to controls, 
posterior thalamic GMV, an area mediating oxygen regulation, was reduced in 
cases of SUDEP and subjects at high risk. The extent of reduction correlated 
with disease duration in all subjects with epilepsy. Increased amygdalo-
hippocampal GMV with right-sided changes is consistent with histopathological 
findings reported in sudden infant death syndrome. We speculate that the right-
sided predominance reflects asymmetric central influences on autonomic 
outflow, contributing to cardiac arrhythmia. Pulvinar damage may impair 
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hypoxia regulation. The imaging findings in SUDEP and people at high risk may 
be useful as a biomarker for risk-stratification in future studies. 
 
 	  
	  	
	 157 
	
9.2 Introduction 
The incidence of sudden death is 20-fold higher in people with epilepsy than in 
the general population; sudden unexpected death in epilepsy (SUDEP) is the 
most common cause of premature death in people with chronic epilepsy. There 
is currently little understanding of the underlying mechanisms of SUDEP, and 
post mortem histopathology has shown no pathognomonic characteristics 
(Shorvon and Tomson, 2011; Surges and Sander, 2012). Meta-analyses of 
SUDEP risk factors (Hesdorffer et al., 2011; Ryvlin et al., 2013) have identified 
frequent convulsive seizures (>= 3/year) as a major risk factor and several 
studies indicate that unsupervised nocturnal seizures significantly contribute to 
SUDEP risk (Lamberts et al., 2012). The Mortality in Epilepsy Monitoring Unit 
Study (MORTEMUS) reported a consistent pattern in video-EEG monitored 
SUDEP cases, of a convulsive seizure, followed by early and fatal 
cardiorespiratory dysfunction (Ryvlin et al., 2013). Some studies support a 
primary respiratory cause with central apnoea, which has been related to 
postictal generalized EEG suppression, indicating profound depression of 
central nervous system function (Lhatoo et al., 2010). Other studies report 
primary peri-ictal cardiac arrhythmias and impaired heart rate variability 
accompanying SUDEP (Surges et al., 2010).  
One recent imaging investigation (Mueller et al., 2014) reported severe volume 
loss in the dorsal mesencephalon in two SUDEP cases. A resting-state 
functional connectivity study identified reduced functional connectivity between 
the pons and right thalamus, the midbrain and right thalamus, the anterior 
cingulate cortex bilaterally and the thalamus, and the right and left thalamus in 
people at high risk compared to those at low risk of SUDEP (Tang et al., 2014). 
Imaging studies in other conditions with high risk of sudden death have also 
shown structural changes in brain regions bearing autonomic regulatory or 
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respiratory functions, i.e. the dorsal and ventral medulla, putamen, and bilateral 
insular cortices in recent-onset obstructive sleep apnoea (Kumar et al., 2014), 
and the hypothalamus, posterior thalamus, caudal raphe, locus coeruleus, 
insular cortex and lateral medulla in congenital central hypoventilation 
syndrome. People suffering from the latter condition are especially at risk for 
sudden death (Patwari et al., 2010). Neuropathological studies in sudden infant 
death syndrome (SIDS) report brain stem abnormalities, i.e. brain stem gliosis 
and defects of neurotransmission in the medulla (Paine et al., 2014). Dentate 
gyrus abnormalities in the hippocampus were reported in a large subset of 153 
SIDS, and may reflect defective neuronal migration and proliferation (Kinney et 
al., 2009a, 2015).   
Mice carrying mutations in the K1.1v potassium and Scn1a sodium channels 
have many phenotypes of human SUDEP, e.g. frequent convulsive seizures 
and premature death. A recent study in these mutant mice demonstrated that 
cortical EEG suppression coincided with spreading depolarization in the dorsal 
medulla, a region controlling cardiorespiratory pace making. Depolarizing 
blockade of these cells prevents normal autoresuscitation and produces 
cardiorespiratory arrest (Aiba and Noebels, 2015). 
To elucidate which brain regions may be implicated in SUDEP, we investigated 
whether regional abnormalities in grey matter volume appear in those who had 
SUDEP, compared to healthy controls. Due to the low incidence of SUDEP, 
exploring enriched risk groups has been suggested as means to increase the 
yield of future studies (Ryvlin et al., 2013). We explored whether regional 
imaging findings in people who died of SUDEP can be reproduced in a larger 
cohort of people at high risk for SUDEP. To assess whether imaging findings 
are common to SUDEP and those at high risk, independent from other epilepsy-
related factors, we compared SUDEP cases and those at high risk to a 
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population presumed to be at low risk of SUDEP. We also compared people at 
high risk and low risk of SUDEP to healthy controls. 
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9.3 Methods 
9.3.1 Study population 
This retrospective study was conducted at a UK tertiary referral centre for 
epilepsy as part of database research on the “Prevention and Risk Identification 
of SUDEP”, approved by the National Research Ethics Committee 
(14/SW/0021).  
The scans for SUDEP cases, those at low and high risk of SUDEP, and healthy 
controls were obtained from an overlapping period of case ascertainment, 
ensuring same imaging protocols were used for acquisition. 
People with epilepsy were identified from a general clinical database at the 
tertiary referral centre. We identified 12 people who died with definite or 
probable SUDEP, and matched those with 53 living people with epilepsy 
identified from the same database according to criteria below. All subjects had 
to have undergone a high-resolution T1 volume scan using the identical 3 Tesla 
MRI scanner as part of their clinical care. Individuals with major brain lesions, 
such as those after partial temporal lobe resection, were not included to avoid 
problems with imaging normalisation. Sufficient clinical data had to be also 
available to subsequently identify subjects at low or high risk of SUDEP, as 
described below. All three groups were matched for gender, age, epilepsy 
syndrome, and epilepsy duration to control for duration-related structural 
changes. Groups were also matched for lesion pathology where possible. 
Healthy controls were comparable to the epilepsy populations for gender and 
age. 
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9.3.1.1 SUDEP cases  	
Those deceased were classified as probable (ten) or definite (two) SUDEP, 
according to a recent classification (Nashef et al., 2012). The median age at 
death was 35.5 (Interquartile range [IQR] 2.8) years. Scans were acquired at a 
median of 2 (IQR 2.8) years ante mortem. Videotelemetry data of seizures were 
available in five SUDEP cases. Further clinical information on the SUDEP cases 
are shown in Table 9.1. SUDEP, people at high or low risk, as well as controls, 
were comparable for gender and age at scan (Table 9.2).  
 
 
9.3.1.2 People at high or low risk for SUDEP 	
A risk score was created for each subject according to the most robust epilepsy-
specific risk factors for SUDEP identified in recent combined-risk factor 
analyses (Hesdorffer et al., 2011) that were also implemented in a recent 
SUDEP imaging study (Tang et al., 2014).  Odds ratios for individual SUDEP 
risk factors were therefore adjusted for different study groups. Those with either 
nocturnal seizures (OR = 3.9), or frequent (>= 3/year) convulsive seizures (OR 
= 15.46), were considered “high risk.” Increased SUDEP risk is also associated 
with young age at disease onset (onset age < 16 years: OR = 1.72), and long 
disease duration (duration > 15 years: OR = 1.95) (Hesdorffer et al., 2011; 
Lamberts et al., 2012). For each subject, odds ratios for risk factors were added 
to define an individual overall risk score. In the SUDEP cohort, 11 of 12 SUDEP 
cases (91.7%) were correctly identified as high risk subjects if the summed risk 
score was at least 3.9 (Median risk score 19.1, IQR 16.7). One subject with 
juvenile myoclonic epilepsy had died, probably from SUDEP, but was not known 
to have suffered from nocturnal seizures nor frequent convulsive seizures. A 
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cut-off of 3.9 was therefore employed to stratify others into those with high (>= 
3.9) and low risk (< 3.9) of SUDEP. 
Individual risk scores and pathology identifed on MRI of people at low and high 
risk for SUDEP are listed in Table 9.5.  
SUDEP cases, and those at low and high risk were matched for epilepsy 
syndrome (SUDEP: 1/12 generalised genetic epilepsy; high risk: 0/34; low risk: 
3/19), and as far as possible for type of pathology (Table 9.3). We were 
primarily interested in identifying common structures and pathophysiological 
mechanisms underlying SUDEP and high risk for SUDEP, and the majority of 
those at low risk (10/19), and high risk (22/34), had no identifiable lesions on a 
high-resolution 3-Tesla epilepsy protocol clinical MRI brain scan. 
Videotelemetry data of seizures were available in 30/34 of those at high risk, 
and 7/19 at low risk. Further information regarding epilepsy classification (as per 
videotelemetry and/or history) is shown in Table 9.4.  
 
 
9.3.1.3 Controls 	
Scans of 15 age- and gender-matched healthy controls were included from a 
previous study (Stretton et al., 2013). All controls had normal MRI scans
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Table 9.1. Additional clinical characteristics of the SUDEP cohort 
 
 
 
 
Epilepsy syndrome SUDEP 
Category 
Lesion on visual inspection of MRI 
by neuroradiologist 
Duration tonic 
phase (sec) 
PGES Duration 
PGES 
(sec) 
1 Juvenile myoclonic 
epilepsy 
Probable no N/A N/A N/A 
2 Focal, left temporal 
Primary generalized 
Probable Bulky left amygdala with mild 
FLAIR signal increase 
N/A no N/A 
3 Focal, bitemporal Probable no 11 yes 30-43 
4 Focal, probably 
bitemporal 
Probable no N/A N/A N/A 
5 Multifocal, left mesial 
temporal and frontal 
Probable Left hippocampal sclerosis 10 yes 33 
6 Focal, frontal Probable no N/A N/A N/A 
7 Focal, unclassified Definite Bilateral periventricular 
leucomalacia 
N/A N/A N/A 
8 Focal, frontal Probable left hippocampal sclerosis N/A yes 5 
9 Focal, left hemisphere 
neocortical 
definite Cavernoma left superior frontal 
gyrus 
6 - 23 no N/A 
 
10 Unclassified 
 
Probable Cavernoma right inferior frontal, in 
white matter 
N/A N/A N/A 
	  	
	 164 
	
 
 
DNET = dysembryoplastic neuroepithelial tumor; EEG = electroencephalography; FLAIR = fluid-attenuated inversion recovery;  
  PGES = Post-ictal generalised EEG suppression; SUDEP = sudden unexpected death in epilepsy 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
11 Focal, probably 
bitemporal 
Probable Enlarged left amygdala > 
hippocampus 
N/A N/A N/A 
12 Focal, left hemisphere Probable Right superior temporal DNET N/A N/A N/A 
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  Table 9.2. Demographic and clinical parameters 
 
 
 SUDEP 
cases 
(n=12) 
At high risk  
(n=34) 
At low risk  
(n=19) 
Controls 
(n=15) 
 
df 
 
X2 
 
p 
Age at scan (yrs) 
Median (IQR) 
 
33.5 (21.5) 
 
30.5 (12) 
 
30.0 (7.5) 
 
37 (16) 
 
3 
 
2.85 
 
0.241 
Age at onset (yrs) 
Median (IQR)) 
 
16.5 (10) 
 
13.5 (7) 
 
14 (6) 
 
N/A 
 
2 
 
6.21 
 
0.045 
Epilepsy duration (yrs) 
Median (IQR) 
 
11.5 (24.3) 
 
17 (11.25) 
 
15 (15) 
 
N/A 
 
2 
 
5.74 
 
0.057 
Gender male 8 19 12 7 3 1.42 0.722* 
>3 CSs/year 8 24 0 N/A 2 26.09 0.000* 
Nocturnal seizures  8 27 0 N/A 2 31.9 0.000* 
polytherapy 4 14 4 N/A 2 2.21 0.347* 
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Pearson’s Chi-Square was employed for dichotomous variables. Since some cells had an expected count less than 5, an exact 
significance test was selected. Kruskal-Wallis test was employed for all other variables. CS = convulsive seizure; IQR = interquartile 
range; SUDEP = sudden unexpected death in epilepsy; yrs=years; p < 0.05; *indicates exact p
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      Table 9.3. Structural abnormalities 
 
 
 
Low risk 
N = 19 
High risk 
N = 34 
 
No lesion 10 
 
22 
Hippocampal 
sclerosis Left/Right 
 
1/0 
 
2/0 
 
Focal cortical 
dysplasia 
Left/Right 
 
3 
1/2 - 1 left/ 1 right temporo-
occipital - 1 right parieto-occipital 
 
 
6 
4/2 - 1 left insular - 1 left medial temporal - 1 right supramarginal gyrus - 1 entire left temporal lobe - 1 left inferior parietal - 1 right anterior temporal 
 
Cavernoma 
Left/Right 
2 
0/2 - right temporal pole - right fusiform gyrus 
1 
0/1 - right temporal pole 
 
 
DNET 
Left/Right 
 
1 
0/1 - left amygdala 
 
 
0 
Hamartoma 0 1 - hypothalamic 
 
Ischaemic lesions 
Left/Right 
1 
 - perinatal, leading to 
ventriculomegaly 
 
1 
0/1 - right parieto-
occipital 
 
Unclassified lesions 
Left/Right 
1 
1/0 - left frontal 
 
1 
1/0 - left superior frontal 
 
Lateralization 
Left/Right 
 
3/5 
 
 
 
7/3 
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       DNET = dysembryoplastic neuroepithelial tumor 
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      Table 9.4. Epilepsy classification in the at risk populations 
 
        
L = left; R = right
 
 
Low Risk 
N = 19 
High risk 
N = 34 
Videotelemetry data 
available 
 
7 
 
30 
Epilepsy syndrome 
temporal 
(left/right/bitemporal) 
4  
(1/1/2) 
6  
(3/2/1) 
temporo-occipital  
(L/R/non-lateralizing) 
2  
(0/2/0) 
1  
(0/0/1) 
   
fronto-temporal 
(L/R/bilateral) 
0 6  
(4/1/1) 
frontal  
(L/R/non-lateralizing) 
0 6  
(1/2/3) 
   
parieto-occipital  
(L/R) 
3  
(1/2) 
3  
(1/2) 
hemisphere (L/R) 0 1 (1/0) 
Lateralisation 2 left / 5 right / 
11 non-lateralized  
10 left / 7 right /  
13 non-lateralized 
Focal, non-localisable 6 6 
Idiopathic generalised 3 0 
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Case group total risk 
score 
early 
onset 
long 
duration 
CS 
>3/year 
nocturnal 
seizures 
lesion on MRI 
1 Low 
risk 
0 0 0 0 0 right temporal occipital FCD 
2 Low 
risk 
1.95 0 1.95 0 0 no lesion 
3 Low 
risk 
1.95 0 1.95 0 0 no lesion 
4 Low 
risk 
3.67 1.72 1.95 0 0 left superior temporal gyrus non specific 
focus 
5 Low 
risk 
3.67 1.72 1.95 0 0 no lesion 
6 Low 
risk 
0 0 0 0 0 no lesion 
7 Low 
risk 
3.67 1.72 1.95 0 0 right inferior parietal cystic lesion (likely 
DNET) 
Table 9.5. Additive odds ratios and individual pathology demonstrated on MRI 
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8 Low 
risk 
1.95 0 1.95 0 0 no lesion 
9 Low 
risk 
1.72 1.72 0 0 0 no lesion 
10 Low 
risk 
1.72 1.72 0 0 0 no lesion 
11 Low 
risk 
0 0 0 0 0 no lesion 
12 Low 
risk 
0 0 0 0 0 no lesion 
13 Low 
risk 
0 0 0 0 0 right anterior temporal/amygdala 
cavernous haemangioma 
14 Low 
risk 
3.67 1.72 1.95 0 0 no lesion 
15 Low 
risk 
3.67 1.72 1.95 0 0 hypoxic injury 
16 Low 
risk 
0 0 0 0 0 exophytic cavernoma or lipoma left 
inferior colliculus 
17 Low 
risk 
1.72 1.72 0 0 0 left hippocampal cavernoma or DNET/left 
hippocampal sclerosis 
18 Low 3.67 1.72 1.95 0 0 right fusiform carvernoma 
	  	
	 172 
	
risk 
19 Low 
risk 
1.72 1.72 0 0 0 left hippocampal sclerosis 
20 High 
risk 
21.08 1.72 0 15.46 3.9 right hippocampal sclerosis 
21 High 
risk 
23.03 1.72 1.95 15.46 3.9 no lesion 
22 High 
risk 
5.62 1.72 0 0 3.9 left hippocampal sclerosis 
23 High 
risk 
7.57 1.72 1.95 0 3.9 left precentral DNET 
24 High 
risk 
15.46 0 0 15.46 0 no lesion 
25 High 
risk 
19.13 1.72 1.95 15.46 0 subtle left insular malformation 
26 High 
risk 
3.9 0 0 0 3.9 no lesion 
27 High 
risk 
19.13 1.72 1.95 15.46 0 right parietal damage or dysplasia 
28 High 
risk 
19.36 0 0 15.46 3.9 no lesion 
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29 High 
risk 
21.08 1.72 0 15.46 3.9 left temporal dysplasia, small left 
hippocampus 
30 High 
risk 
7.57 1.72 1.95 0 3.9 no lesion 
31 High 
risk 
5.62 1.72 0 0 3.9 no lesion 
32 High 
risk 
19.36 0 0 15.46 3.9 left hippocampal sclerosis 
33 High 
risk 
7.57 1.72 1.95 0 3.9 right inferior parietal cortical dysplasia 
34 High 
risk 
23.03 1.72 1.95 15.46 3.9 no lesion 
35 High 
risk 
3.9 0 0 0 3.9 no lesion 
36 High 
risk 
21.31 0 1.95 15.46 3.9 left frontal non specific white matter focus 
37 High 
risk 
7.57 1.72 1.95 0 3.9 no lesion 
38 High 
risk 
19.36 0 0 15.46 3.9 right superior temporal gyrus/polar 
haematoma (old) 
39 High 23.03 1.72 1.95 15.46 3.9 cerebellar atrophy 
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risk 
40 High 
risk 
5.62 1.72 0 0 3.9 no lesion 
41 High 
risk 
19.13 1.72 1.95 15.46 0 no lesion 
42 High 
risk 
23.03 1.72 1.95 15.46 3.9 mature damage left>right gyrus rectus 
43 High 
risk 
21.31 0 1.95 15.46 3.9 no lesion 
44 High 
risk 
15.46 0 0 15.46 0 no lesion 
45 High 
risk 
7.57 1.72 1.95 0 3.9 hypothalamic hamartoma 
46 High 
risk 
23.03 1.72 1.95 15.46 3.9 no lesion 
47 High 
risk 
19.13 1.72 1.95 15.46 0 no lesion 
48 High 
risk 
19.13 1.72 1.95 15.46 0 no lesion 
49 High 
risk 
21.08 1.72 0 15.46 3.9 no lesion 
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50 High 
risk 
23.03 1.72 1.95 15.46 3.9 no lesion 
51 High 
risk 
23.03 1.72 1.95 15.46 3.9 no lesion 
52 High 
risk 
21.08 1.72 0 15.46 3.9 left supramarginal gyrus dysplasia 
53 High 
risk 
23.03 1.72 1.95 15.46 3.9 no lesion 
54 SUDEP 0 0 0 0 0 no lesion 
55 SUDEP 23.03 1.72 1.95 15.46 3.9 bulky left amygdala with mild FLAIR 
signal increase 
56 SUDEP 19.36 0 0 15.46 3.9 no lesion 
57 SUDEP 15.45 0 0 15.46 0 no lesion 
58 SUDEP 19.13 1.72 1.95 15.46 0 left hippocampal sclerosis 
59 SUDEP 5.85 0 1.95 0 3.9 no lesion 
60 SUDEP 21.08 1.72 0 15.46 3.9 bilateral periventricular leucomalacia 
61 SUDEP 23.03 1.72 1.95 15.46 3.9 left hippocampal sclerosis 
62 SUDEP 3.9 0 0 0 3.9 cavernoma left superior frontal gyrus 
63 SUDEP 21.08 1.72 0 15.46 3.9 cavernoma right inferior frontal, in 
white matter 
64 SUDEP 19.13 1.72 1.95 15.46 0 enlarged left amygdala > hippocampus 
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65 SUDEP 3.9 0 0 0 3.9 right superior temporal DNET 
  
        DNET = dysembryoplastic neuroepithelial tumor, FCD = focal cortical dysplasia, SUDEP = sudden unexpected death in epilepsy
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9.3.2 MRI data acquisition 
All participants had been previously scanned on the same 3 Tesla GE Signa 
HDx scanner (General Electric, Milwaukee, Wisconsin, U.S.A.), and were 
scanned with identical acquisition parameters. We used standard imaging 
gradients, with a maximum strength of 40 mT/m and slew rate of 150 T/m/s. As 
part of the clinical sequences, a coronal T1-weighted volumetric (3D) scan was 
acquired with 170 contiguous 1.1 mm thick slices (matrix 256 × 256, in-plane 
resolution 0.9375 × 0.9375 mm). 
 
 
9.3.3 MRI data analysis 
We used the Voxel Based Morphometry (VBM) 8 toolbox (http://dbm.neuro.uni-
jena.de/vbm), implemented in Statistical Parametric Mapping (SPM) 8 software 
(http://www.fil.ion.ucl.ac.uk/spm) for data analysis. Preprocessing included 
spatial normalisation to the Montreal Neurological Institute (MNI) template, 
segmentation into the different tissue classes (grey matter, white matter, 
cerebrospinal fluid), and modulation to correct for volume changes due to 
normalisation. Intersubject registration was optimized by employing the 
DARTEL (Diffeomorphic Anatomical Registration Through Exponentiated Lie 
Algebra) algorithm. A quality check implemented in the VBM8 Toolbox did not 
identify any outliers, and grey matter (GM) images were then smoothed with a 
10 mm full-width at half maximum Gaussian kernel (Yasuda et al., 2010). The 
smoothed GM images were entered into a full-factorial design with group as 
factor to test for local differences in GM volume between groups. Voxels with 
GM values <0.2 (absolute threshold masking), were excluded to avoid edge 
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effects between different tissue types. Age at scan was entered as a nuisance 
variable into the model.  
The statistical threshold was set at p < 0.001, with a minimum cluster size of 30 
contiguous voxels.  
 
 
9.3.4 Statistical analysis of demographical and clinical data 
Statistical analysis of demographical and clinical data was performed with 
SPSS Version 20.0 (SPSS Inc., Chicago, IL, USA). Pearson’s Chi-Square test 
with an exact significance test for cells with a count of less than five was used 
for dichotomous data. Kruskal-Wallis test was employed for all other data (Table 
9.2).  
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9.4 Results 
9.4.1 Demographic and clinical data 
All groups were comparable for gender and age at scan. Epilepsy groups were 
generally comparable for clinical parameters, except for factors included in the 
risk scoring, i.e. frequent convulsive seizures, nocturnal seizures, and onset of 
disease (Table 9.2). Of the epilepsy groups, 66.7 % of SUDEP cases, 35.3% of 
high risk and 47.3% of low risk had a lesion on the scan (Table 9.3). 
 
9.4.2 Voxel Based Morphometry results 
SUDEP cases showed increased grey matter volume within the right anterior 
hippocampus, and parahippocampal gyrus (Figure 9.1 A), and decreased GMV 
in the pulvinar of the thalamus bilaterally (Figure 9.1 C), compared to controls. 
In those at high risk, we found similar changes within these regions, i.e. GMV 
increase in the right hippocampus and parahippocampal gyrus (Figure 9.1 B), 
and decreased GMV in the left pulvinar (Figure 9.1 C), when compared to 
controls.  
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Figure 9.1. Regional grey matter volume differences between 
SUDEP and people at high risk and controls. A: SUDEP cases show 
increased grey matter volume in the right hippocampus and 
parahippocampal gyrus compared to healthy subjects. B: Similarly to 
SUDEP cases, people at high risk show increased grey matter volume 
in the right hippocampus and parahippocampal gyrus compared to 
healthy controls. C: Compared to controls, grey matter volume is 
decreased in SUDEP cases in the pulvinar bilaterally. D: Likewise, grey 
matter volume is decreased in those at high risk in the left pulvinar, 
compared to healthy controls. 
T – values are represented in the coloured bars. (p < 0.001, 30 voxel 
threshold extent) 
L = left; R = right 
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A post-hoc analysis across all cases suggested a negative correlation of GMV 
within the pulvinar bilaterally with disease duration (Figure 9.2; p < 0.005, 30 
voxel threshold extent).  
 
 
 
Figure 9.2. Correlation of grey matter volume with disease 
duration. Regional grey matter volume in bilateral thalamic 
pulvinar shows a negative correlation with epilepsy duration, i.e. 
grey matter volume decreases with longer duration (p < 0.005, 30 
voxel threshold extent). T – values are represented in the 
coloured bar.    
L = left; R = right 
 
 
Both SUDEP cases and those at high risk showed areas of increased GMV in 
the right hippocampus and parahippocampal gyrus, compared to those at low 
risk (threshold of significance p < 0.05, 30 voxels threshold extent; Figure 9.3).  
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Figure 9.3. Regional grey matter volume differences between SUDEP 
cases and those at high risk in comparison to people at low risk.  
A: Similar to findings in comparison to controls (Fig 9.1 A), but at a lower 
threshold level (p < 0.05, 30 voxels threshold extent), SUDEP cases show 
increased grey matter volume in the right hippocampus and 
parahippocampal gyrus in comparison to those at low risk. B: People at high 
risk and SUDEP cases share common areas of increased grey matter 
volume within the right hippocampus and parahippocampal gyrus when 
compared to those at low risk (conjunction, p < 0.05, 30 voxels threshold 
extent). 
T – values are represented in the coloured bars. 
L = left; R = right 
 
 
 
9.4.3 Subgroup analyses 
To ensure that the findings were not driven by gross brain pathologies, we 
conducted a subgroup analysis in those at risk who had non-lesional MRI scans 
(low risk n = 10; high risk n = 22). In the majority of SUDEP cases (66.7%), 
lesions were evident on clinical scans; hence, due to small sample size, the 
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same subgroup analysis could not be conducted. Age at scan was entered as a 
nuisance variable. Compared to controls, those at high risk and without lesions 
still showed increases in anterior hippocampal GMV, as well as in the 
amygdala, albeit this time bilaterally (Figure 9.4 A). Similarly, GMV in both 
hippocampi and amygdalae was increased in people at high risk compared to 
those at low risk, but more prominent in the right than left amygdala and 
hippocampus (Figure 9.4 B).  
 
To explore whether findings in the right medial temporal lobe are only related to 
frequent convulsive seizures, we compared those with more than three 
convulsive seizures per year to those with fewer convulsive seizures per year in 
the high risk and SUDEP groups. Fourteen subjects had fewer convulsive 
seizures (four SUDEP, ten high risk) and 32 had frequent convulsive seizures 
(eight SUDEP, 24 high risk). Age at scan and gender were entered as nuisance 
variables. There were no differences within the medial temporal region between 
both groups. Compared to controls, both groups showed common areas of 
increased GMV in the right hippocampus (conjunction, p < 0.005; Figure 9.5). 
We also compared total right hippocampal volumes in both groups using an 
automated segmentation tool (Winston et al., 2013). There were no significant 
differences in right hippocampal volumes between subjects with frequent and 
less frequent convulsive seizures (right hippocampal volume in cm3 in subjects 
with < 3 convulsive seizures/year: Median 3.036, IQR 0.65; in subjects with >= 3 
convulsive seizures/year: Median 2.90, IQR 0.52 cm3; Mann-Whitney U = 
130.000, p = 0.646). 
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Figure 9.4. Regional grey matter volume differences between those at 
low and high risk with non-lesional epilepsy and controls. Findings 
appear similar to previous findings in the whole sample (Figure 9.1), but are 
more bilateral: People at high risk without identifiable pathology on clinical 
structural scans show an increase of GMV in both anterior hippocampi and 
amygdalae when compared to controls (A; p < 0.001, 30 voxels threshold 
extent) and when compared to people at low risk (B; p < 0.005, 30 voxels 
threshold extent). Grey matter volume is decreased in the bilateral posterior 
thalamus in those at high risk when compared to controls (C; p < 0.005, 30 
voxels threshold extent). 
T – values are represented in the coloured bars 
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To relate seizure onset site to right medial temporal findings, subjects with right 
temporal seizure onset were compared to those with a different, right 
extratemporal or left hemisphere onset. Ictal EEG data was available in nine 
SUDEP, 30 high risk and four low risk individuals. In six high risk and one 
SUDEP case, seizure onset could not be localised and these cases were 
therefore excluded. There were no differences between these two groups in 
volumetric findings. In comparison to controls, both groups showed an increase 
in GMV in the right hippocampus (p < 0.005, 30 voxels threshold extent; Figure 
9.6).       
 
 
 
Figure 9.5. Common areas of 
increased grey matter volume in 
subjects with frequent and less 
frequent convulsive seizures 
compared to controls.  
Amongst SUDEP cases and 
people at high risk of SUDEP, 
subjects with frequent convulsive 
seizures (i.e. >= 3/year) and less 
frequent convulsive seizures (< 
3/year) share common areas of 
increased grey matter volume in 
the right hippocampus when 
compared to healthy controls. 
(conjunction, p < 0.005); T – values 
are represented in the coloured 
bars. 
L = left; R = right 
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Figure 9.6. Grey matter volume changes in subjects with and without 
right temporal seizure onset. In comparison to healthy controls, subjects 
with right temporal seizure onset (Figure 9.6 A), as well as those without 
(Figure 9.6 B) showed an increase of grey matter volume in the right 
hippocampus  (p < 0.005, 30 voxels threshold extent).       
T – values are represented in the coloured bars. 
L = left; R = right 
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9.5 Discussion   
9.5.1 Anatomical differences between people with SUDEP and 
high risk versus those at low risk  
  
We identified increased GMV within the right hippocampus and 
parahippocampal gyrus in SUDEP cases and in people at high risk for SUDEP, 
compared to people at low risk and controls. There was increased GMV in both 
hippocampi, extending to the amygdala when comparing non-lesional high and 
low risk people.  
The posterior thalamus (pulvinar) showed disease duration dependent GMV 
reduction in all patient groups.   
MRIs of all cases and controls were subsequently reviewed again by an 
experienced neuroradiologist, specifically looking for the presence or absence 
of hippocampal pathology (Table 9.1, Table 9.3). No new lesions within these 
regions were identified on visual inspection of individual cases, suggesting that 
the findings are at a group level.   
Neuropathological studies in sudden unexplained death in childhood (SUDC) 
and in sudden infant death syndrome (SIDS) have found abnormalities in the 
same region; dentate gyrus abnormalities in a large subset of 153 SIDS cases 
(Kinney et al., 2015) were interpreted as a developmental vulnerability, 
potentially leading to respiratory/ autonomic instability, or even autonomic 
seizures and death during sleep when challenged by homeostatic stressors. 
Hippocampal and temporal lobe anomalies were also described in 62% of 
SUDC cases (Kinney et al., 2009a). Microdysgenetic features of the 
hippocampal formation included dentate gyrus and subicular anomalies, 
granular nodular heterotopia, subventricular neuroblasts and hamartia, all 
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indicative of aberrant neurodevelopment. Similar to SUDEP cases, those SUDC 
individuals with structural anomalies were found dead during sleep and in the 
prone position, and more commonly had an individual or family history of febrile 
seizures, creating a potential link between hippocampal/temporal lobe 
maldevelopment, susceptibility to seizures, and sudden death.  
Increase in GMV, which has appeared in several epilepsy syndromes in 
previous VBM studies, has been suggested as indicative of dystopic neurons 
and diminished grey-white matter demarcation (Yasuda et al., 2010), and 
findings in the current study may therefore reflect abnormal 
neurodevelopmental processes. Neuropathological studies in SUDEP show that 
pathology can be present in the hippocampus (e.g. gliosis) (Zhuo et al., 2012). 
There are so far, however, no quantitative neuropathological studies of the 
hippocampus in SUDEP, which would be needed to confirm any subtle 
abnormalities such as microdysgenesis. 
 
Increased grey matter volumes in the hippocampus may also represent gliosis. 
Gliosis is a response to injury, and includes neuronal and synaptic functional 
alterations (Sofroniew, 2009) that have been associated with hyperexcitability in 
epilepsy. Gliosis within the hippocampus may therefore alter neuronal activity 
facilitating the risk of SUDEP, e.g. through hyperexcitability and/or limbic 
network dysfunction implicating also autonomic function (Binder and 
Steinhäuser, 2006).  
A recent study evaluating structural imaging prediction patterns for seizure 
freedom after surgery in temporal lobe epilepsy found unilateral or bilateral 
atrophy of the hippocampus, amygdala and entorhinal cortex in most subjects, 
although one subgroup showed bilaterally increased hippocampal and 
amygdala volumes (Bernhardt et al., 2015). Subjects in this group were more 
likely to have unsuccessful epilepsy surgery, supporting the concept that gliosis 
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may facilitate processes of treatment-resistant disease. Histopathology 
confirmed hippocampal gliosis in almost all subjects of this subgroup. 
Astrogliosis and cellular hypertrophy have been described in neuropathological 
studies in hippocampal tissue of subjects with refractory temporal lobe epilepsy 
(Das et al., 2012). Mild gliosis is also present in cases of amygdala enlargement 
(Minami et al., 2015). 
Longitudinal VBM studies report a decrease of GMV in mesiotemporal 
structures and the thalamus with longer disease duration and more active 
disease, i.e. frequent seizures (Bernhardt et al., 2009; Coan et al., 2009). 
Similarly, changes in the posterior thalamus correlate with disease duration in 
our cohort and this suggests a dynamic origin of GMV alterations in our study. A 
potential mechanism for gliosis in epilepsy could be repeated hypoxic insults, 
particularly through convulsive seizures (Macey et al., 2009).  
That increased grey matter volume may represent gliosis and plasticity following 
neural injury (Yasuda et al., 2010) is corroborated by data in other sudden 
death entities: Increased grey matter volume in the putamen appears in people 
with newly-diagnosed obstructive sleep apnoea, who are subjected to repeated 
hypoxic episodes, with the increased volumes usually attributed to transitional 
processes in glial death accompanying the neural injury in the syndrome 
(Kumar et al., 2014).  
 
 
9.5.2 Association with autonomic dysfunction and 
significance of laterality of findings 
Several functional imaging studies in humans (e.g. (Shoemaker et al., 2012, 
2015)), and stimulation studies in animals (Terreberry and Neafsey, 1987) have 
identified the hippocampus as an essential component of limbic circuitry 
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modulating autonomic function, with substantial influences on blood pressure 
regulation (Harper et al., 2000).  
Major hippocampal influence on autonomic activity through efferent projections 
can also be assumed from intracerebral stimulation studies in people with 
refractory epilepsy (Catenoix et al., 2011). These influences are corroborated by 
reports of people with mesial temporal lobe epilepsy who show decreased heart 
rate variability (HRV) in relation to seizures and interictal epileptic discharges, 
which were more pronounced during sleep, when most cases of SUDEP occur 
(Moseley et al., 2011). Of interest, HRV normalizes in some after successful 
TLE surgery (Hilz et al., 2002).  
Hippocampal grey matter volume increases in our cohort may partially underlie 
seizure generation and ictal and periictal autonomic dysfunction. However, 
increased right hippocampal grey matter volume was even present in those 
individuals with known right medial temporal epilepsy when compared to 
healthy controls (no cases of hippocampal sclerosis in either group). The 
increased grey matter volume was highly surprising, as longitudinal VBM data 
describe progressive atrophy of the ipsilateral hippocampus in the medial 
temporal lobe, especially in those people with higher seizure frequency and 
longer epilepsy duration, i.e. higher SUDEP risk (Bernhardt et al., 2009; Coan et 
al., 2009). This may suggest that our findings are not associated with a primarily 
seizure-related autonomic dysfunction; but they may be associated with an 
interictal autonomic dysregulation. At this time this is a speculative suggestion, 
and needs investigation of autonomic function in similar cohorts. 
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9.5.3 Asymmetry of grey matter volume increases 
A significant aspect of the grey matter volume hippocampal increase in SUDEP 
cases and people at high risk was the asymmetry, with the volume changes on 
the right side. The lateralization of tissue change in an autonomic regulatory 
area poses a serious concern for sympathetic and parasympathetic outflow. If 
laterality on sympathetic influences is preserved to medullary output nuclei, the 
consequences to cardiac arrhythmia generation are severe, since asymmetric 
sympathetic outflow leads to such phenomena as potentially fatal long QT 
syndrome (Schwartz, 1998). The right insula plays a more prominent role with 
sympathetic regulation, while parasympathetic regulation is primarily mediated 
on the left insula (Oppenheimer, 2006) as determined by a series of stimulation, 
lesion, stroke, and imaging studies, including human epilepsy surgical studies 
(Oppenheimer et al., 1992). Both injury to the right limbic system and direct 
insular stimulation have been associated with sympathetic overregulation 
(Oppenheimer, 2006). Sudden death after acute right-sided insular strokes and 
increased complex arrhythmias appear more often than in any other lesion 
localization (Sörös and Hachinski, 2012). Right insular injury in obstructive sleep 
apnoea show distorted blood pressure recovery patterns to a challenge (Harper 
et al., 2003; Henderson et al., 2003) and right hemisphere strokes, particularly 
when involving the insula, are accompanied by increased nocturnal blood 
pressure, higher noradrenaline levels and QTc prolongations (Oppenheimer, 
2006). The insular effects appear to be mediated by projections to the ventral 
medial frontal cortex, hypothalamus, and hippocampus through integrated 
circuitry (Shoemaker et al., 2015). The lateralized (right) increased 
mesiotemporal grey matter volume in our cohort may contribute to chronic, 
asymmetric hyper-sympathetic activation, or a sympathetic system lacking in 
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appropriate responsiveness, which would contribute to mechanisms that pose a 
risk for sudden death.  
Similar scenarios develop for obstructive sleep apnea and for heart failure, 
which induce severe injury preferentially in the right insula, and consequential 
very high resting, and unresponsive, sympathetic tone (Macey et al., 2002; Woo 
et al., 2005). An imbalance between parasympathetic and sympathetic drive 
places an individual at risk, resulting in a tendency to postictal 
bradycardia/asystole as noted in the MORTEMUS study (Ryvlin et al., 2013). 
 
 
9.5.4 Decreased grey matter volume in the posterior thalamus  
A second major finding was that grey matter volume was reduced in the 
posterior thalamus, and correlated with disease duration. The finding was not 
unique to SUDEP.  A decrease of grey matter volume in the posterior thalamus 
correlated with disease duration in all people with epilepsy (Figure 9.2), and one 
may speculate that those changes may develop in low risk people, given 
sufficient duration of seizures. However, the finding of posterior thalamic GMV 
should be taken in the context of roles for that structure in respiratory regulation. 
Substantial evidence, ranging from lesion and stimulation studies in the foetal 
lamb (Koos et al., 1998, 2004), to fMRI studies in adolescents and children with 
congenital central hypoventilation syndrome (Macey et al., 2005) show the 
significant role of the posterior thalamus in mediating breathing responses 
following manipulation of oxygen levels, with special participation in the 
inhibition of breathing following hypoxic exposure (Koos et al., 1998, 2004). We 
speculate that injury to the posterior thalamus is common in people with 
epilepsy, that the evidence suggests that disease duration potentiates that 
injury, and that such injury poses particular risk to the hypoxia normally 
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accompanying ictal episodes, causing thalamic structures to fail to adequately 
recover from low oxygen. A thalamic role must, however, be viewed in the 
context that in people who succumbed to SUDEP or who were at high risk also 
were burdened with right-sided grey matter volume increases in the 
hippocampal region, which would compromise appropriate blood pressure 
responses that accompany apnoea. Thus, the combination of injury, diminished 
posterior thalamic and altered right-sided hippocampal grey matter volume may 
impose a set of circumstances leading to vital failure. 
The mechanisms underlying decreased thalamic grey matter volume should be 
considered; the decline emerges in several epilepsy syndromes (Yasuda et al., 
2010), and appears to be, in part, independent of epilepsy severity, presence of 
MRI lesions, and duration (Keller et al., 2002). Strong relationships of disease 
duration and declines in grey matter volume and changes in white matter tract 
microstructure, i.e. mean fractional anisotropy (FA) declines, have been 
described, and may underlie progressive brain changes in response to active 
disease, i.e. recurrent seizures (Keller et al., 2012). 
High risk for SUDEP has been reported in those who fail epilepsy surgery 
(Sperling et al., 2005). Persistent seizures in subjects who had undergone 
amygdalo-hippocampectomy for unilateral temporal lobe epilepsy were 
associated with pre-operative atrophy of bilateral dorsomedial and pulvinar 
thalamic regions (Keller et al., 2015), with the investigators arguing that these 
regions are important hubs of seizure modulation and spread. We suggest that 
the risk may stem from failure of a combined interaction of breathing and blood 
pressure control.  
 
	  	
	 194 
	
9.5.5 Limitations 
The criteria used to define our risk groups, and the cut-off between high and low 
risk, were arbitrary. The finding that SUDEP and those at high risk show similar 
patterns is consistent with our definition of risk groups. Eleven of 12 SUDEP 
cases were classified as high risk with our criteria. 
A major limitation of our study is to disentangle whether our finding of right 
hippocampal GMV increase is a specific SUDEP risk factor or rather a marker 
of severe epilepsy. 
As there was only one low risk case in our SUDEP group, we could not 
establish whether increased right hippocampal GMV is present in SUDEP cases 
despite being labelled low risk. This would have marked our finding as more 
SUDEP specific. In vivo imaging biomarkers of SUDEP risk should be present 
in both, people who later on died from, and those at high risk of, SUDEP. We 
argue that the smaller the difference we observe between those two groups, the 
better our classification and definition of high risk criteria. Similarly, main risk 
factors for SUDEP, like frequent, uncontrolled convulsive seizures, will have to 
be present in both SUDEP and high risk groups (Hesdorffer et al., 2011), and 
hence, are also the major distinguishing factor of high risk versus low risk 
subjects in our study. By the nature of SUDEP and our study, it is therefore 
impossible to fully disentangle the effect of severe epilepsy from a specific 
SUDEP biomarker itself. 
Due to methodological challenges (Ashburner and Ridgway, 2012), there are 
only few longitudinal VBM studies in people with mesial temporal lobe epilepsy. 
All of them show grey matter atrophy within mesial temporal structures and 
beyond (e.g. thalamus) over time, which are more progressive with longer 
disease duration and higher seizure frequency (Bernhardt et al., 2009; Coan et 
al., 2009). Evaluation of subregional mesiotemporal disease progression 
	  	
	 195 
	
revealed that progressive atrophy particularly involves the anterior part of the 
hippocampus (Bernhardt et al., 2013). These reports are in clear contrast to our 
findings of increased GMV particularly in the anterior hippocampus and suggest 
that these are not only caused by frequent seizures. There are poor data on 
exact seizure counts in our groups, but when subjects in the high risk and 
SUDEP groups where dichotomized into those with frequent (i.e. > 3 convulsive 
seizures/year) and those with less frequent convulsive seizures, there were no 
significant group differences within the right hippocampus but both groups 
showed common areas of increased right hippocampal GMV when compared to 
healthy controls (Figure 9.5). In addition, total right hippocampal volume 
measures did not differ between groups. This underscores our argument that 
the findings represent more specific SUDEP markers than just markers of 
severe epilepsy.  
In keeping with the longitudinal data, posterior thalamic grey matter atrophy 
correlates with disease duration in our cohort and we can therefore confirm that 
this finding is not a specific SUDEP biomarker.   
We appreciate that epilepsy groups in this study combine various different 
epilepsy subtypes, and include people with lesional and non-lesional MRI scans 
(Table 9.3). Right hippocampal sclerosis was, however, not present in either 
epilepsy group, and therefore does not explain differences in right hippocampal 
GMV. Structural abnormalities were common among our SUDEP population 
(66.7% of cases), and we acknowledge that our SUDEP group may therefore 
not be representative of all SUDEP cases. 
A previous study (Mueller et al., 2014) described decreased midbrain volume 
using graph analysis methodology in two SUDEP cases compared to controls. 
We did not aim to examine brainstem volumes, although our whole-brain 
analysis included the brainstem; we found no abnormal changes in the 
brainstem within any group. Voxel based morphometry has substantial 
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limitations in evaluating brainstem segmentation, due to the difficulty in 
resolving internal brainstem architecture reliably and consistently (Lamberts et 
al., 2012). Disturbances in brainstem attributes may be better evaluated with 
newer procedures for examining tissue changes, such as diffusion MRI.  
 
 
9.5.6 Conclusions 
Increased right hippocampal and parahippocampal GMV and GMV decline in 
the posterior thalamus appears to be related to SUDEP risk. In the case of GMV 
increases, the relationship is independent of markers of severe epilepsy, such 
as frequent convulsive seizures. The volume increases are potentially of 
dynamic origin, representing gliosis in response to repetitive injury from severe 
epilepsy, while the thalamic volume declines may result from excitotoxic or 
other injury sources. The thalamic injury may lead to an inability to recover 
breathing to a hypoxic challenge from apnoea, while the 
hippocampal/parahippocampal pathology may contribute to asymmetric 
influences on autonomic outflow, establishing circumstances for cardiac 
arrhythmia and hypotension. The structural changes may be useful biomarkers 
to assist determination of pathophysiology of SUDEP.  
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Chapter 10: Conclusions and outlook 
10.1 Imaging endophenotypes in juvenile myoclonic 
epilepsy  
Using fMRI and a working memory paradigm, we identified a functional 
endophenotype in patients with JME and their unaffected siblings. Our findings 
underscore previous results in JME from our group, i.e. attenuated deactivation 
of the motor system and increased functional and structural connectivity 
between fronto-parietal cognitive networks and the motor cortex. Similar 
functional findings in unaffected siblings support our hypothesis of a genetically 
determined neurodevelopmental condition.  
Though the findings offer a pathophysiological explanation for both subtle 
frontal lobe cognitive impairment and cognitively triggered jerks in JME, their 
syndrome specificity is yet to be proven. Reflex mechanisms have been 
described in other epilepsy syndromes, particularly in genetic generalised 
epilepsies, and impaired functional segregation of large scale networks is likely 
a common pathomechanism of GGE (Badawy et al., 2013; Koepp et al., 2016). 
Future studies ideally employing the same fMRI working memory paradigm in 
other GGE syndromes, such as childhood and juvenile absence epilepsies, are 
necessary to establish whether our findings are truly syndrome specific for JME. 
One may criticize that the endophenotypes described in this work have only 
been identified at group level so far, rendering practical applications at single 
subject level, e.g. identifying “cases” for genetic studies, difficult (Berkovic and 
Jackson, 2014). One possible application for gene discovery is to use the 
described functional imaging findings as a quantitative trait in a probabilistic 
approach in conjunction with genome-wide association, as previously employed 
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in schizophrenia (Potkin et al., 2009). In addition, studies ideally in untreated, 
newly-diagnosed patient groups, removing confounding factors of treatment and 
disease duration, may help to eventually translate findings to the single subject 
level.  
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10.2  Pharmacological fMRI 
In two retrospective studies in patients with refractory epilepsy, I was able to 
show drug specific effects on cognitive networks. Levetiracetam lead to 
normalisation of mesial temporal lobe deactivation. Our study design allowed us 
to show that this was a syndrome and task specific effect, i.e. it was observed in 
the right temporal lobe during a non-verbal working memory task in in right TLE, 
and in the left temporal lobe during a verbal working memory task in left TLE. 
Topiramate and Zonisamide were associated with a dysfunction of language, 
sustained-attention and working memory specific activation networks. This 
included a decrease of activation in task-relevant regions. In addition, TPM 
showed regionally and task specific impaired attenuation of task-negative 
networks. This was in keeping with an overall poorer cognitive performance 
than observed for ZNS in this study, and with the clinical experience that ZNS 
has less negative effects on cognition than TPM. 
  
Limitations of these studies are, that they were both conducted in patients with 
chronic and refractory epilepsy, in who one expects a higher degree of cognitive 
impairment due to disease duration and uncontrolled seizures than for example 
in recent-onset patients who are treatment-responders. In addition, the majority 
of patients were on co-medication. Even though we included co-medications as 
regressor of no interest into our statistical models, we could not fully control for 
AED interactions, as well as additive detrimental effects on cognitive function 
due to polytherapy (Witt et al., 2015). 
To study more specific AED effects and their dynamic changes over disease 
duration and/or their interaction with the disease, future studies will have to 
prospectively assess the effects of AEDs on both cognitive and epileptogenic 
networks. Ideally AEDs should be studied in mono-therapy, or at least as first 
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add-on drug to reduce medication confounders, and pre- and post treatment 
initiation.  
Furthermore, it has been suggested by other researchers in the field (Borsook 
et al., 2013), that drug efficacy is probably best studied via functional 
connectivity analysis, whereas task-based regional activation may be more 
appropriate for evaluation of specific cognitive side effects. 
Longitudinal resting state and task-based imaging studies may thus enable us 
to understand long-term drug effects on specific cognitive or more disease 
related networks. They may help to understand whether chronic AED exposure 
can eventually lead to normalisation of aberrant, disease/seizure-related 
functional networks, and mechanisms in non-responders, or more dynamic 
changes, such as development of treatment resistance to a substance that 
previously lead to long-term symptom benefit.  
Overall, ph-MRI studies in epilepsy are sparse. However, we know from studies 
in other disease entities, particularly affective disorders and pain research 
(Nathan et al., 2014), that ph-MRI studies show consistent and reproducible 
changes on disease relevant networks and prove sufficiently sensitive to detect 
dose-dependent network changes early, prior to clinical change, and can predict 
long-term efficacy, providing promising new tools for a personalised treatment 
planning and future CNS drug-development. 
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10.3 Imaging markers of sudden death in epilepsy 
Our structural imaging analysis in patients who either died or were at high risk 
of sudden unexpected death in epilepsy (SUDEP) showed increased right 
hippocampal and parahippocampal grey matter volume (GMV) and GMV 
decline in the posterior thalamus.  
In our exploratory analysis in a relatively small data set, we could not yet 
disentangle whether the abnormalities indicate seizure-induced damage/ 
response to repetitive seizure-related damage, i.e. gliosis, or signify a-priori 
changes. The latter is intriguing given similar changes in sudden infant and 
childhood death cases, though not on imaging but in neuropathological studies 
(Kinney et al., 2009a, 2015). Implicated regions lie within autonomic regulatory 
circuits, as well as within or in proximity to critical epilepsy/seizure network 
hubs, and are therefore interesting targets for further exploration in future 
studies.  
A further problem that other studies exploring SUDEP biomarkers also face is 
the specificity of our findings in the context of potential effects of high disease 
load, which in itself is a risk factor for SUDEP.  
Apart from the obvious next steps to try to confirm or refute our findings in larger 
data-sets, additional directions could be a refinement of risk stratification 
through electrographic and autonomic data from video-telemetry units and a 
multimodal imaging approach including functional and structural connectivity, as 
well as looking at neuroimaging data across (neurological) sudden death 
entities, such as sleep apnoea and stroke.  
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